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 Epigenetic mechanisms have recently emerged as key regulators of many cellular 
processes. Among such mechanisms, covalent post-translational modifications to histone 
are the most studied. Such covalent modifications include methylation, ubiquitination, 
sumoylation and acetylation which impact the chromatin structure. Histone acetylation by 
histone acetyl transferase (HAT) results in the unwinding of the chromatin leading to the 
accessibility of the cellular transcription machinery to the genome. HAT's function is 
counterbalanced by that of histone deacetylase (HDAC) leading to a highly coiled 
chromatin thus silencing genes. To date, there are 11 zinc dependent HDAC isoforms, 





dependent isoforms. Despite being referred to as HDACs, substrates of these 
enzymes include non-histone proteins. Due to their involvement in gene regulation, 
HDACs are upregulated in various malignancies leading to the development of HDAC 
inhibitors (HDACi) as potential cancer therapeutics. Most inhibitors of HDACs follow a 
pharmacophoric model which includes a surface recognition group connected by a linker 
to a zinc binding group (ZBG). HDAC as a target for cancer chemotherapy was validated 
by the approvals of SAHA and FK228 (Romidepsin) by the FDA in 2006 and 2009 
respectively for the treatment of cutaneous T cell lymphoma. Despite the successes of 
these inhibitors against leukemias and lymphomas as demonstrated through various 
clinical trials, there are many problems associated with the clinical use of HDACi 
including the lack of efficacy against solid tumors. SAHA which constitutes the gold 
standard of HDACi, is a pan-inhibitor thus inhibits isoforms not involved in 
 xxvi 
tumorigenesis such as HDAC4, 5, 7 and 9 resulting in adverse side effects. Furthermore, 
both clinically approved agents have been associated with a severe cardiotoxicity. 
 My thesis work aimed at addressing some of the aforementioned issues through 
the development of isoform-selective HDACi, and the targeted delivery of isoform- 
selective HDACi and HDAC pan-inhibitors. Previous work in our lab by Dr. Vishal Patil 
identified the 3-hydroxy-pyridin-2-thione (3-HPT) as a novel ZBG for HDAC inhibition. 
Incorporation of this novel ZBG into the pharmacophoric model conferred a selectivity 
towards HDAC6 or 8 as the small molecules obtained were devoid of HDAC1 inhibition. 
I established that the 3-HPT containing HDACi possess anticancer activity against 
various cancer cell lines including the androgen independent prostate cancer line DU-
145, the androgen dependent prostate cancer LNCaP, the T cell leukemia Jurkat and its 
mutant subline Jurkat Jγ which was resistant to SAHA-induced apoptosis. Furthermore, 
these selective HDACi were not cytotoxic to the healthy cell Vero at the highest tested 
concentration of 20 μM.  
 Based on the previously described overexpression of the folate receptors (FR) in 
cancer cells, I also selectively delivered various HDACi to FR positive (+) tumors such 
the oral carcinoma KB and the cervical cancer cell line HeLa. Pan-inhibition of HDACs 
in cancer cell constitutes an important methodology for cancer therapy as the damages 
inflicted can be compounded. However, the risk of having off target effects due to 
toxicity to healthy cells is also increased. As such, using the folic and pteroic acids which 
have been shown to deliver cytotoxic cargo to cancer cells, I designed and synthesized 
folate- and pteroic- based HDAC inhibitors bearing the hydroxamate ZBG. These folate 
and pteroic based inhibitors may not only be less cytotoxic to healthy cells which lack the 
 xxvii 
FR but will also lead to high intratumoral drugs concentration thus addressing the 
described lack of efficacy of HDACi against solid tumors. These constructs were 
achieved by incorporating the folate or the pteroic acid in the pharmacophoric model as 
surface recognition groups. From the structure activity relationship (SAR) conducted, the 
pteroic based hydroxamates were pan-inhibitors, whereas the folate based were selective 
for HDAC6.  I also selectively delivered isoform selective HDACi using the folic acid as 
homing tool. This represented the first time that both methodologies were combined 
yielding folate based biaryl benzamide HDACi selective for HDAC1. It followed from 
cell viability assays that only the pteroic based hydroxamates HDACi possess anticancer 
activity against the KB and HeLa cells. I confirmed the intracellular targets of the pteroic 
based hydroxamates (HDAC1 and 6) through immunoblotting. Furthermore, I established 
that in KB cells HDAC1 inhibition led to cell death whereas HDAC6 inhibition has no 
impact on cell viability. To my knowledge, this represents the first literature report of 
such impact of HDAC isoform inhibition in KB cells.  
 Understanding the mechanisms of resistance to HDACi constitutes another 
avenue by which their clinical use can be improved. Such knowledge can result in the 
selection of appropriate drugs to be used alongside HDACi as part of combination 
therapy thus potentiating their therapeutic effects. Balasubramanian et al. reported that 
the lack of phospholipase C-γ1 (PLC-γ1) conferred to Jurkat Jγ cells resistance to 
apoptosis induced by a HDAC8 selective inhibitor. Through my thesis work, I was able 
to demonstrate that Jurkat Jγ cells were also resistant to apoptosis induced by HDAC1 or 
HDAC6 selective inhibitors, pan-inhibitors including SAHA and the clinically approved 
 xxviii 
FK228 (Romidepsin) suggesting that a loss-of-function mutation of PLC-γ1 can 
constitute a novel mechanism of resistance to HDACi-induced apoptosis. 
 Although my thesis work aimed at improving HDACi therapy from the drug 
discovery perspective, improvements still need to be made from the clinical standpoint 
such as the identification of patients who can truly benefit from HDACi therapy and the 










1.1. Background     
 Since its initial use by Conrad Waddington in 1939, the term "epigenetics" has 
evolved from the interactions between genes and their products leading to a phenotype to 
be understood as the study of mechanisms controlling gene expression.
1,2
 The study of 
epigenetic mechanisms is not only crucial in fields such as developmental biology but has 
become prominent for biomedical research as many of pathological conditions can be 
linked to the cellular epigenetic machinery going awry.
1,3
 Such diseases include cancer 
whose hallmarks are all controlled by epigenetic mechanisms.
4,5,6
 Among the epigenetic 
mechanisms which include DNA methylation, histone modifications and nucleosome 
positioning, certain covalent changes to histone have been suggested to affect the 
chromatin structure through modulation of electrostatic interactions between DNA and 
histones and provide interfaces for proteins-proteins interactions.
2,7
  
 Post-translational modifications to histones encompass methylation, 
phosphorylation, ubiquitination, sumoylation and acetylation.
8
 Although all these 
modifications are crucial for epigenetic regulation of cellular activity, acetylation and 
deacetylation have now emerged as key regulatory mechanisms not only for histones 
activities but for more than 2000 proteins.
9





1.2. Histone acetylation 
  Despite being called histone acetyl transferases (HATs), these enzymes catalyze 
the addition of an acetyl group to lysine residue of various targets including non-histone 
proteins.
10
 Histone acetylation results in the unwinding of the chromatin allowing the 
cellular transcription machinery to access the genome. Aberrant HAT activity has been 
linked to diseases such as asthma, COPD, cancer and viral infections such as HIV.
11
 In 
cancer, the altered HAT activity is a result of mutation as opposed to change in 
expression levels in asthma or COPD.
12,13
 Even though HATs inhibition seem to be a 
way forward in the treatment of selected illnesses, current inhibitors suffer from low 
cellular permeability resulting in a decreased interest in their clinical development and 
use.
11,14
 Moreover, the activity of HAT is modulated by the multiproteins complexes they 




1.3. Histone deacetylation 
 Just as acetylation is crucial for the regulation of a multitude of proteins, 
deacetylation is also key in their activity. Substrates targeted by deacetylation include 
HSP90, tubulin, androgen receptors, p53, histones, etc.
12, 15
 For instance, the 
deacetylation of HSP90 results in its dissociation from its clients proteins leading to their 
degradation, whereas histones deacetylation leads to chromatin structure remodeling. The 
deacetylation of proteins including histones is mediated by histone deacetylases 






1.4. Histone deacetylase (HDAC) 
 Equally important to histones acetylation is their deacetylation suggesting that the 
overall activity of histone is dictated by the equilibrium between acetylated and 
deacetylated lysine residues. The removal of acetyl groups from histone tails yields 
positive charges on the lysine residues leading to favorable electrostatic interactions with 
the negatively charged phosphate backbone of the DNA. This results in a tightly coiled 
chromatin leading to gene silencing. Based on their sequences, there are 18 HDAC 
isoforms grouped into four classes comprised of the zinc dependent classes I, II and IV 
and the NAD
+
 dependent class III (Table 1.1). Members of Class I HDAC are HDAC1, 2, 
3, and 8 which are localized in the nucleus. HDAC4, 5, 7 and 9 form the class IIa which 
shuttle between the nucleus and the cytoplasm. The cytoplasmic HDAC6 and 10 
constitute the class IIb. The final zinc dependent, HDAC11, is the sole member of class 
IV.
16
 The class III HDAC is comprised of the NAD
+
 dependent sirtuins which will not be 
the focus of my discussion. Any further mention of HDAC will be referring to the zinc 
dependent isozymes. The active site of these enzymes is located inside a hydrophobic 
pocket and has a Zn
2+
(Fig. 1.2). During the hydrolysis of the acetylated lysine residue, it 
penetrates the enzymatic pocket enabling the coordination of its acetate moiety by the 
Zn
2+
 followed by the nucleophilic attack of water yielding a tetrahedral intermediate 











Figure 1.1: Proposed mechanism of acetyl-Lys deacetylation by HDAC8. G151 refers to 











Table 1.1: Characteristics of Zinc dependent HDACs.
12,16
  
Class Isoform Cellular localization Substrate 































Figure 1.2: Cross section of the homology model of HDAC1 built from HDAC2 (PDB 
code: 3MAX). Key regions of the enzyme are highlighted. Interactions of a potential 
inhibitor with the vicinity of the surface of the HDAC channel, the hydrophobic channel 
and Zn
2+
 are crucial for optimal anti-HDAC activity. 
 
1.5. Role of HDACs in healthy cells 
 Knockout experiments of HDAC in mice revealed the importance of class I 
enzymes for cellular proliferation. The lack of HDAC1 is lethal during the embryonic 
stage and that of HDAC2 results in severe proliferation defect of cardiomyocytes.
15,18
 
HDAC6 knockout is not detrimental to the overall health of mice, whereas the lack of any 
class IIa isoforms lead to various degree of cardiovascular anomalies.
12, 15
 Other studies 
designate HDAC6 as the primary deacetylase of non-histone proteins such as tubulin and 





Acetate exit channel 
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many other cytosolic proteins.
19
 Although these knockout experiments in mice 
demonstrated the crucial role of HDACs in embryonic development and survival, 















1.6. Regulation of HDAC activity 
 The function of HDACs is modulated through complex protein-protein 
interactions and covalent modifications, such as sumoylation and phosphorylation, whose 
impact is determinant for the cellular localization of class IIa isoforms. Specifically, 
phosphorylation of HDAC4 and 5 results in their association with 14-3-3 proteins 
preventing their translocation to the nucleus where they function as transcription 
repressor.
21
 Phosphorylation although not involved in the cellular localization of class I 
HDACs is still crucial for the modulation of HDAC1 activity as HDAC1 mutant lacking 





















) has a reduced activity including 
transcription repression. Other regulation mechanisms of HDAC activity include the 




1.7. HDAC in cancer 
 Due to their involvement in gene regulation, HDACs are implicated in various 
biological phenomena such as embryogenesis, metabolic homeostasis and diseases such 
as neurodegenerative, parasitic infections and cancer.
23-31
 The correlation between the 
latter and HDAC activity has been best described in leukemias where fusion proteins 
resulting from chromosomal translocations recruit HDAC enzymes as part of gene 
silencing complexes non-responsive to cellular control.
13
 In acute promyelocytic 
leukemia (APL), chromosomal translocations result in an aberrant fusion protein 
containing the retinoic acid receptor (RAR) α and promyelocytic-leukemia protein 
(PML), which upon dimerization binds to the DNA, recruits HDACs and represses the 
RAR controlled genes. The ensuing gene silencing cannot be overcome in the presence of 
retinoic acid as it is the case in healthy cells.
32
 Despite the scarcity of cancer resulting 
from direct mutations of HDACs, a multitude of malignancies have been reported to 
possess altered HDAC expression levels (Table 1.2). In prostate cancer, class I HDACs 
such 1, 2, and 3 are overexpressed relative to healthy prostate cells.
33
 A similar HDAC 
pattern was also detected in selected subtypes of ovarian and endometrial cancers,
34
 
whereas in cutaneous T-cell lymphoma (CTCL), the overexpressed trio is comprised of 
HDAC1, 2 and 6.
35
 Furthermore, selective silencing of HDAC1 through siRNA 
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knockdown resulted in the growth inhibition of human cancer cells such as MCF7, 




Table 1.2: HDACs overexpression in cancer.
35
 
Malignancy HDAC isoforms 
Cutaneous T-cell lymphoma 1, 2, 6 
Gastric carcinoma 1, 2, 3 
Colorectal carcinoma 1, 2, 3 
Hepatocellular carcinoma 1 
Prostate carcinoma 1, 2, 3 
Ovarian serous carcinoma 1, 2, 3 
Ovarian endometrioid carcinoma 1, 2, 3 
Endometrial endometrioid carcinoma 1, 2, 3 
Estrogen positive breast carcinoma 6 
Breast carcinoma 6 
 
 
1.8. HDAC inhibitor (HDACi) for cancer therapy 
 Based on the involvement of HDAC in the tumorigenesis of selected 
malignancies, HDAC inhibition has become an attractive target for cancer therapy. 
Starting from DMSO in 1971 which induced differentiation of leukemia cells, many 
HDAC inhibitors (HDACi) have been designed resulting today in a myriad of small 




1.8.1. HDACi pharmacophoric model 
 Most HDACi are competitive inhibitors of the acetylated lysine substrate. Hence, 
HDACi need to bind to the enzyme's active site to elicit anti-deacetylase activity. For 
optimum interaction with HDAC active sites, all HDACi have a pharmacophoric model 
consisting of: a surface recognition group which interacts with the amino acid side chains 
at the enzyme outer rim in the vicinity of the active site; a linker traversing the 
hydrophobic channel leading to the active site; and a zinc binding group (ZBG) which 
chelates the zinc ion at the base of the active site (Figures 1.4 and 1.5). Although many 
ZBGs such benzamide, carboxylic acid, thiols, etc. have been used to achieve zinc 
chelation, hydroxamic acid remains by far the most employed due to the strength of its 






Figure 1.4: HDACi pharmacophoric model. The various structures displayed under each 
segment represent examples of chemical moieties used in the literature to model the said 
segment. Note the color code, Blue: surface recognition group; Black: linker; Red: Zinc 





Figure 1.5: Example of HDACi. Note the color code, Blue: surface recognition group; 








1.8.2. Mechanisms of action of HDACi 
 Exposure of malignant cells to HDACi can result in phenotypical outcomes such 
as differentiation, immunogenicity, and apoptosis (Figure 1.6).
13
 The induction of 
apoptosis has been linked to an increased reactive oxygen species (ROS) production, 
expression of p21, activation of both extrinsic (death toll receptors) and intrinsic 
(mitochondrial) apoptotic pathways and acetylation of the chaperone HSP90 resulting in 
the degradation of its clients proteins (Figure 1.7).
38
 Furthermore, HDACi downregulate 
proangiogenic factors such as VEGF and genes contributing to metastasis resulting in a 




Figure 1.6: Phenotypical outcome of HDACi on healthy and cancer cells. Exposure of 
malignant cells to HDACi results in two phenotypes: cell cycle arrest leading to 
differentiation or apoptosis, whereas similar cell cycle arrest has no impact on healthy 
cells rendering cancer cells more sensitive to HDACi.
13
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1.9. HDACi clinical trials 
 Since the first clinical trial of the HDACi phenyl butyrate in patients with 
refractory malignancies in the 1990's, there has been a tremendous increase in clinical 
trials exploring the anticancer potential of HDACi (Figure 1.8).
40
 Up-to-date, there have 
been 354 clinical trials reported to clinicaltrials.gov that looked or are looking at HDACi 
as monotherapy or in combination with other chemotherapeutic agents, but the exact 
number may potentially be higher as a time delay can exist between a trial beginning and 
its report date to the database.  
 
Figure 1.8: Clinical trials of HDACi as monotherapy or in combination with other 








1.9.1. Monotherapy trials 
1.9.1.1. Hydroxamic acids       
SAHA (Vorinostat) 
 
 SAHA, a hydroxamate-based HDAC pan-inhibitor, was the first clinically 
approved HDACi by the FDA in 2006 for patients with CTCL.
41
 During one of its 
clinical trials in patients with refractory CTCL, almost 30% of patients showed an 
objective response lasting more than 185 days. Moreover, 21% of participants had been 
relieved of their pruritis, a debilitating symptom often associated with the disease.
42,43
 In 
another trial, up to 45% of pruritic patients saw a reduction of their symptoms.
44
 
Although well tolerated by participants of the trials, administration of SAHA was 
associated with side effects seen with other chemotherapy agents such nausea, vomiting, 







 Following the approval of SAHA, other hydroxamate-based HDACi including 
PCI-24871 have been designed and are currently in clinical trials.  Despite the 
observation of side effects such as nausea, vomiting, fatigue and diarrhea, PCI-24871 was 
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well tolerated and disease stabilization was observed in 5 out of 13 patients with 
refractory advanced solid tumors.
45
 Although the majority of novel hydroxamate based 
HDACi (Figure 1.9) are relative well tolerated by clinical trials participants, early 
indications suggest that they are more efficacious in hematological malignancies 













1.9.1.2. Cyclic peptides 
FK228 (Romidepsin) 
 
 This antibiotic agent isolated from Chromobacterium Violaceum is the second 
HDACi approved for clinical use in patients with CTCL by the FDA in 2009.
47,48
 During 
a phase II trial, it demonstrated a similar response rate as SAHA in patients with CTCL, 
however, the median duration response was significantly higher (13.7 months). 
Furthermore, three patients with Sézary syndrome, the most severe form of the disease, 
had complete remission. Side effects, such as fatigue, nausea and vomiting and 
hematologic abnormalities such as pancytopenia, were observed. In 71% of subjects, an 







 Although this class I selective HDACi has been shown to possess anti-
proliferative effect in preclinical studies 
50,51
 and its oral administration is well tolerated 
during clinical trials
52
, it has shown little to no efficacy in patients with refractory 
 18 
leukemia and metastatic melanoma.
53,54
 This lack of efficacy during the oral 
administration may not be linked to its stability in the plasma as its half life (T1/2) was 




1.9.1.4. Short fatty acid 
 
 This class of HDACi is not as potent as their hydroxamate or benzamide 
congeners but is well tolerated. Valproic acid, a prototypical carboxylic acid based 




1.9.2. Combination therapy of HDACi with other chemotherapy agents 
 Except SAHA and FK228 (Romidepsin), no other HDACi has been approved for 
the treatment of cancer. Clinical indication of these drugs is solely for CTCL, a 
lymphoma, highlighting their lack of efficacy as monotherapy against solid tumors.
56,57,58
 
The only silver lining is the disease stabilization observed during their clinical trials as 
standalone therapeutic agents, suggesting that their combination with other chemotherapy 
may yield more efficacious treatments against solid tumors. Indeed, SAHA, FK228, 
valproic acid and other HDACi inhibitors are currently being evaluated in combination 
with tamoxifen, Isotretinoin, gemcitabine paclitaxel, bortezomib and many other 
drugs.
59,60,39,55
 A potential setback for such combination therapies may be a premature 
development of resistance by the cancer to the other chemotherapeutic used in the 
combination. HDACi, through gene expression modulation, upregulate the P-
 19 
glycoprotein (P-gp) multidrug resistance protein 1 (MDR-1) which efflux chemotherapy 
drugs from cancer cells.
61,62
 As such, the efficacy of the combination chemotherapy 
agents may be undermined by the efflux pumps upregulated upon exposure to HDACi. 
 
1.10. Problems associated with HDACi therapy 
 Besides the lack of clinical efficacy of HDACi against solid tumors, other issues 
have been associated with their clinical trials and use. Like other chemotherapy drugs, 
HDACi are associated with multiple side effects (Table 1.3). I limit my discussion to the 
side effects induced by the FDA approved HDACi as they are the most studied. 
 
1.10.1. Gastrointestinal 
 Nausea and vomiting were commonly observed leading to the prophylactic 
recommendation of anti-emetic. Dehydration was also present in several patients. Other 





 Fatigue was the most common side effect related to HDACi although fever was 
also noted. These effects are believed to be cytokine (Interleukin-6) mediated as they did 





 A transient pancytopenia is associated with HDACi therapy, however, the blood 
counts returned to baseline within 10 days after the removal of the offending agents 
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suggesting a lack of true myelosuppression. Furthermore, in vitro studies revealed that 
the IC50 of FK228 (Romidepsin) during a granulocyte-macrophage colony forming assay 
was greater than 3 μM, whereas its peak plasma concentration was 700 nM in CTCL 






 Based on the side effect profile of HDACi discussed thus far, they appear to be 
well tolerated compared to other chemotherapy agents. However, ECG changes have 
been observed in individuals treated with HDACi leading to an extensive monitoring of 
their cardiac functions. ECG changes described in patients receiving SAHA or FK228 
(Romidepsin) include ST depression and QT prolongation which can lead to the 
potentially fatal ventricular arrhythmia torsades de pointes.
64
 Although the QT 
prolongation due to HDACi may be clinically insignificant, it becomes a greater concern 
in patients with predisposing factors such as diabetes mellitus, obesity, hypothyroidism, 
and long QT syndrome.
65
 Prior cerebrovascular and heart diseases can also exacerbate 
minor QT prolongation.
65,66
 A baseline ECG study in cancer patients prior to therapy 
revealed the existence of cardiac abnormalities such as atrial fibrillation in 36% of 
participants, putting this population group at an increased risk of HDACi induced adverse 
cardiac event.
67
 Predisposition to QT prolongation can be iatrogenic as well. Antiemetics, 
antibiotics, antifungal, and antidepressants which are concomitantly administered with 
chemotherapy drugs to alleviate side effects can increase QT interval.
66,65,68
 Furthermore, 




 Metabolic disturbances such as electrolyte imbalance ensuing from 









Side effects SAHA Romidepsin 
Fatigue 59 53 
Nausea 49 57 
Vomiting 20 38 
Anorexia 38 38 
Weight loss 29 3 
Diarrhea 53 12 
Anemia 23 29 
Thrombocytopenia 39 33 
Neutropenia 4 24 
 
 
1.11. Mechanisms of QT prolongation 
 To date, QT prolongation has been linked to improper cellular trafficking or 




 Opening of the hERG 
channel during the cardiac cycle is required for proper ventricular repolarization, hence 




drugs known to block this membrane protein, thus impeding on K
+
 transport, bind to the 
inner cavity where key aromatic amino acids mitigate hydrophobic interactions with 
various lipophilic molecules.
72
 Although the hERG channel binding is the most accepted 
mechanism of drug-induced QT prolongation, increased degradation rate of the said 
channel can have the same outcome on QT interval as proven by Guo and coworkers with 
probucol, a cholesterol lowering drug known to induce QT prolongation.
73
 Impact of 
HDACi on any key regulators of hERG channel activity such as MinK can also increase 
the QT interval in the absence of direct binding of the HDACi to the channel.
72,74,75
 
Moreover, HDACi, as modulators of gene expression, can affect the expression of the 
hERG channel and that of its coregulators. Finally, the hERG channel has been the sole 
ion channel studied for HDACi-induced QT prolongation, however, enhancement of the 
Na
+
 channel can have similar impact on QT interval as demonstrated with Alfuzosin a 




1.12. Improving HDACi therapy 
 Despite the involvement of HDAC in tumorigenesis, HDAC inhibition as a 
monotherapeutic agent for cancer is only effective and approved in CTCL, highlighting 
the need to develop novel HDACi. Extension of HDACi clinical use to other 
malignancies including solid tumors will require collaboration between researchers in the 





Figure 1.10: Key strategies for improving HDACi therapy.   
 
1.12.1. Drug discovery 
1.12.1.1. Incorporation of cardiac safety assessment in early stages of drug development 
 Currently, measuring the cardiac safety of a drug requires data from early clinical 
studies, where significant financial resources have already been used. To minimize the 
financial loss caused by failed clinical trials, incorporating a cardiac safety assay during 
the early (pre-clinical) stages of the drug development is an attractive avenue. Doing so 
will not only be beneficial for HDACi but also for other drugs as well. Shultz and his 
coworkers have used this method to develop HDACi with no hERG channel binding and 
potentially safe for the endocardium, however, clinical data is still needed to ensure that 





1.12.1.2. Isoform selective HDACi 
 Most HDACi shown to increase the QT interval clinically are pan-inhibitors.
78
 
Although hERG channel blocking has been the most accepted mechanism of 
cardiotoxicity of these drugs, it is conceivable that inhibition of class IIa isoforms may 
generate cardiotoxicity as HDAC5 and 9 have been shown to be cardioprotective by 
preventing the stress-induced cardiac remodeling.
79
 Furthermore, these class IIa isoforms 
are not overexpressed in cancer as their class I congeners rendering their inhibition 
unnecessary. These facts suggest that isoform selective inhibitors devoid of class IIa 
inhibition may have fewer side effects and be well tolerated than the pan-inhibitors. 
Indeed earlier clinical trials results seem to support this observation as MS275 and CI-
994, class I selective HDACi, are well tolerated and lack any QT effects.
78
 The safety of 
isoform selective HDACi extend beyond that of class I selective compounds as ACY-
1215, a selective HDAC6 (class IIb) inhibitor, is also safe with no dose-limiting 
toxicity.
80
 If selective HDACi are well tolerated during clinical trials, the jury is still out 
when it comes to their efficacy as a monotherapy, although clinical trials with MS275 
point to a lack of therapeutic efficacy.
53,54
 From a safety standpoint, isoform selective 
inhibitors are an attractive way for boosting clinical development and use of HDACi, 
however, their lack of efficacy highlighted during preliminary clinical trials suggest that 
their combination with other chemotherapy agents that are not substrates of the efflux 





1.12.1.3. Targeted delivery of HDACi 
 The clinically approved SAHA, a pan-inhibitor, is efficacious as a single agent 
against CTCL whereas most isoform selective inhibitors are not. These observations 
point to pan-inhibitors as the sole HDACi with potential use as monotherapy agents 
against cancer. In such a case, addressing the side effects (cardiotoxicity) ensuing from 
HDAC pan-inhibition becomes primordial. Targeting these small molecules has the 
potential of increasing their intratumoral concentration while minimizing delivery to 
healthy cells. This may not only address HDACi off target cytotoxic profile but also 
solve their lack of efficacy against solid tumors. The basic methodology for this targeted 
delivery which is localized administration is currently being evaluated in clinical trial 
through the use of the topical formulation of FK228 (Romidepsin) for CTCL patients 
with limited disease.
81
 Minimal systemic exposure of FK228 (Romidepsin) in this 
formulation may lessen its side effects. A prodrug strategy has also been utilized to 
selectively accumulate the HDACi CHR-2845 in monocytes/macrophages and monocytic 
malignancies expressing the intracellular esterase human carboxylesterase-1 (hCE1).
82
 
Subsequent hydrolysis of the cell permeable CHR-2845 results in a charged molecule 
whose intracellular accumulation leads to a 20- to 100-fold increase in potency against 
tumors from monocytic lineage while being well tolerated by patients.
83
 Another active 
targeting approach which has yet to go into clinical trials has been developed in our 
laboratory. This involves the modification of the HDACi pharmacophoric model to 
include ligands such as folic acid, antiestrogens and antiandrogen, whose receptors’ 
expression is upregulated in cancer cells, leading to a selective accumulation in malignant 
cells (Figure 1.11) (Unpublished data).
84,85
 An alternate choice of ligand such as 
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macrolides can result in selective HDACi accumulation in the lung enabling the targeting 
of various cancers involving this organ.
86
 The attractiveness of our active targeting 
strategies lies in their potential to minimize side effects while boosting anticancer activity 
against tumors. Recent studies have described the de novo expression of hERG channel in 





suggesting a potentially novel mechanism of action for the HDACi with affinity for the 
hERG channel. The targeted delivery of these inhibitors will ensure the selective 




































Figure 1.11: Active targeting of HDACi. A) The malignant cell overexpresses on its 
plasma membrane the receptors of a ligand required for its metabolism such as folate; B) 
The HDACi is conjugated to the ligand and exposed to the cell leading to binding of the 
ligand/HDACi complex to the receptors; C) Endocytosis of the HDACi/ligand 
conjugates; D) Release of the HDACi/ligand conjugates from the receptors and escape 
from the endosome into cytoplasm; E) Recycling of the receptors to cell surface; F) The 
HDACi is in the cytoplasm where it can hit its target (cytoplasmic HDAC isoforms) or 















1.12.2. Clinical improvement to HDACi therapy 
 Designing isoform-selective HDACi or targeting their delivery to malignant cells 
are only the initial steps in the endeavor aiming at making HDACi part of our medicine 
cabinets. The steps needed to be taken from the clinical standpoint are equally as 
important as those asked from the drug discovery field. 
 
1.12.2.1. Patients stratification 
 Patient care has been moving towards personalized medicine since the advent of 
the human genome sequencing. This novel approach to medicine aims at developing 
diagnostic and therapeutic tools based on individual or patient specific biomarkers.
88
 The 
use of HDACi for cancer treatment fits well with this main objective of personalized 
medicine as the HDAC overexpression pattern may vary from one patient to another. It 
becomes crucial to identify the patient population that may benefit from a specific 
HDACi as to not only maximize positive outcome from clinical trials but also the 
therapeutic benefits for patients. The implementation of personalized medicine in HDACi 
therapy should lead to a systematic profiling of intratumoral HDAC isoforms in patients 
and the modification of the HDACi clinical trial inclusion criteria to include the 
overexpression of HDAC isozymes shown to be inhibited by the said HDACi during 
preclinical studies. The HDACs overexpression status is a specific example that can 





1.12.2.2. Identification and use of predictive biomarkers 
 HDAC enzymes as biomarkers for HDACi therapy are attractive options, 
however, certain tumors may be sensitive to HDACi despite lacking HDACs 
overexpression.  As such, the use of predictive biomarkers can be beneficial. A marker 
which has recently garnered attention is HR23B, a protein which transports ubiquitinated 
substrates to the proteosome for degradation.
89
 In various CTCL cell lines, depletion of 
HR23B through siRNA resulted in resistance to SAHA-induced apoptosis suggesting a 
positive correlation between HR23B level and the responsiveness to HDACi.
90
 
Furthermore, an analysis of biopsies from CTCL patients who received SAHA during a 
phase II clinical trial corroborates the aforementioned positive correlation. Individuals 
whose biopsies showed marked expression of HR23B prior to the treatment had an 
objective response rate of 68.8%, giving HR23B a positive predictive value (PPV) of 
nearly 70%.
90
 Similar PPVs were also observed in CTCL patients receiving other HDACi 
such as FK228 (Romidepsin), LBH589.
90
 To highlight the importance of the HR23B as a 
positive predictor of response to HDACi therapy, a clinical trial evaluating the novel 
HDACi CXD101 has established a high HR23B expression as an inclusion criterion in 
patients with solid tumors, lymphoma and myeloma.
91
     
 
1.12.2.3. Understanding the mechanisms of HDACi-induced side effects 
 The side effects of HDACi can be minimized but never completely eliminated. As 
such, management of these adverse reactions is important, but one ought to first 
understand the mechanism of these side effects. Unlike most anticancer agents, whose 




thrombocytopenia is not due to a reduction in platelets half-life but to a decreased 
shedding of platelets from megakaryocytes.
93,94
 Moreover, a megakaryocyte hyperplasia 
was observed due to an increase in thrombopoietin (TPO). Despite the supraphysiological 
level of TPO, the transient TCP was overcome by the counterintuitive use of the TPO 
mimetic AMP-4. The example of HDACi-induced TCP represents a vivid example where 
the understanding of the mechanism of side effects can yield a clinical management 
protocol for patients receiving HDACi. 
 
1.12.2.4. Understanding of mechanisms of resistance to HDACi 
 Though certain mechanisms of resistance to HDACi have been described, there 
are still many which remained to be elucidated. The understanding of such mechanisms 
may not only help in the patients stratification by selecting individuals whose 
malignancies are sensitive to HDACi but also in the design of combination therapy with 
other agents which can interfere with the HDACi resistance pathways. 
 
1.13. Conclusion 
 Epigenetic mechanisms such DNA methylation, histones positioning and post-
translational histone modifications are involved in various cellular processes including 
pathological conditions. Among the covalent histone modifications, acetylation and 
deacetylation have been shown to be indispensable for the regulation of more than 2000 
proteins and implicated in various diseases including cancer, making HATs and HDACs 
important targets in cancer therapy. HDACi have been investigated in several clinical 
trials culminating with the approvals of SAHA and FK228 (Romidepsin) for CTCL. 
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Despite the successes of these drugs, the full therapeutic potential of HDACi in cancer 
remains untapped due to severe cardiotoxicity or lack of efficacy in solid tumors. 
Expanding the clinical indications of HDACi in our pharmacopeia may require designing 
isoform-selective HDACi, thus sparing the cardioprotective effects of class IIa isoforms, 
targeting pan-inhibitors to cancer cells, using predictive biomarkers such as HR23B to 
identify the patients population who can benefit from HDACi and understanding the 
mechanisms of side effects in order to provide a better clinical management of HDACi-
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ISOFORM SELECTIVE HDAC INHIBITORS 
This work has been published in two articles:  
 
Journal of Medicinal Chemistry 2013, 56 (9), 3492-3506  





 Due to their role as transcription repressors, HDACs are overexpressed in various 
malignancies establishing them as valid targets for cancer therapy.
1
 Among the 11 zinc 
dependent HDAC isoforms identified to date, isoforms 1, 2 and 3 are overexpressed in 
gastric, colorectal and ovarian carcinomas whereas hepatocellular carcinoma and 
estrogen receptor positive (ER+) breast cancer overexpress HDAC1 and 6, respectively.
2
 
The observed correlation between these malignancies and HDAC isoforms 
overexpression suggests that isoform selective inhibitors may be equally as effective as 
HDAC pan-inhibitor such as SAHA for cancer chemotherapy. For example, an HDAC1 
selective inhibitor can be effective against hepatocellular carcinoma and class I selective 
HDACi against gastric and colorectal cancers. 
 Each HDAC isoform possesses a specific role in proper cellular homeostasis as 
demonstrated through a series of knockout experiments in mice (Table 2.1). Such studies 
established the requirement of HDAC1 in cellular proliferation, whereas HDAC3 and 5 
were indispensable for cardiomyocytes development and function respectively.
3
 
Furthermore, there are many cellular processes (metabolic enzymes, chaperones, etc) 
requiring the involvement of an HDAC or HAT (Figure 2.1).
4
 A pan-inhibitor of HDAC 
can interfere with all the pathways aforementioned in healthy cells and result in severe 
side effects. In such instances, cancer patients stand to benefit from isoform selective 
 42 
HDAC inhibitors as the specific isoform overexpressed can be targeted while minimizing 
inhibition of other isoforms not involved in the tumorigenesis. 




Class Isoforms Phenotype Related disease 
 
I 
1 Lethal. Severe proliferation 
defects 
- 
2 Death 24 hrs after birth. 
Severe cardiac defect 
Cardiac diseases 






4 Lethal Skeletal diseases 
5 Viable but cardiac defects Cardiac diseases 
7 Embryonic lethality. 
Vascular instability 
Vascular diseases 
9 Viable but cardiac defects Cardiac diseases 

























Most HDACi, including the clinically useful SAHA, fit a pharmacophoric model 
comprised of a surface recognition group connected by a linker to a zinc binding group 




 Approaches to designing 
isoform selective inhibitors include modifications of the surface recognition group or the 
ZBG as to exploit the differences in amino acids sequences in each isoform.
6,7
 
                                                
                                                                   i) 
                     
                          ii)                                                             iii) 
                           
                           iv)                                                               v) 
Figure 2.2: Structures of selected HDACi: i) HDACi pharmacophoric model with SAHA 
as prototypical HDACi (Note color code: Blue, surface recognition group; Black, linker; 
Red, ZBG); ii) Tubastatin A as an HDAC6 selective inhibitor
6
 (Example of surface 
recognition group modification); iii) MS275 as an HDAC1 selective inhibitor
7
 (Example 
of ZBG modification); iv) 1
st














2.2. 3-hydroxypyridin-2-thione as novel ZBG for HDAC inhibition 
 A vast majority of HDACi have incorporated the hydroxamic acid as the preferred 
ZBG due to its strong Zn
2+
 chelation. However, due to pharmacokinetic challenges ( 
short half-life) ensuing from enzymatic hydrolysis and poor bioavailability 
10,11,12
, 
extensive efforts have been deployed to develop novel ZBG for HDAC inhibition.
13,14
 A 
fragment-based approach used in our laboratory by Dr. Vishal Patil has identified 
previously used zinc chelating moieties for matrix metalloproteases (MMP) inhibition as 
potential candidates for HDAC inhibition. He identified the 3-hydroxypyridin-2-thione 
(3-HPT) as a valid replacement for the metabolically liable hydroxamate resulting in the 
synthesis of the first generation of 3-HPT based inhibitors with phenyl or biphenyl 
linkers and second generation of inhibitors with alkyl linkers.
8,9
 Furthermore, the 3-HPT 
conferred isoform selectivity as the 3-HPT based inhibitors were devoid of HDAC1 












Table 2.2: Inhibition of HDAC1, 6 and 8 by 1
st
 generation 3-HPT based inhibitors. 
 
Compound R HDAC1 
 IC50 (nM) 
HDAC6 
 IC50 (nM) 
HDAC8 
 IC50 (nM) 
1 
 
NI 457 ± 27 1272±200 
2 
 













NI 372 ± 35 1907±771 
6 
 




NI 812 ± 286 2496±1180 
8 
 




NI NI 2858±944 
10 
 






2204 ± 355 2780±323 
12 
 
NI 41% 1570±1067 
13 
 
NI 1023 ± 99 1868±723 
SAHA - 38 ± 2 144 ± 23 232 ± 19 
NI: No Inhibition (below 20% Inhibition at 10 µM concentration) 
% inhibition of the compounds at 10 µM are given if the IC50 was above 10 µM                                                                
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Table 2.3: Inhibition of HDAC1, 6 and 8 by 2
nd
 generation 3-HPT inhibitors.  
 











2 NI 14% 56% 
 




16 4 NI 1085±333 3303±260 
17 5 NI 911± 173 917±139 
18 
 
6 NI 22% 6751±910 
 













NI 807 ± 207 
 
2533 ± 823 
21 
 
NI 1100  443 
 
1660 ± 416 
22 
 
NI 637 ± 160 2402 ± 263 
23 
 













NI 661 ± 121 
 
2258 ± 1005 
SAHA - - 38±2 144±23 232±19 
NI: No Inhibition (below 20% Inhibition at 10 µM concentration) 





2.3. Anticancer activity of the 1
st
 generation of 3-HPT based inhibitors 
 Using the MTS assay, I evaluated the anticancer activity of several of these 1
st 
generation compounds in cell lines such as DU145 (androgen independent prostate 
cancer), LNCaP (androgen dependent prostate cancer) and the T-cell leukemia cell line 
Jurkat.  The tested compounds included a selective HDAC8 inhibitor 9, dual inhibitors of 
HDAC6 and 8, 5 and 8, and a triazole-based inhibitor 12 that was selective for HDAC8.  
 Although 3-HPT is active against HDAC6 (IC50 = 681 ± 110 nM) and to some 
extend against HDAC8 (IC50 = 3675 ± 1201 nM), it is inactive against the three cancer 
cell lines tested (Table 2.4). The discrepancy between the HDAC inhibition profile and 
the anti-proliferative activity of 3-HPT may be due to solubility problems that limit its 
diffusion across the cell membrane.
15
 Against DU145, a prostate cancer line known to be 
responsive to HDACi such as SAHA or TSA, only 8 exhibited a weak activity; all other 
compounds were inactive at the highest tested concentration of 20 μM (Table 2.4). 
SAHA, which was used as a positive control, had an IC50 value comparable to that 
reported in the literature.
16
  
The compounds were more active on the LNCaP cell line (Table 2.4). Compound 
8 is the most potent of the biphenyls, followed by 5 and 9. Interestingly, the cell growth 
inhibition activity of the triazolyl compound 12 is comparable to that of 5 although 12 is 
a weak HDAC6 inhibitor (only 41% inhibition at 10μM). With the exception of 12, the 
observed trend of the cell growth inhibition activity mirrored that of the HDAC6 
inhibition seen in Table 2. This may be due to the fact that LNCaP cells are sensitive to 
the acetylation state of HSP90. Hyperacetylation of HSP90, induced by the tested 3-HPT 
 48 
derived HDACi, attenuates its  interactions with proteins such as androgen receptors, 






Table 2.4: MTS Cell Viability Assay. IC50 of selected 1
st
 generation of 3-HPT based 








NI NI NT 
5 >20 14.7 ± 0.8 9.0 ± 0.7 NT 
8 13.6 ± 2.9 7.8 ± 0.7 3.2 ± 0.3 NI 
9 >20
 
16.2 ± 1.1 10.6 ± 0.7 NI 
12 >20 13.1 ± 1.5 4.7 ± 0.3 NI 
SAHA 2.5 ± 0.2 2.3 ± 0.7 1.5 ± 0.1 NI 
NT = Not Tested; NI = No inhibition 
 
 
Because T-cell-derived leukemia cell line Jurkat has been previously shown to be 
sensitive to selective HDAC8 inhibitor,
19
 we investigated the effects of our compounds 
on the viability of Jurkat cells. Overall, all the compounds, excluding 3-HPT, potently 
induce Jurkat cell death with low IC50 values (Table 2.4). Compound 8, which inhibited 
both HDAC6 and HDAC8, is the most potent against the Jurkat cells (IC50 = 3.19 µM) in 
a similar manner to its activity against LNCaP cells. The HDAC8 selective compounds 9 
and 12 are cytotoxic to the Jurkat cells with 12, the more potent HDAC8 inhibitor of the 
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two, being twice as potent. The enhanced cytotoxicity of 12 relative to 9 could suggest a 
causal relationship between HDAC8 inhibition and the apoptotic effect against Jurkat 
cells.  
 The apoptotic pathway, which is mediated by the activity of phospholipase C-γ1 
(PLC-γ1) in Jurkat cells,  is believed to be initiated by an HDAC8 specific enzyme.
19
 
Balasubramanian and coworkers reported that an HDAC8 specific inhibitor, PCI-34051, 
lost its ability to induce apoptosis in Jurkat J.γ, a mutant Jurkat cell line which has no 
detectable PLC-γ1 activity.
19
 To further delineate the contribution of HDAC8 to 
apoptosis induction, we probed the effect of compounds 8, 9, 12 and SAHA on the 
viability of Jurkat J.γ cells.  As anticipated for HDAC8 selective inhibitors, compounds 9 
and 12 are devoid of anti-proliferative activity against Jurkat J.γ (Table 2.4). Quite 
unexpectedly, 8 (which inhibited HDACs 6 and 8) and SAHA (a much broader HDACi) 
are non-cytotoxic to this mutant Jurkat cell line. The inactivity of 9 and 12 against Jurkat 
J.γ confirmed HDAC8 contribution to their bioactivity. In the Jurkat cell line, Ca
2+
 
released through PLC-γ1 triggers cascade of events resulting in mitochondrial 
cytochrome c release and caspase-dependent apoptosis. The defect in intracellular Ca
2+
 
mobilization in the Jurkat J.γ mutant may also explain the inactivity of 8 and SAHA as 
this prevents the increase in cytochrome c release observed in the wild type Jurkat.
19
 
Alternatively, the observed dependence of the cytotoxicity activity of 8 and SAHA on 
PLC-γ1 activity may be due to the attenuation of caspase-dependent apoptosis which is 
crucial for the cytotoxicity of HDACi.  
 There is a discrepancy between HDAC inhibition and the whole cell activities of 
some of the tested compounds. This is to be expected as it is not unusual to observe such 
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a lack of correlation between the two experiments. It is however possible that compound 
solubility could play a significant role in cell penetration which may perturb the whole 
cell activities. Therefore, we estimated the solubility of all compounds tested in cell 
growth inhibition assay to probe for the effect of solubility on anti-proliferative activity 
(Table 2. 5). 
 
Table 2.5: Aqueous solubility of selected 1
st
 generation 3-HPT inhibitors.  







* 40 mM DMSO stock solution was made in order to 
achieve final concentrations above 500 µM 
 
 
  Among these compounds, 3-HPT and 9 had solubility less than 65µg/mL which 
is the solubility threshold that can limit a drug's cellular activity. For these two 
compounds, poor solubility may explain the lack of cellular activity.
20, 21
 However, the 
solubility of the other compounds tested are beyond the suggested solubility threshold.
20, 
21
 Hence, the reduced efficacy of many of these compounds may be attributable to factors 
other than solubility issues.  
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2.4. Anticancer activity of 2
nd
 generation 3-HPT inhibitors 
 We also tested selected 2
nd
 generation 3-HPT based compounds 17 and 24 and 
comparable compounds 19 and 22 on the survival of DU145, LNCaP, T-cell leukemia 
cell line Jurkat and Jurkat J.γ, a mutant Jurkat cell line resistant to HDAC inhibition using 
the MTS assay.
8,19
   
  Table 2.6 shows the IC50 values of each compound against the cancer cell lines 
studied. The lead meta-cyano compound 24 is about 2-fold more potent, relative to the 
unsubstituted congener 19, against DU145 and LNCaP prostate cancer cell lines. Such 
improved sensitivity with 24 toward prostate cancer lines, particularly LNCaP, may be 
rationalized by its HDAC6 selectivity.
22
 Inhibition of HSP90 has been shown to 
compromise the viability of DU145 offering a similar rationale for the enhanced 
cytotoxicity of 17 against this cell line.
23,17
 Compounds 17 and 24 are equipotent against 
the wild type Jurkat cell line, despite the enhanced HDAC8 inhibition activity of the 
former (Table 2.3) which is expected to favor cytotoxicity to the Jurkat cell line.
19,24
 It is 
reasonable that the compensation of the weaker HDAC8 inhibition activity of 24 by the 
3-fold increase in its anti-HDAC6, relative to that of 17, may contribute to its cytotoxicity 
in the Jurkat cell. The cytotoxicity of 19, analog containing a seven-methylene linker, and 
the ortho-methyl substituted five-methylene compound 22 do not completely trend with 
the pattern of their HDAC inhibition activities. Against both prostate cancer lines 
investigated, 19 is 2- and 3-fold less cytotoxic compared with lead compounds 17 and 24 
respectively, while it is 3-fold less cytotoxic relative to both lead compounds against the 
wild type Jurkat cell line. The ortho-substituted compound 22 is 2-fold less cytotoxic 
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against DU145 while it is only marginally less cytotoxic against LNCaP and wild type 
Jurkat cell line compared with 24. 
Although 17 and 19 have similar IC50 against HDAC6, the latter has a 
significantly higher cellular IC50 against LNCaP cells. Against Jurkat cell line, 22 and 24 
also display similar incongruity, which we first attributed to solubility differences. To 
partially account for such pharmacokinetic liabilities, we estimated the solubility of each 
tested compound 
20,21
 but found that the four compounds had solubilities greater than the 
threshold of 65 μg/mL proposed to adversely affect cell activity (Table 2.7). This 
suggests that the observed discrepancies may be attributed to factors other than solubility. 
 
Table 2.6. MTS Cell Viability Assay. IC50 of selected 2
nd
 generation of 3-HPT based 




DU-145 LNCaP Jurkat Jurkat J.γ Vero 
17 9.3 ± 1.0 
5.4 ± 0.5 3.3 ± 0.60 
1.9 ± 0.2 >20  
19 17.7 ± 3.3 
11.0 ± 1.9 9.0 ± 1.3 >20 
NT 
22 11.1 ± 2.4 
5.0 ± 0.4 5.2 ± 1.2 NT 
NT 
24 5.0 ± 1.1 
3.5 ± 0.3 3.4 ± 0.6 0.90 ± 0.1 
>20 
SAHA 2.5 ± 0.2 2.3 ± 0.7 1.5 ± 0.1 NI 5.2 ± 1.0* 
Tubastatin A NT 10.9 ± 1.5 3.4 ± 0.3 NI >20 
 NT: Not Tested  
NI: No inhibition at 20μM; * :reference 
25




Table 2.7: Aqueous solubility of selected 2
nd
 generation 3-HPT based inhibitors. 






We have shown previously that the Jurkat Jγ cell line, a mutant Jurkat cell line 
lacking phospholipase C activity, is resistant to SAHA.
8
 To check if the 2
nd
 generation 3-
HPT compounds would be similarly innocuous, we investigated the effect of the lead 
compounds 17, 19 and 24 on Jurkat Jγ cell growth. We observed that compound 19 is 
significantly less cytotoxic to Jurkat Jγ cells versus their wild type counterpart. 
Surprisingly, both 17 and 24 are potently cytotoxic to Jurkat Jγ cells with IC50 values of 1 
and 2 µM respectively. Comparatively, the IC50s of 17 and 24 against the healthy 
mammalian cell line Vero were estimated to be greater than 20μM, the highest tested 
concentration (Table 2.6). In order to indirectly evaluate the contribution of HDAC6 
inhibition to the anticancer activity of the compounds, the anti-proliferative activity of the 
HDAC6 selective inhibitor tubastatin A was evaluated against these cell lines as well. 
Although tubastatin A was as potent as 17 and 24 in Jurkat cells, it was 2 to 3 fold less 
potent against LNCaP and inactive against Jurkat Jγ (Table 2.6). Given that the pan-
inhibitor SAHA and the HDAC6 selective tubastatin A are inactive against Jurkat Jγ, the 
cytotoxic activity of lead compounds 17 and 24 against Jurkat Jγ could be through 
inhibition of other yet to be identified cellular target(s).     
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Toward identifying other possible targets of the lead compounds 17 and 24, we 
screened for their effect on the activity of a collection matrix metalloproteases (MMPs) 
which have been suggested to be involved in apoptosis.
26
 The rationale for screening 
against MMPs is based on the fact that 3HPT has been previously used as ZBG for MMP 
inhibition.
27
 At the tested concentration of 10μM, 17 and 24 were inactive against 
MMP1, 2, 3, 7, 9 and 14, while the activity of MMP13 was halved at this very high 
concentration (Figure 2.3). Despite the inhibition of MMP13, MMP inhibition is less 
likely to have contributed to the observed cellular activity as the HDAC enzymatic IC50s 
were in the nanomolar range. We also tested these lead compounds against HDAC2 
which has been shown to be upregulated in certain malignancies and whose inhibition 
could result in apoptosis.
28,29
 However, the IC50 of 17 and 24 were 5840 ± 740 nM and 
3680 ± 800 nM respectively suggesting that HDAC2 may not be a target responsible for 












2.5. Intracellular target validation of 3-HPT based inhibitors 
 Among the 1
st
 generation compounds tested for anti-cancer activity, 8 is 
approximately 10-fold more selective toward HDAC6 compared to HDAC8. To probe 
the contribution of HDAC6 inhibition to the cytotoxic activity of 8, we determined the 
level of tubulin acetylation, a common marker for intracellular HDAC6 inhibition, in 
LNCaP cells through Western blot. We observed that 8 led to an increase in tubulin 
acetylation in LNCaP cells at IC50 concentration and at 20μM (Figure 2.4). While SAHA, 
used as a positive control, showed concentration dependent tubulin hyperacetylation as 
observed before.
30
 This data provides evidence for the involvement of intracellular 
HDAC6 inhibition as part of the mechanisms of anti-proliferative activity of 8.  
 
         1                2                3                 4                      5 
          Acetylated-Tubulin  
         Tubulin 
         Actin 
Figure 2.4: Western blot analysis of tubulin acetylation (HDAC6 inhibition) in LNCaP 
cell line (1
st
 generation 3-HPT based inhibitors). Lanes - 1. SAHA (20 μM); 2. SAHA 
IC50 (2.31 μM); 3. Control; 4. 8 (20 μM); 5. 8 IC50 (7.75 μM).  
 
 
 The data presented above showed that some of these 2
nd 
generation 3-HPT based 
compounds were HDAC6 inhibitors (Table 2.3); we nevertheless sought to confirm the 
involvement of HDAC6 inhibition in the mechanism of action of compounds 17 and 24. 
We examined the level of tubulin acetylation in LNCaP cells following exposure to 17, 
24 
31
 and the positive control SAHA. We observed that 17 and 24 increased tubulin 
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acetylation but to a lesser extent than SAHA (Figure 2.5). These data propose that 
compounds 17 and 24 may derive their anti-proliferative effects in LNCaP cell line from 
an HDAC6-dependent pathway.  
     1          2          3         4        5       6          7 
 Acetylated tubulin 
Tubulin 
Actin 
Figure 2.5. Western blot analysis of tubulin acetylation (HDAC6 inhibition) in LNCaP 
cell line (2
nd
 generation 3-HPT based inhibitors). Lanes - 1. 17 (20 μM); 2. 17 (5.43 μM – 
IC50); 3. 24 (20 μM); 4. 24 (3.49 μM – IC50); 5. SAHA (20 μM); 6. SAHA (2.31 μM – 




 In an attempt to address the metabolic liabilities and the pan-inhibition of the 
prototypical HDACi SAHA, a fragment-based approach was used in our laboratory to 





 generations of HDACi with 3HPT as ZBG. All the 3HPT derived 
compounds reported herein are inactive against HDAC1 but many possessed varying 
degrees of activity against HDAC6 and HDAC8. Additionally, a subset of these 
compounds is cytotoxic to various cancer cell lines including Jurkat J-γ1 against which 
SAHA and Tubastatin A are inactive. The increase in acetylated tubulin level induced by 
representative compounds confirmed the contribution of HDAC6 inhibition to their 
bioactivity. Due to their anticipated immunity to many of the metabolic and 
pharmacokinetic that has beleaguered the hydroxamate, these 3HPT derived HDACi may 
display improved in vivo activity. 
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2.7. General procedures and experimental 
 DU145, LNCaP, Jurkat J.γ were obtained from ATCC (Manassas, VA, USA), 
Jurkat E6-1 cell line was kindly donated by Dr. John McDonald and grown on 
recommended medium supplemented with 10% fetal bovine serum ( Global Cell 
Solutions, Charlottesville, VA, USA) and 1% pen/strep (Cellgro, Manassas, VA) at 37°C 
in an incubator with 5% CO2. Mouse anti-acetylated α-Tubulin antibody was obtained 
from Invitrogen (Life Technologies, Grand Island, NY, USA), rabbit anti-actin, rabbit 
anti-tubulin α antibodies and Tubastatin A were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Secondary antibodies, goat anti-rabbit conjugated to IRDye680 and 
goat anti-mouse conjugated to IRDye800 were purchased from LI-COR Biosciences 
(Lincoln, NE, USA). The CellTiter 96 AQueous One Solution Cell Proliferation assay 
(MTS) kit was purchased from Promega (Madison, WI, USA). 
 
2.7.1. Histone deacetylase inhibition (Performed by James Kornacki at 
Northwestern University) 
 The HDAC activity in presence of various compounds was assessed by SAMDI 
mass spectrometry. As a label-free technique, SAMDI is compatible with a broad range 
of native peptide substrates without requiring potentially disruptive fluorophores.   To 
obtain IC50 values, we incubated isoform-optimized substrates (50μM, detailed below) 
with enzyme (250nM, detailed below) and inhibitor (at concentrations ranging from 
10nM to 1.0mM), in HDAC buffer (25.0 mM Tris-HCl pH 8.0, 140 mM NaCl, 3.0 mM 
KCl, 1.0 mM MgCl2, 0.1 mg/mL BSA) in 96-well microtiter plates (60 min, 37°C). 
Solution-phase deacetylation reactions were quenched with trichostatin A (TSA) and 
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transferred to SAMDI plates to immobilize the substrate components. SAMDI plates 
were composed of an array of self-assembled monolayers (SAMs) presenting maleimide 
in standard 384-well format for high-throughput handling capability. Following 
immobilization, plates were washed to remove buffer constituents, enzyme, inhibitor, and 
any unbound substrate and analyzed by MALDI mass spectrometry using automated 
protocols.
32
 Deacetylation yields in each triplicate sample were determined from the 
integrated peak intensities of the molecular ions for the substrate and the deacetylated 
product ion by taking the ratio of the former over the sum of both. Yields were plotted 
with respect to inhibitor concentration and fitted to obtain IC50 values for each isoform-
inhibitor pair.  
 Isoform-optimized substrates were prepared by traditional FMOC solid phase 
peptide synthesis (reagents supplied by Anaspec) and purified by semi preparative HPLC 
on a reverse phase C18 column (Waters). The peptide of sequence GRK
ac
FGC was 
prepared for HDAC1 and HDAC8 experiments, while the peptide of sequence 
GRK
ac
YGC was prepared for HDAC6 and HDAC2 experiments. Isoform preference for 
the indicated substrates was determined by earlier studies on peptide arrays.
33
 
 HDAC1, HDAC6, and HDAC2 were purchased from BPS Biosciences. The 
catalytic domain of HDAC8 was expressed as previously reported.
33
 Briefly, an amplicon 
was prepared by PCR with the following primers: forward 5’-3’ 
TATTCTCGAGGACCACATGCTTCA and reverse 5’-3’  
ATAAGCTAGCATGGAGGAGCCGGA. A pET21a construct bearing the genetic insert 
between NheI and Xho1 restriction sites was transformed into E. coli BL21(DE3) 
(Lucigen) and expressed by standard protocols. Following purification by affinity 
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chromatography, the His-tagged enzyme-containing fractions were purified by FPLC 
(AKTA) on a superdex size exclusion column (GE), spin concentrated, and stored at -
80°C in HDAC buffer with 10% glycerol. 
 
2.7.2. Cell viability assay 
 DU145 and Vero cells were maintained in EMEM and DMEM respectively 
supplemented with 10 % FBS and 1% pen/strep while all other cell lines were maintained 
in RPMI 1640 supplemented with 10 % FBS and 1% pen/strep. DU145, Vero and LNCaP 
cells were incubated on a 96-wells plate (4500 cells/well) for 24 hours prior to a 72 hours 
drug treatment while Jurkat and Jurkat J.γ cells (25,000 cells/well) were incubated in 
media containing the various compounds for 72 hours. Cell viability was measured using 
the MTS assay according to manufacturer protocol (Promega, CellTiter 96® AQueous One 
Solution Cell Proliferation Assay, Catalog# G3580). The DMSO concentration in the cell 
media during the cell viability experiment was maintained at 0.1%.   
  
2.7.3. Solubility Measurement 
 This experiment was performed according to reported protocol using a 10 mM 
stock solution of the test compound in DMSO.
20
 The DMSO was kept at 5% of the final 
volume. Following incubation at room temperature and centrifugation to remove 
precipitate, the absorbance was measured using a UV-vis spectrophotometer (Varian, 




2.7.4. Western blot analysis for tubulin acetylation 
 LNCaP cells were plated for 24 hours and treated with various concentrations of 
compounds for 4 hours. The cells were washed with PBS buffer and resuspended in 
CelLytic™M buffer containing a cocktail of protease inhibitor (Sigma-Aldrich, St. Louis, 
MO, USA). Following quantification through a Bradford protein assay, equal amount of 
protein was loaded onto an SDS-page gel (Bio-Rad, Hercules, CA, USA) and resolved by 
electrophoresis at a constant voltage of 100V for 2 hours. The gel was transfer onto a 
nitrocellulose membrane and probed for selected proteins using primary antibodies 
against: for acetylated tubulin (LifeTechnologies, catalog# 32-2700), tubulin (Sigma-
Aldrich, catalog# SAB4500087) and actin (Sigma-Aldrich, catalog# A2066).  
 
2.7.5. MMP assay 
 MMP inhibitor profiling kit was purchased from Enzo Life Sciences 
(Farmingdale, NY). The selection of the MMP tested was guided by the reported anti-
proliferative of AG3340, a MMP inhibitor selective for isoforms 1, 2, 3, 7, 9, 13, 14.
26
 
Each MMP was incubated with the inhibitor (10μM) for 30 minutes at 37°C in the assay 
buffer. The OmniMMP™ fluorogenic substrate peptide was added and the reaction was 
allowed to proceed at 37°C for 30 minutes. The fluorescence was measured using a 








2.7.6. Statistical analysis 
 The values reported as mean ± standard deviation from at least 2 independent 
triplicate experiments. A student’s t-test was performed in Excel, and results with p value 
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TARGETED DELIVERY OF HDAC INHIBITORS USING FOLATE 




Recent advances in cancer biology have led to the identification of novel targets 
for cancer therapy.
1,2
 Such, targets include histone deacetylases (HDACs) which are 
components of the cellular epigenetic machinery.
3,4,5
 There are 11 zinc dependent HDAC 
isoforms grouped into 3 classes (Classes I, II and IV) and 7 NAD
+
 dependent which form 
the class III. The class I include HDAC1, 2, 3 and 8 located in the nucleus. Isoforms 4, 5, 
7 and 9 constitute the class IIa which shuttle between the nucleus and the cytoplasm. The 
cytoplasmic HDAC6 and 10 are members of the class IIb and HDAC11 represents the 
sole member of class IV. HDACs catalyze the removal of acetyl group from lysine 
residues of histones tail resulting in favorable electrostatic interactions between the 
phosphate backbone of DNA and the positively charged lysine residues. Such interactions 
lead to chromatin condensation which concomitantly impedes the access of transcription 
factors to promoter segments within the condensed chromatin.
3
 HDACs substrates are not 
limited to histone proteins. Other non-histone proteins whose activities are directly 
regulated by HDACs include HSP90, tubulin, androgen receptors, p53 etc.
6,7
 The activity 
of the HDACs is counterbalanced by histone acetyl transferases (HATs) which add acetyl 
groups to lysine residues.
3
 
Due to their involvement in gene expression regulation, HDACs are recruited into 
various complexes by many cancers to purposely silence key pro-apoptotic genes. 




Inhibition of HDACs activity is now recognized as a novel approach for cancer treatment. 
Efforts by several pharmaceutical and academic laboratories have led to various histone 
deacetylase inhibitors (HDACi), many of which have been evaluated in clinical trials 
against hematological and solid tumors. These efforts have so far resulted in the FDA 
approvals of Vorinostat and Romidepsin for the treatment of cutaneous T-cell lymphoma 
(CTCL) in 2006 and 2009 respectively.
10,11
  Similar to many anticancer drugs, HDACi 
have been associated with various side effects including neutropenia, thrombocytopenia 
and potentially fatal cardiac arrhythmias.
12
 In light of these shortcomings, HDACi 
therapy could benefit from a targeted therapeutic approach as it is the case for some 
currently available drugs.
13
 Furthermore, this approach may address other deficiencies of 
HDACi, primarily their lack of efficacy towards solid tumors attributable to low 
therapeutic concentration within the malignant cells.
14,15
   
To meet their high metabolic demands, cancer cells overexpress various ligands 
receptors including those of vitamins.
16,17
 Such receptors include the folate receptor (FR) 
whose expression is limited to certain epithelial cells including the choroid plexus, lung, 
thyroid, kidneys and various malignancies.
18-20
 This selective overexpression in cancer 
cells has made the FR an ideal candidate for targeted cancer therapy. FR mediated 
endocytic uptake of folate conjugates into malignant cells has been exploited for the 
delivery of diagnostic and therapeutic agents 
21-24
 while minimizing delivery to healthy 
cells since folate delivery to healthy cells is mediated by the ubiquitously expressed 
reduced folate carrier (RFC) which does not uptake folate conjugates.
25,26
 Herein we 
describe the development of tumor-homing HDACi which derive their tumor selective 
accumulation from targeting FR. Although both folate- and pteroic acid- based 
 69 
hydroxamates were potent inhibitors of HDAC1 and 6, only the pteroic conjugated 
HDACi displayed anticancer activities against the folate receptor positive (FR+) tumors 
KB and HeLa. Moreover, HDAC1 inhibition is sufficient to induce apoptosis in KB cells 
whereas HDAC6 inhibition has no impact on KB cells' survival. 
 
3.2. Design of Folate receptor ligand-HDACi conjugates 
 Folic acid, which is comprised of pteroic acid and a glutamate residue (Figure 
3.1), has been commonly used to target the FR. Recent reports have however suggested 
that pteroic acid is also capable of mediating selective delivery of ligands to FR 
overexpressing tumors despite having minimal affinity for the FR.
27,28,29
 Our main 
objective in this study is to investigate the prospect of folic and pteroic acids as mediators 
of selective delivery of HDACi to FR overexpressing cancer cells. To this end, I designed 
a set of folate- and pteroate-HDACi conjugates in which the folate or pteroate moiety is 
integrated into the surface recognition group of a prototypical HDACi.
3
 This design 
approach furnished minimally-perturbed folate and pteroate analogs (Figure 3.1C) and 
morphed folate- and pteroate-HDACi hybrids (Figures 3.3, 3.5 and 3. 7).  
 
3.3. folate γ-hydroxamic and pteroic hydroxamic acids as HDAC inhibitors 
 Due to the structural similarity of the pteroate group with HDACi surface 
recognition groups, we envisioned that the substitution of the carboxylic acid group of 
folic and pteroic acids with a zinc binding group (ZBG), essential for HDAC inhibition, 
will furnish the corresponding tumor-homing HDACi. Hence, the γ-carboxyl of folate 
and the carboxylate moiety of pteroic acid were converted to hydroxamic acid, the most 
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commonly used ZBG for HDAC inhibition, to furnish compounds 6 and 7 respectively     




                                                                                                                             
                              i)                                                                        ii) 
C) 
  
                               i)                                                                          ii)     
                                                                                                                                                                                                               
Figure 3.1: HDACi pharmacophoric model A) and structures of folic acid (Bi), pteroic 
acid (Bii), folate γ-hydroxamic acid (Ci) and pteroic hydroxamic acid (Cii).  
 
3.3.1. Synthesis of folate γ-hydroxamic and pteroic hydroxamic acids 
 The reaction route for the synthesis of the folate γ-hydroxamate 6 and pteroic 
hydroxamate 7 is shown in Scheme 3.1. L-Glutamic acid α-tert-butyl ester was subjected 
to diazo-transfer resulting quantitatively in the α-azido L-glutamic acid α-tert-butyl ester 
1.
30
 The α-azido glutamic acid 1 was coupled with O-tritylhydroxylamine in the presence 




 The azide moiety was then reduced to an amine with Zn and NH4Cl 
yielding compound 3.
32
 The coupling of 3 with pteroyl azide 4 (see Appendix, scheme S1 
for the synthesis of 4) in the presence of tetramethylguanidine (TMG)
33
 resulted in the 
penultimate intermediate 5. Exposure of this intermediate to trifluoroacetic acid (TFA) in 




To obtain the pteroic hydroxamate 7, N10-(Trifluoroacetyl)pyrofolic acid (See 
Appendix scheme S1), an intermediate in the synthesis of pteroyl azide 4,
33
 was reacted 





















Scheme 3.1: Syntheses of folate γ-hydroxamate 6 (A) and pteroic hydroxamate 7 (B). a) 
TfN3, K2CO3, CuSO4.5H2O, DCM, H2O, MeOH, rt; b) IBCF, NMM, NH2-O-trityl; c) 
NH4Cl, Zn, EtOH/H2O (3:1), reflux; d) Pteroyl azide (4), TMG, DMSO, rt; e) TFA, 
TIPS; f) 50% aqueous NH2OH, DMSO, rt.  
 
3.3.2. HDAC inhibition profile of folate γ-hydroxamic and pteroic hydroxamic acids 
 We then investigated the HDAC inhibition potential of the folate γ-hydroxamate 6 
and pteroic hydroxamate 7  against HDAC1, 6 and 8 using SAMDI mass spectrometry 
HDAC activity assay as previously described.
35,36
 We observed that the folate γ-
hydroxamate 6 was inactive against all three isoforms while the pteroic hydroxamate 7 
inhibited all three HDACs.  Compound 7 is particularly more effective against HDAC6 
with an IC50 of 17.6 nM, and HDAC6 selectivity of 130- and 32-fold relative to HDAC1 
and HDAC8 respectively (Table 3.1).  
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Table 3.1: Inhibition profile of folate γ-hydroxamic and pteroic hydroxamic acids (IC50 
in nM) 
 HDAC1 HDAC6 HDAC8 
Folate γ-hydroxamate (6) NI NI NI 
Pteroic hydroxamate (7) 2390±470 17.6 ± 2.2 581±198 
NI: No inhibition (inhibition below 20% at 10μM) 
 
 
3.3.3. Molecular docking studies. 
 To rationalize the lack of HDAC inhibition by the folate γ-hydroxamate 6, it was 
docked against the homology models of HDAC1 and 6 built respectively from human 
HDAC2 (PDB code: 3MAX) and HDAC8 (PDB code: 3F0R) using Autodock 4.2 as 
previously described.
35,36
 Although with both isoforms the folate γ-hydroxamate 6 adopts 
poses resulting in Zn
2+
 chelation, it does so by positioning the α-carboxylate moiety in 
locations that are entropically unfavorable. With HDAC6, the α-carboxylate is inserted 
deep into the hydrophobic pocket where aromatic amino acids are located  (Figure 3.2i). 
The ensuing interactions are so unfavorable potentially preventing entrance of the 
channel. Docking with HDAC1 provide a different picture. Due to the shallow enzyme 
channel, the α-carboxylate is precluded from entering the channel resulting in its being in 
close proximity (<3 Å) to the carboxylate of ASP99 near the channel's entrance (Figure 
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3.2ii). The repulsion due to this close proximity may prevent the insertion of the ZBG 




      
                                i)                                                                       ii) 
Figure 3.2: Molecular docking studies of folate γ-hydroxamate 6 with homology models 
of HDAC1 and 6. For Zn
2+
 chelation to occur, the α-carboxylate must be involved in 
unfavorable interactions;  i) In HDAC6: The α-carboxylate is inserted in the hydrophobic 
pocket; ii) HDAC1: The α-carboxylate of 6 is unable to enter the hydrophobic channel 
but is placed in close proximity of the carboxylate of ASP99. 
 
3.4. SAR on pteroic based hydroxamate HDAC inhibitors 
 In light of the lack of HDAC inhibition by the folate γ-hydroxamate 6, we focused 
on the pteroic acid construct in order to optimize the observed HDAC inhibition profile 
of the pteroic hydroxamate 7. Toward this end, we designed various pteroic acid based 
HDACi which incorporated the pteroate moiety into HDACi surface recognition group, 
maintained the hydroxamic acid as the ZBG but vary the length of the methylene linker 







Figure 3.3: Structure of Pteroic based hydroxamates 11a-g. 
 
3.4.1. Synthesis of pteroic based hydroxamates 
 The synthesis of the pteroate hydroxamates 11a-g is depicted in Scheme 3.2. 
Reduction of the previously described trityl azido hydroxamates 8a-g with PPh3 
furnished the corresponding amines 9a-g which were subsequently reacted with pteroyl 
azide 4 to yield the O-trityl protected hydroxamates 10a-g.
37,38
 The trityl protecting group 





Scheme 3.2: Synthesis of Pteroic based hydroxamates 11a-g. a) i)PPh3, THF, rt ii) H2O; 







3.4.2. HDAC inhibition profile of pteroic based hydroxamates 
 To evaluate the impact of the linker on their potency and isoform selectivity, we 
profiled the HDAC inhibition activity of hydroxamates 11a-g against HDACs 1, 6 and 8 
(Table 3.2). Relative to the linkerless compound 7, the 3-methylene linker compound 11a 
is a significantly weaker HDACi. Despite the loss of potency, 11a is also selective for 
HDAC6. Subsequent increase in the methylene linker length, up to 8-methylene groups 
largely resulted in improved HDAC1 and HDAC6 inhibition activities. We observed that 
a further increase in linker length is detrimental to HDAC inhibition activity (Table 3.2, 
compare 11f and 11g). Among these pteroate hydroxamates, 11e is the most potent 
HDAC1 inhibitor whereas 11f is the most potent HDAC6 inhibitor. Interestingly, we did 
not notice any direct correlation between changes in the linker length and the HDAC8 













Table 3.2: HDAC inhibition of Pteoric based hydroxamates (IC50 in nM) 
 
 n HDAC1 HDAC6 HDAC8 
11a  (1) 22.1 ± 1.7% 1460 ± 310 25 ± 18% 
11b  (2) 6150 ± 1320 212 ± 15 39 ± 6% 
11c  (3) 79.6± 12.6 43.6 ± 8.4 41 ± 17% 
11d  (4) 23.4 ± 4.2 12.2 ± 0.2 1060 ± 320 
11e  (5) 16.1 ± 2.8 55.4 ± 2.2 9380 ± 1720 
11f  (6) 524± 36 10.2 ± 1.0 7590 ± 2120 
11g  (7) 53± 7% 476 ± 48 40 ± 10% 
SAHA - 38 ± 2 144 ± 23 232 ± 19 










3.4.3. Molecular docking studies of pteroic based hydroxamates 
 To understand the basis of HDAC1 inhibition by the pteroic based hydroxamates, 
11a, 11c and 11e were docked against the homology model of HDAC1 built from 
HDAC2 (PDB code: 3MAX). To provide similar insights into the HDAC6 inhibition, 
11a, 11c and 11f were docked against the homology model of HDAC6 built HDAC8 
(PDB code: 3F0R). 
 With HDAC1, Zn
2+
 chelation seems to be the major determinant of HDAC 
inhibition. The 3-carbon methylene linker of 11a was not long enough to achieve optimal 
Zn
2+ 
chelation (Figure 3.4Ai). An increase to 5 carbon-methylene linker as in 11c brought 
the ZBG closer to Zn
2+
 to achieve chelation. Besides the zinc chelation, 11e is further 
stabilized by a T-shape interaction between its pterin ring and the aromatic ring of 
TYR204 (Figure 3.4Aii). Analysis of the docking poses of the compounds 
aforementioned with HDAC6 suggest the involvement of Zn
2+
 chelation along with 
additional stabilizing interactions in the HDAC6 inhibition trend. All three compounds 
display optimal Zn
2+
 chelation (Figure 3.4Bi), however, 11a is not further stabilized by 
any other observable interaction. On the other hand, the pterin moiety of 11c and 11f is 
involved in π-stacking interaction with the aromatic ring of PHE680. The geometry of the 
π-stacking may explain the increased potency of 11f compared to 11c as the pterin ring in 







     
                               i)                                                                ii) 
B) 
  
                           i)                                                                   ii) 
Figure 3.4 : Molecular docking poses explaining the inhibitory profile of selected pteroic 
based hydroxamates against HDAC1 and HDAC6; A) HDAC1: i) Both 11c (purple) and 
11e (grey) chelate the active site Zn
2+
 but 11a (green) does not due to a short linker; ii) 
Besides the Zn
2+
 chelation, 11e (grey) is further stabilized by a T-shape interaction 
between its pterin and the aromatic ring of TYR204. B) HDAC6: i) All three inhibitors, 
11a (green), 11c (purple) and 11f (orange) chelate the Zn
2+
; ii) Both 11c and 11f are 
further stabilized by a π-stacking between their respective pterin ring and PHE680, 
furthermore the pterin ring of 11f is perfectly parallel to the aromatic ring of PHE680 















3.5. Folic acid based hydroxamate HDACi 
 Encouraged by the results from the aforementioned SAR study on the pteroate 
hydroxamates, we performed similar structural alterations to the folate template (Figure 
3.5) as folate-derived compounds may possess greater affinity for the FR compare to their 
pteroic acid congeners. The synthesis of the folate-derived hydroxamates 15a-g is 
depicted in Scheme 3.3. 
3.5.1. Synthesis of folate based hydroxamic acids 
 The α-azido L-glutamic acid α-tert-butyl ester 1 was coupled to the trityl amino 
hydroxamates 9a, 9d, 9e, 9f in the presence of IBCF and NMM yielding the azido trityl 
protected hydroxamate compounds 12a-d.
31,39
 Subsequent azide reduction with NH4Cl 
and Zn followed by coupling to the pteroyl azide 4 as previously mentioned gave the 
protected folate based hydroxamate HDACi 14a-d.
32,33
 Removal of the trityl and t-Butyl 









Scheme 3.3: Synthesis of folate based hydroxamates. a) IBCF, NMM; b)Zn, NH4Cl, 
EtOH/H2O (3:1), reflux; c) Pteroyl azide 4, TMG, DMSO, rt; d) TFA, TIPS 
 
3.5.2. HDAC inhibition profile of folate based hydroxamic acids 
 Unlike the folate γ-hydroxamate 6, compounds 15a-d displayed linker length-
dependent anti-HDAC activity with a clear preference for HDAC6 (Table 3.3). Against 
the three HDAC isoforms investigated, 15b is the most potent among this series of 
HDACi. Relative to pteroate hydroxamates 11a-g, compounds 15a-d are generally less 
potent. However, selected members of this series – 15c and 15d – are more active against 








Table 3.3:  HDAC inhibition of folate based hydroxamates (IC50 in nM) 
 
 
 n HDAC1 HDAC6 HDAC8 
15a  (1) NI 8050 ± 330 40 ± 5% 
15b  (4) 1770 ± 100 132 ± 23 2390 ± 640 
15c  (5) 1800 ± 180 193 ± 41 2370 ± 430 
15d  (6) 2760 ± 550 179 ± 19 1560 ± 340 
SAHA - 38 ± 2 144 ± 23 232 ± 19 
% inhibition at 10 μM are given if the IC50 was above 10 μM.                                                                                  
NI: No Inhibition (below 20% Inhibition at 10 µM concentration) 
 
3.5.3. Molecular docking studies of the folate based hydroxamate compound 15c 
 To understand the basis of the HDAC6 selectivity by the folate based 
hydroxamates, 15c was docked against the homology models of HDAC1 and 6 built 
respectively from human HDAC2 (PDB code: 3MAX) and HDAC8 (PDB code: 3F0R) 
using Autodock 4.2 as previously described.
35,36
 Against HDAC6, the hydroxamate ZBG 
of 15c chelates to the zinc (Figure 3.6Ai) and is stabilized by hydrogen bonds with the 
side chain of ASP567 and the C=O backbone of PHE566. Further stabilizing interactions 
may also be provided by the π-stacking interaction between the pterin ring and the phenyl 
ring of PHE680 (Figure 3.6Aii). With HDAC1, the zinc chelation is not optimal due to 
other interactions obliging the hydroxamate ZBG to adopt the observed binding mode 
(Figure 3.6Bi). These interactions include hydrogen bonds between 15c and side chains 
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of GLU146, ASN95, ASP99, backbone C=O of GLU203, NH of PHE205 whose phenyl 
ring also participate in a T-shape interaction with the pterin ring of 15c (Figure 3.6Bii).   
A) 
 
                               i)                                                                      ii) 
B) 
 
                            i)                                                                        ii) 
Figure 3.6 : Molecular basis for isoform selectivity of 15c. A) Molecular docking of 15c 
with HDAC6 homology model built from HDAC8 (PDB code: 3F0R); i) Zinc chelation 
by 15c; ii) Polar interactions between 15c and HDAC6 homology model and π-stacking 
of phenyl of PHE680 with 15c; B) Molecular docking of 15c with HDAC1 homology 
model built from HDAC2 (PDB code: 3MAX); i) Orientation of the hydroxamate ZBG at 
the active site; ii) Stabilizing interactions between 15c and HDAC1 homology model 






















3.6. Targeted delivery of isoform selective HDACi 
 From the observation that the class I selective inhibitor MS275 and HDAC6 
selective inhibitor ACY-1215 are well tolerated in clinical trials, isoform selectivity of 
HDACi has been suggested as a mean of enhancing the safety of HDACi therapy.
3,40
 I 
decided to combine this approach to the targeted delivery by designing folate based 
benzamide HDACi. Such compounds will embody the targeted delivery of HDAC1 
selective inhibitors which may be well tolerated as MS275 while having a significantly 
high intratumoral concentration (Figure 3.7). 
 
Figure 3.7: Structure of folate based biaryl benzamide HDACi. 
 
 
3.6.1. Synthesis of folate based biaryl benzamide compounds 
 Precursor of the biaryl benzamide ZBG 16 was synthesized as previously reported 
(See Appendix scheme S2).
41
 The biaryl benzamide ZBG 17 was obtained following the 
reduction of the nitro group in presence of Zn in dioxane/H2O (4:1) (Scheme 3.4).
42
 In 
presence of EDCI and HOBT, the ZBG 17 was coupled to various azido carboxylic acids 
(18a-d) yielding compounds 19a-d.
37,31
 Following the reduction of the azide  with zinc 
and NH4Cl, compounds 20a-d were coupled to α-azido glutamic acid 1 resulting in the 
intermediates 21a-d, which were reduced prior to their coupling with pteroyl azide 4. 
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Final removal of protecting groups was conducted in TFA containing TIPS to afford the 





Scheme 3.4: Synthesis of folate based biaryl benzamide HDACi. a) Zn, Dioxane/H2O 
(4:1), 70°C; b) EDCI, HOBT, DMF, 70°C; c) Zn, NH4Cl, EtOH/H2O (3:1), reflux; d) 












3.6.2. HDAC inhibition profile of folate based biaryl benzamide HDACi 
 As opposed to their hydroxamate congeners, the biaryl benzamides are devoid of 
HDAC6 and 8 inhibition (Table 3.4). This selectivity for HDAC1 was expected as the 
biaryl benzamide ZBG is selective for HDAC1.
41
 A trend in the potency against HDAC1 
is observable starting from the 3-methylene linker 24a (least potent) to the 7-methylene 
spacer 24c which is the optimal inhibitor in the series.  
 




 n HDAC1 HDAC6 HDAC8 
24a (C4) (1) 2940 ± 330 22.8 ± 0.3% 23 ± 6% 
24b (C7) (4) 435 ± 35 NI NI 
24c (C8) (5) 287 ± 53 NI 67 ± 1% 
24d (C9) (6) 309 ± 74 NI NI 
SAHA - 38 ± 2 144 ± 23 232 ± 19 
% Inhibition at 10 μM are given if the IC50 was above 10 μM.                                                                                        






3.7. Anticancer activity of pteroate and folate-derived HDACi 
 Most HDACi are unselective for tumor cells, consequently they have off-target 
toxic effects.
3
  Tumor cell-selective uptake of HDACi could potentially ameliorate many 
of their shortcomings. To evaluate the influence of the FR on the cytotoxic activity of the 
folate- and pteroate-derived HDACi identified above, we investigated  the effects of their 
exposure on the viability of two FR (+) transformed cell lines, KB (oral carcinoma) and 
HeLa (cervical carcinoma) cells.
43
 We observed that none of the folate-based 
hydroxamates and biaryl benzamides was active against both cell lines. Among the 
pteroate hydroxamates, only the 6- and 7-methylene linkers 11d and 11e, respectively, 
were active with micromolar IC50 (Table 3.5). KB cells were more responsive to these 
compounds as reflected by the lower IC50 compared to those in HeLa cells. This observed 
difference in sensitivity is in agreement with previous observations since HeLa cells have 
a lower FR density than the KB cells.
44
  
 To confirm the FR as the route of entry of the pteroic based hydroxamates into the 
KB cells, we measured the cell viability in the presence and absence of folic acid as 
previously described.
45
 The presence of 250 μM of folic acid reduced the cytotoxicity 
effects of 25 μM of 11e in KB cells (Figure 3.8). Furthermore, we observed that both 11d 
and 11e are inactive against the FR (-) lung cancer cell line A549. The inactivity against 
the A549 along with the reduced cytotoxicity of 11e during the folate competition assay 
suggest the involvement of the FR in cellular uptake of the pteroic hydroxamate 
compounds.
46





Table 3.5:  Folate receptor-dependent anti-proliferative activity of folate- and  pteroate -
derived hydroxamates (IC50 in μM). 
 




11a 1  NI NI  NT 
11b 2  NI  NI  NT 
11c 3  25 ± 2%  NI  NT 
11d 4  53.7 ± 2.4  34 ± 3%  NI 
11e 5  30.3 ± 2.1  56.6 ± 1.1  NI 
11f 6  33 ± 3% 35 ± 3% NT 
11g 7  47 ± 3% 36 ± 8% NT 
 
15a 1  NT NT  NT 
15b 4 NI  NI  NT 
15c 5  NI  NI  NT 
15d 6   NT 
SAHA  -  1.8 ± 0.3  3.7 ± 0.2  NT 





Figure 3.8: Folic acid (FA) competition assay. Viability of    cells treated with 25 μM 
of 11e in the absence and presence of FA. *p < 0.01 (Student's t-test). 
 
 
3.8. Intracellular targets validation  
 I decided to parse out the contribution of each isoform inhibition in the cellular 
activity of 11d and 11e as selective inhibition of HDAC1 or 6 have been associated with 
cancer cell death.
47,41,48
 The most potent HDAC6 selective inhibitor synthesized thus far, 
pteroic hydroxamate 7 (Table 3.1) was tested against KB and HeLa cell lines. However, 
no cytotoxicity effect was observed up to 100 μM. The lack of activity of the pteroic 
hydroxamate 7 may suggest that HDAC6 inhibition does not lead to KB cell death or 7 is 
unable to penetrate the cell. However, when docked against the FR crystal structure (PDB 
code: 4LRH) using Autodock 4.2, the pteroic hydroxamate 7 binds to the FR and its 
pterin moiety is involved in stabilizing interactions similar to those between the active 




pterin ring of the pteroic hydroxamate 7, 11d, 11e and the FR are analogous to those 
previously reported between folic acid and its receptor (Figure 3.9) suggesting the 





























Figure 3.9: Molecular docking of the FR (PDB code: 4LRH) with folic acid (green), 
Pteroic hydroxamate 7 (purple), 11d (pink) and 11e (blue). A) The pterin ring of pteroic 
hydroxamate 7, 11d and 11e have a similar binding mode to the ligand binding pocket as 
folic acid. B) Stabilizing interactions between the FR and the pterin ring of Pteroic 










 In light of the suggestions derived from the in silico studies, we measured the 
cellular response to HDAC6 inhibition, tubulin acetylation, following exposure to pteroic 
hydroxamate 7, 11d, 11e and SAHA.
50
 As expected, SAHA and the lead-compounds 11d 
and 11e, induced an increase in acetylated tubulin level at IC50 and at higher doses 
confirming HDAC6 as a target of these inhibitors (Figure 3.10). Similar increase was also 
seen upon exposure to 100 μM of pteroic hydroxamate 7 (Figure 3.10). This finding 
suggested that the pteroic hydroxamate 7, a selective HDAC6 inhibitor, is absorbed 
through the FR leading to an increase in acetylated tubulin level, however, such isoform 
inhibition does not result in cytotoxicity to KB cells.  
 
     1            2          3           4          5        6          7         8 




Figure 3.10: Western blot analysis of tubulin acetylation in KB cell. 1) Control; 2) 
SAHA (2μM); 3) SAHA (20μM); 4) 11d (50μM); 5) 11d (100μM); 6) 11e (30μM); 7) 
11e (100μM); 8) 7 (100μM). 
 
 
 To confirm the HDAC1 inhibition as the mechanism of cytotoxicity of the pteroic 
based hydroxamates 11d and 11e to KB cells, the selective HDAC6 inhibitor Tubastatin 




                            
    Tubastatin A                                                         SHI-1:2 
 
HDAC1  (μM)        16.4*                                                                   0.007†                                    
HDAC6 (μM)         0.015*                                                                 > 10† 
 







 In KB cells, Tubastatin A had an IC50 of 14.81 ± 2.74 μM suggesting that 
selective HDAC6 inhibition may result in cellular death. However, the cellular IC50 of 
Tubastatin A was similar to its reported IC50 against HDAC1 (16.4 ± 2.6 μM), as such, 
the observed cytotoxicity may still be a consequence of HDAC1 inhibition.
51
 To 
determine the plausibility of this scenario, the cellular response to HDAC1 inhibition 
(histones acetylation) was measured in KB cells in response to SAHA, pteroic 
hydroxamate 7, 11d, 11e and Tubastatin A.
50
 As expected, SAHA, 11d and 11e, led to a 
dose-dependent increase in histone H4 acetylation establishing the intracellular HDAC1 
inhibition of these compounds (Figure 3.12). At 14 μM, Tubastatin A also show a 
significant increase in H4 acetylation, confirming indeed that its cellular activity against 
KB cells can be attributed to HDAC1 inhibition. To our surprise, pteroic hydroxamate 7 
at 100 μM led to only a minimal increase in H4 acetylation compared to the control 
implying that it is devoid of HDAC1 activity (Figure 3.12). Furthermore, the HDAC1 
selective SHI-1:2 was more potent (IC50 = 5.27 ± 0.84 μM) than Tubastatin A. 
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Figure 3.12: Western blot analysis of Histone H4 acetylation in KB cell. 1) Control; 2) 
SAHA (2μM); 3) SAHA (20μM); 4) 11d (50μM); 5) 11d (100μM); 6) 11e (30μM); 7) 
11e (100μM); 8) 7 (100μM); 9) Tubastatin A (14μM). 
 
 The correlation between HDAC1 inhibition and KB cell viability may explained 
the lack of anticancer activity of the folate based hydroxamates compounds, but seems to 
be in contradiction with the inactivity of the folate based biaryl benzamides. In an attempt 
to understand this apparent contradiction, I speculated that the biaryl benzamide ZBG 
may be perturbing the FR binding. However, molecular docking studies of 24b and 24c 
reveal that the binding interactions with the FR that are similar to the ones between the 
receptor and folic acid (Figure 3.13) suggesting that the ZBG is not perturbing the 
stabilizing interactions between these compounds and the FR and as such they are being 
delivered to the cell.  Recent studies have described the proton-coupled folate transporter 
(PCFT) as responsible for the export of folates from endosomes following endocytosis.
52
 
The folate based biaryl benzamides may not be efficiently transported by the PCFT 
leading to their retention in the endosomes upon endocytosis. Although the folate 
receptor has been successfully targeted for the delivery of therapeutic agents, 
observations made by Philip Low revealed that only 15 to 25% of the bound FR release 
their substrates following endocytosis, the rest of the bound receptors are returned to the 
cell surface.
22
 With such a low delivery efficiency, it is possible that compounds which 
Acetyl Histone H4 
Total Histone H4 
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are very potent against their primary target (in our case HDAC1) may be the ones to 
possess cellular activity through FR targeting.
21
    
 
 
Figure 3.13: Molecular docking of the FR (PDB code: 4LRH) with folic acid (pink), 24b 
(gold) and 24c (green) showing similar binding mode between the pterin moiety and its 





 Despite having great success against hematological malignancies, HDACi have 
not being efficacious against solid tumors. In an attempt to address this concern and 
improve their cytotoxicity profile, I targeted HDACi to FR (+) cancers by modifying their 
pharmacophoric model to encompass folic and pteroic acids. The pteroic based 
hydroxamates were potent inhibitors of HDAC1 and 6, whereas the presence of the α- 
carboxylate conferred a HDAC6 selectivity to the folate based hydroxamates. 
Furthermore, only the pteroic hydroxamates displayed anticancer activity against KB and 
HeLa cells. I also established that inhibition of HDAC1 correlate with KB cells viability, 
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justifying the lack of anticancer activity of the folate based hydroxamate compounds 
which were weaker HDAC1 inhibitors with IC50s in the micromolar. The combination of 
targeted delivery with isoform selectivity, the other strategy suggested to improve 
HDACi therapy, led to the design of folate based biaryl benzamide HDACi. To my 
knowledge, this represents the first attempt to selectively deliver isoform selective 
HDACi. These inhibitors, though selective for HDAC1, failed to show any anticancer 
activity against KB cells. This suggests that for a drug to be successfully targeted using 
the FR, it must be very potent against its primary target as the FR has a low delivery 
















3.10. Experimental section 
3.10.1. Materials and methods 
 Folic acid and other reagents used were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) and Alfa Aesar (WardHill, MA, USA). Analtech silica gel plates (60 F254) 
were used for analytical TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) 
were used for purification.  UV light was used to examine the spots. Silica gel (200–400 
Mesh) was used in column chromatography. NMR spectra were recorded on a Varian-
Gemini 400 magnetic resonance spectrometer.  
1
H NMR spectra were recorded in parts 
per million (ppm) relative to the peak of CDCl3, (7.24 ppm), CD3OD (3.31 ppm), or 
DMSO-d6 (2.49 ppm).  
13
C spectra were recorded relative to the central peak of the 
CDCl3 triplet (77.0 ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm), and 
were recorded with complete heterodecoupling.  Multiplicities are described using the 
abbreviation s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; and app, apparent. 
High-resolution mass spectra were recorded at the Georgia Institute of Technology mass 
spectrometry facility in Atlanta. KB and A549 cells were obtained from ATCC 
(Manassas, VA, USA), HeLa cell line was kindly donated by Dr. Christoph Farhni and 
grown on folate free RPMI medium supplemented with 10% fetal bovine serum ( Global 
Cell Solutions, Charlottesville, VA, USA) and 1% pen/Strep (Cellgro, Manassas, VA) at 
37°C in an incubator with 5% CO2. Mouse anti-acetylated α-Tubulin antibody was 
obtained from Invitrogen (Life Technologies, Grand Island, NY, USA), rabbit anti-actin, 
rabbit anti-tubulin α, rabbit anti-histone H4 antibodies and Tubastatin A were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Secondary antibodies, goat anti-rabbit 
conjugated to IRDye680 and goat anti-mouse conjugated to IRDye800 were purchased 
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from LI-COR Biosciences (Lincoln, NE, USA). The CellTiter 96 AQueous One Solution 
Cell Proliferation assay (MTS) kit was purchased from Promega (Madison, WI, USA). 
 
3.10.2. Histone deacetylase inhibition (Performed by James Kornacki at 
Northwestern University) 
 The HDAC activity in presence of various compounds was assessed by SAMDI 
mass spectrometry. As a label-free technique, SAMDI is compatible with a broad range 
of native peptide substrates without requiring potentially disruptive fluorophores.   To 
obtain IC50 values, we incubated isoform-optimized substrates (50μM, detailed below) 
with enzyme (250nM, detailed below) and inhibitor (at concentrations ranging from 
10nM to 1.0mM), in HDAC buffer (25.0 mM Tris-HCl pH 8.0, 140 mM NaCl, 3.0 mM 
KCl, 1.0 mM MgCl2, 0.1 mg/mL BSA) in 96-well microtiter plates (60 min, 37°C). 
Solution-phase deacetylation reactions were quenched with trichostatin A (TSA) and 
transferred to SAMDI plates to immobilize the substrate components. SAMDI plates 
were composed of an array of self-assembled monolayers (SAMs) presenting maleimide 
in standard 384-well format for high-throughput handling capability. Following 
immobilization, plates were washed to remove buffer constituents, enzyme, inhibitor, and 
any unbound substrate and analyzed by MALDI mass spectrometry using automated 
protocols.
53
 Deacetylation yields in each triplicate sample were determined from the 
integrated peak intensities of the molecular ions for the substrate and the deacetylated 
product ion by taking the ratio of the former over the sum of both. Yields were plotted 
with respect to inhibitor concentration and fitted to obtain IC50 values for each isoform-
inhibitor pair.  
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 Isoform-optimized substrates were prepared by traditional FMOC solid phase 
peptide synthesis (reagents supplied by Anaspec) and purified by semi preparative HPLC 
on a reverse phase C18 column (Waters). The peptide of sequence GRK
ac
FGC was 
prepared for HDAC1 and HDAC8 experiments, while the peptide of sequence 
GRK
ac
YGC was prepared for HDAC6 and HDAC2 experiments. Isoform preference for 
the indicated substrates was determined by earlier studies on peptide arrays.
54
 
 HDAC1, HDAC6, and HDAC2 were purchased from BPS Biosciences. The 
catalytic domain of HDAC8 was expressed as previously reported.
54
 Briefly, an amplicon 
was prepared by PCR with the following primers: forward 5’-3’ 
TATTCTCGAGGACCACATGCTTCA and reverse 5’-3’  
ATAAGCTAGCATGGAGGAGCCGGA. A pET21a construct bearing the genetic insert 
between NheI and Xho1 restriction sites was transformed into E. coli BL21(DE3) 
(Lucigen) and expressed by standard protocols. Following purification by affinity 
chromatography, the His-tagged enzyme-containing fractions were purified by FPLC 
(AKTA) on a superdex size exclusion column (GE), spin concentrated, and stored at -
80°C in HDAC buffer with 10% glycerol.  
 
3.10.3. Molecular docking analysis  
 The docking studies were performed as previously reported with Autodock Vina 
through PyRx.
55,56
 Following the 3D energy minimization of the ligand by 
ChemBioDraw 3D, the docking was run in a 25 Å cubic space encompassing the active 
site, the binding pocket and its surrounding.  
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3.10.4. Cell viability assay 
 KB and HeLa cells were maintained in folate free-RPMI supplemented with 10 % 
FBS and 1% pen/strep while A549 cells were maintained in DMEM supplemented with 
10 % FBS and1% pen/strep. All cells were incubated on a 96-wells plate (4500 
cells/well) in folate free-RPMI for 24 hours prior to a 72 hours drug treatment. Cell 
viability was measured using the MTS assay according to manufacturer protocol 
(Promega, CellTiter 96® AQueous One Solution Cell Proliferation Assay, Catalog# 
G3580). The DMSO concentration in the cell media during the cell viability experiment 
was maintained at 0.1%.     
 
3.10.5. Western blot analysis for tubulin and histone H4 acetylation 
 KB cells were plated for 24 hours and treated with various concentrations of 
compounds for 4 (tubulin acetylation) or 24 hours (histone H4 acetylation). The cells 
were washed with P S buffer and resuspended in CelLytic™M buffer containing a 
cocktail of protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Following 
quantification through a Bradford protein assay, equal amount of protein was loaded onto 
an SDS-page gel (Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a 
constant voltage of 100V for 2 hours. The gel was transfer onto a nitrocellulose 
membrane and probed for selected proteins using primary antibodies against: acetylated 
tubulin (LifeTechnologies, catalog# 32-2700); tubulin (Sigma-Aldrich, catalog# 
SAB4500087); acetylated histone H4 (Sigma-Aldrich, catalog# SAB4500307); histone 
H4 (abcam, catalog# ab31830) and actin (Sigma-Aldrich, catalog# A2066). Following 
the detection of acetylated H4 level, the membrane was stripped using a stripping buffer 
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(LI-COR, NewBlot Nitro Stripping Buffer, part # 928-40030) and probed for total histone 
H4. 
   
3.10.6. Statistical analysis 
 The values reported as mean ± standard deviation from at least 2 independent 
triplicate experiments. A student’s t-test was performed in Excel, and results with p value 
less than 5% were considered statistically different. 
 
Trifluoromethanesulfonyl Azide.  NaN3 (1.36 g, 20.86 mmol) was dissolved in DCM 
(7.5 mL) and H2O (4.5 mL) and cooled in an ice bath. Upon addition of triflyl anhydride  
(0.71 mL, 4.17 mmol) dropwise, the reaction was stirred at room temperature for 2 hours. 
The DCM layer was removed using a separatory funnel and the aqueous layer was 
extracted with DCM (2 x 4 mL). The organic layers were combined and washed with 
Na2CO3 and dried with Na2SO4. No further purification was done. 
 
(S)-4-Azido-5-(tert-butoxy)-5-oxopentanoic acid (1). 
L-Glutamic acid α-tert-butyl ester (0.5 g, 2.09 mmol), K2CO3 (0.43 g, 3.13 mmol), and 
CuSO4.5H2O (0.0050 g, 0.021 mmol) were dissolved in MeOH (18 mL) and H2O (9 mL). 
The previously synthesized TfN3 in DCM was added and the mixture was stirred 
overnight at room temperature. The organic solvents were evaporated off and the aqueous 
layer was acidified to pH 2 with a 2M HCl solution and extracted with DCM (4 x 20mL) 
. The DCM extracts were combined, washed with brine and dried with Na2SO4. 
Evaporation of the DCM resulted in 1 (0.52 g, quantitative yield). 
1
H NMR (400 MHz, 
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CDCl3) δ 3.85 (dd, J = 8.7, 5.2 Hz, 1H), 2.47 (t, J = 6.8 Hz, 2H), 2.17 – 2.04 (m, 1H), 
2.01 – 1.88 (m, 1H), 1.47 (d, J = 1.5 Hz, 9H).
 13
C NMR (101 MHz, CDCl3) δ 178.6, 
169.0, 83.4, 61.4, 29.9, 27.9, 26.1. 
 
 (S)-tert-Butyl 2-azido-5-oxo-5-((trityloxy)amino)pentanoate (2): Representative 
procedure for amide bond formation through a mixed anhydride intermediate. 
A THF solution of 1 (0.49 g, 2.15 mmol) and N-methylmorpholine (0.22 g, 2.15 mmol) 
was cooled to -15°C and stirred for 5 min. Isobutylchloroformate (0.29 g, 2.15 mmol) 
was added and the mixture stirred at -15°C for 10 min. O-Tritylhydroxylamine (1.19 g, 
4.30 mmol) and N-methylmorpholine (0.44 g, 4.30 mmol) were added and the reaction 
was stirred at -15°C for 15 min and at room temperature for 2 h. Upon reaction 
completion, DCM was added and the mixture was washed with H2O, NaHCO3 (1X), 1M 
HCl (1X), brine (1X) and dried with Na2SO4. Following the evaporation of the organic 
layer, the crude product was dissolved in EtOAc and addition of Hexanes resulted in the 
precipitation of the product 2 as a white solid (0.69 g, 66% yield). 
1
H NMR (400 MHz, 
CDCl3) δ 7.61 – 7.28 (m, 15H), 3.66 – 3.49 (m, 1H), 2.06 – 1.91 (m, 1H), 1.80 – 1.66 (m, 
2H), 1.62 – 1.55 (m, 1H), 1.46 (s, 9H).
 13
C NMR (101 MHz, cdcl3) δ 175.8, 169.2, 141.8, 
141.0, 129.1, 128.2, 93.6, 82.8, 61.6, 28.0, 27.4, 25.3. 
 
 (S)-tert-Butyl 2-amino-5-oxo-5-((trityloxy)amino)pentanoate (3): Representative 
procedure for azide reduction to amine using Zn and NH4Cl. 
To a solution of 2 (0.25 g, 0.51 mmol) in EtOH (3 mL) and H2O (1 mL), NH4Cl (0.066 g, 
1.23 mmol) and zinc powder (0.047 g) were added and the resulting mixture was stirred 
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at room temperature. After completion of the reaction, the mixture was filtered through a 
cilite pad. Following the removal of the solvent, the crude product was purified by 
preparative TLC with DCM:MeOH (20:1) yielding 3 ( 0.15 g, 61% yield). 
1
H NMR (400 
MHz, CDCl3) δ 7.55 – 7.18 (m, 15H), 3.12 – 3.01 (m, 1H), 2.17 – 1.98 (m, 1H), 1.96 – 
1.83 (m, 1H), 1.81 – 1.56 (m, 2H), 1.41 (s, 9H). 
13
C NMR (101 MHz, CDCl3) δ 177.8, 




Representative procedure for amide bond formation from acyl azide and amine. 
Pteroyl azide (0.13 g, 0.40 mmol) and 3 (0.14g, 0.30 mmol) were dissolved in DMSO. 
Upon addition of tetramethylguanidine (0.07 g, 0.61 mmol), the reaction was stirred 
overnight at room temperature. Dropwise addition of acetonitrile resulted in a yellow 
precipitate which was collected by centrifugation and washed by Et2O. The crude product 
was purified by preparative TLC with Et2O:NH4OH:Isopropanol:EtOH (2:1:1:1) to yield 
a yellow powder 5 (0.048 g, 21%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.59 
(d, J = 8.4 Hz, 2H), 7.29 (s, 15H), 6.60 (d, J = 7.5 Hz, 2H), 4.47 (s, 2H), 4.20 – 3.87 (m, 
1H), 1.98 – 1.77 (m, 2H), 1.74 – 1.49 (m, 2H), 1.34 (s, 9H).
 13
C NMR (101 MHz, 
DMSO-d6) δ 171.8, 166.8, 154.3, 151.2, 149.0, 142.8, 129.4, 128.4, 128.0, 121.7, 111.6, 




(hydroxyamino)-5-oxopentanoic acid (6): Representative procedure for protecting 
groups removal. 
Compound 5 (0.046 g, 0.061 mmol) was dissolved in neat TFA (2 mL) containing TIPS 
(0.5 mL) and stirred at room temperature for 2 h. The slurry residue obtained upon the 
TFA evaporation was added to acetonitrile dropwise resulting in a precipitate which was 
collected by centrifugation. The precipitate was washed with Et2O (4 x 40 mL) and dried 
yielding a yellow powder 6 (0.028 g, quantitative yield). 
1
H NMR (400 MHz, DMSO-d6) 
δ 8.67 (s, 1H), 7.60 (d, J = 8.6 Hz, 2H), 6.61 (d, J = 8.5 Hz, 2H), 4.51 (s, 2H), 4.27 – 4.17 
(m, 1H), 2.12 – 1.96 (m, 3H), 1.95 – 1.83 (m, 1H). 
13
C NMR (126 MHz, DMSO-d6) δ 
174.2, 174.0, 168.9, 166.7, 151.1, 148.9, 129.3, 128.2, 121.6, 111.5, 52.4, 30.7, 29.3. 
HRMS (ESI) calcd for C19H21N8O6 [M+H]
+




An intermediate in the synthesis of pteroyl azide, N10-(trifluoroacetyl)pyrofolic acid ( 
0.25 g), was dissolved in DMSO (6 mL) followed by the addition of a 50% aqueous 
hydroxylamine solution (0.15 mL). After stirring at room temperature for 5 h, the 
reaction was added dropwise to acetonitrile. The yellow precipitate thus obtained was 
collected by centrifugation and washed with Et2O (4X), MeOH (2 x 30 mL) and dried. 
Multiple rounds of DMSO dissolution and precipitation were conducted to obtain the 
desired purity of 7, a dark yellow precipitate (0.050 g, 32% yield).
 1
H NMR (400 MHz, 
DMSO-d6) δ 8.62 (s, 1H), 7.49 (d, J = 8.7 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 4.44 (d, J = 
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6.2 Hz, 2H). 
13
C NMR (126 MHz, DMSO-d6) δ 167.7, 165.1, 154.1, 152.2, 150.9, 148.9, 
131.4, 128.6, 128.2, 120.3, 118.4, 111.6, 46.2. HRMS (ESI) calcd for C14H14N7O3 
[M+H]
+
 328.1153 found 328.1160. 
 
4-Amino-N-(trityloxy)butanamide (9a): Representative procedure of azide reduction 
with PPh3. 
Trityl protected hydroxamate azide 8a (1.5 g, 3.88 mmol) and PPh3 (2.44 g, 9.32 mmol) 
were dissolved in anhydrous THF (6 mL) and stirred at room temperature under inert 
atmosphere overnight. H2O was then added and the reaction allowed to proceed at room 
temperature for 2 h. DCM was added to the reaction and washed with H2O (3 x 50 mL) 
,brine (50 mL) and dried with Na2SO4. The crude product was purified by column 
chromatography eluted with DCM:MeOH:NH4OH (10:1:0.1) to yield 9a (0.91 g, 65% 
yield).
 1
H NMR (400 MHz, DMSO-d6) δ 7.29 (dd, J = 13.7, 4.6 Hz, 15H), 2.29 (t, J = 6.4 
Hz, 2H), 1.81 (t, J = 7.0 Hz, 2H), 1.36 – 1.22 (m, 2H).
 13
C NMR (101 MHz, CDCl3) δ 
174.7, 146.0, 144.9, 133.0, 132.0, 131.6, 131.5, 96.9, 44.2, 34.0, 31.4. 
 
5-Amino-N-(trityloxy)pentanamide (9b): 
Compound 8b (1.5 g, 3.75 mmol) was reacted with PPh3 (2.36 g, 8.99 mmol) in THF as 
described for the synthesis of 9a to give 9b (0.8 g, 57% yield).
 1
H NMR (400 MHz, 
DMSO-d6) δ 7.28 (dd, J = 10.3, 3.6 Hz, 15H), 2.35 (t, J = 7.0 Hz, 2H), 1.74 (t, J = 7.3 
Hz, 2H), 1.26 – 1.15 (m, 2H), 1.09 – 1.00 (m, 2H). 
13
C NMR (101 MHz, CDCl3) δ 141.8, 




Compound 8c (0.5 g, 1.21 mmol) was reacted with PPh3 (0.76 g, 1.9 mmol) in THF as 
described for the synthesis of 9a to give 9c (0.34 g, 72 % yield).
 1
H NMR (500 MHz, 
CDCl3) δ 7.64 – 7.21 (m, 15H), 2.61 (t, J = 6.2 Hz, 2H), 1.95 – 1.82 (m, 1H), 1.69 – 1.53 
(m, 1H), 1.49 – 0.96 (m, 6H).
 13
C NMR (126 MHz, CDCl3) δ 177.0, 141.9, 140.9, 128.9, 
128.0, 127.8, 127.5, 93.2, 50.1, 41.5, 32.7, 31, 26.1, 24.6, 23. 
 
7-Amino-N-(trityloxy)heptanamide (9d): 
Compound 8d (1.5 g, 3.5 mmol) was reacted with PPh3 (2.2 g, 8.4 mmol) in THF as 
described for the synthesis of 9a to give 9d (1.25 g, 89% yield).
 1
H NMR (400 MHz, 
DMSO-d6) δ 7.30 (s, 15H), 2.43 (t, J = 6.8 Hz, 2H), 1.75 (t, J = 7.0 Hz, 2H), 1.27 – 1.02 
(m, 6H), 0.98 – 0.87 (m, 2H).
 13
C NMR (101 MHz, DMSO-d6) δ 170.7, 142.9, 129.4, 
127.9, 127.8, 92.1, 41.9, 33.3, 32.4, 28.7, 26.5, 25.3. 
 
8-Amino-N-(trityloxy)octanamide (9e): 
Compound 8e (1.5 g, 3.39 mmol) was reacted with PPh3 (2.13 g, 8.13 mmol) in THF as 
described for the synthesis of 9a to give 9e (1.16 g, 82 % yield).
 1
H NMR (400 MHz, 
DMSO-d6) δ 7.38 – 7.15 (m, 15H), 2.46 (t, J = 5.3 Hz, 2H), 1.75 (t, J = 7.2 Hz, 2H), 1.32 
– 1.21 (m, 2H), 1.20 – 1.01 (m, 6H), 0.99 – 0.88 (m, 2H).
 13
C NMR (101 MHz, DMSO-
d6) δ 170.6, 143.0, 129.4, 128, 127.8, 92.1, 55.4, 42.0, 33.6, 29.1, 28.8, 26.7, 25.2. 
9-Amino-N-(trityloxy)nonanamide (9f): 
Compound 8f (0.98 g, 2.15 mmol) was reacted with PPh3 (1.35 g, 5.15 mmol) in THF as 
described for the synthesis of 9a to give 9f (0.8 g, 86 % yield).
 1
H NMR (400 MHz, 
 107 
CDCl3) δ 7.56 – 7.21 (m, 15H), 2.65 (t, J = 7.0 Hz, 2H), 1.65 – 1.50 (m, 2H), 1.48 – 1.36 
(m, 2H), 1.31 – 0.98 (m, 10H).
 13
C NMR (101 MHz, CDCl3) δ 177.4, 141.1, 129.0, 128.1, 
128.1, 105.0, 93.3, 53.4, 42.0, 33.5, 29.2, 29.0, 26.8, 23.5. 
 
10-Amino-N-(trityloxy)decanamide (9g): 
Compound 8g (1.5 g, 3.19 mmol) was reacted with PPh3 (2.0 g, 7.65 mmol) in THF as 
described for the synthesis of 9a to give 9g (1.22 g, 86 % yield).
 1
H NMR (400 MHz, 
CDCl3) δ 7.63 – 7.13 (m, 15H), 2.71 (t, J = 6.8 Hz, 2H), 2.01 – 1.70 (m, 2H), 1.57 – 1.47 
(m, 2H), 1.33 – 0.93 (m, 12H).
 13
C NMR (101 MHz, CDCl3) δ 177.4, 141.1, 129.0, 128.8, 




Compound 9a (0.2 g, 0.55 mmol) was coupled to pteroyl azide (0.24 g, 0.72 mmol) in the 
presence of TMG (0.13 g, 1.11 mmol) in DMSO as described for the synthesis of 5 to 
yield 10a (0.11 g, 31% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.54 (d, J = 
8.5 Hz, 2H), 7.29 (s, 15H), 6.59 (d, J = 8.6 Hz, 2H), 4.45 (d, J = 5.8 Hz, 2H), 2.98 (dd, J 
= 12.5, 7.1 Hz, 2H), 1.77 (t, J = 7.5 Hz, 2H), 1.39 (t, J = 8.1 Hz, 2H).
 13
C NMR (101 
MHz, DMSO-d6) δ 166.6, 161.8, 154.4, 150.9, 149.0, 142.8, 129.3, 129.1, 128.0, 127.9, 






Compound 9b (0.2 g, 0.53 mmol) was coupled to pteroyl azide (0.23 g, 0.69 mmol) in the 
presence of TMG (0.12 g, 1.07 mmol) in DMSO as described for the synthesis of 5 to 
yield 10b (0.12 g, 33% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.57 (d, J = 
8.0 Hz, 2H), 7.29 (s, 14H), 6.60 (d, J = 8.0 Hz, 2H), 4.45 (d, J = 5.9 Hz, 2H), 3.09 – 2.93 
(m, 2H), 1.90 – 1.69 (m, 2H), 1.30 – 1.02 (m, 4H).
 13
C NMR (101 MHz, DMSO-d6) δ 
166.4, 154.3, 150.9, 149.0, 142.9, 129.4, 129.0, 128.4, 127.9, 127.8, 122.6, 111.6, 92.1, 




Compound 9c (0.2 g, 0.52 mmol) was coupled to pteroyl azide (0.26 g, 0.77 mmol) in the 
presence of TMG (0.12 g, 1.03 mmol) in DMSO as described for the synthesis of 5 to 
yield 10c ( 0.10 g, 29% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.57 (d, J 
= 8.3 Hz, 2H), 7.30 (s, 14H), 6.59 (d, J = 8.1 Hz, 2H), 4.45 (d, J = 5.7 Hz, 2H), 3.07 (dd, 
J = 11.6, 6.0 Hz, 2H), 1.74 (t, J = 11.6 Hz, 2H), 1.38 – 1.11 (m, 4H), 1.04 – 0.88 (m, 2H).
 
13
C NMR (101 MHz, DMSO-d6) δ 166.4, 154.3, 150.9, 149.0, 142.9, 129.4, 129.0, 127.9, 









Compound 9d (0.2 g, 0.5 mmol) was coupled to pteroyl azide (0.22 g, 0.65 mmol) in the 
presence of TMG (0.11 g, 0.99 mmol) in DMSO as described for the synthesis of 5 to 
yield 10d (0.14 g, 41% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 7.56 (d, J = 
8.1 Hz, 2H), 7.29 (s, 16H), 6.58 (d, J = 8.8 Hz, 2H), 4.44 (d, J = 5.2 Hz, 2H), 3.13 – 3.03 
(m, 2H), 1.80 – 1.68 (m, 2H), 1.41 – 1.28 (m, 2H), 1.20 – 1.04 (m, 4H), 1.00 – 0.87 (m, 
2H).
 13
C NMR (101 MHz, DMSO-d6) δ 172.7, 166.4, 154.3, 150.9, 149.9, 149.0, 129.4, 




Compound 9e (0.2 g, 0.48 mmol) was coupled to pteroyl azide (0.21 g, 0.62 mmol) in the 
presence of TMG (0.11 g, 0.96 mmol) in DMSO as described for the synthesis of 5 to 
yield 10e (0.15 g, 45% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 7.57 (d, J = 
8.5 Hz, 2H), 7.29 (s, 15H), 6.59 (d, J = 8.5 Hz, 2H), 4.44 (d, J = 5.9 Hz, 2H), 3.13 (d, J = 
6.0 Hz, 2H), 1.73 (t, J = 7.5 Hz, 2H), 1.44 – 1.32 (m, 2H), 1.24 – 1.08 (m, 6H), 0.97 – 
0.87 (m, 2H).
 13
C NMR (101 MHz, DMSO-d6) δ 166.4, 154.3, 150.9, 149.0, 142.9, 129.4, 







Compound 9f (0.2 g, 0.46 mmol) was coupled to pteroyl azide (0.20 g, 0.60 mmol) in the 
presence of TMG (0.11 g, 0.93 mmol) in DMSO as described for the synthesis of 5 to 
yield 10f (0.088 g, 26% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.58 (d, J 
= 8.6 Hz, 2H), 7.30 (s, 15H), 6.60 (d, J = 8.7 Hz, 2H), 4.45 (d, J = 5.8 Hz, 2H), 3.19 – 
3.10 (m, 2H), 1.74 (t, J = 7.8 Hz, 2H), 1.42 (t, J = 8.5 Hz, 2H), 1.22 – 1.00 (m, 8H), 0.99 
– 0.88 (m, 2H).
 13
C NMR (101 MHz, DMSO-d6) δ 166.4, 154.3, 150.9, 149.0, 142.9, 




Compound 9g (0.2 g, 0.45 mmol) was coupled to pteroyl azide (0.2 g, 0.59 mmol) in the 
presence of TMG (0.10 g, 0.89 mmol) in DMSO as described for the synthesis of 5 to 
yield 10a (0.15 g, 45% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.57 (d, J = 
8.8 Hz, 2H), 7.30 (s, 15H), 6.59 (d, J = 8.8 Hz, 2H), 4.44 (d, J = 5.9 Hz, 2H), 3.14 (dd, J 
= 12.8, 6.4 Hz, 2H), 1.74 (t, J = 7.9 Hz, 2H), 1.48 – 1.35 (m, 2H), 1.26 – 1.04 (m, 10H), 
0.98 – 0.87 (m, 2H).
 13
C NMR (101 MHz, DMSO-d6) δ 166.4, 154.3, 150.9, 149.0, 142.9, 







Compound 10a (0.099 g, 0.15 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11a (0.05 g, 81% yield) 
was obtained as described for the synthesis of 6. 
1
H NMR (500 MHz, DMSO-d6) δ 8.65 
(s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 6.63 (d, J = 8.0 Hz, 2H), 4.48 (d, J = 5.3 Hz, 2H), 3.24 – 
3.13 (m, 2H), 1.98 (t, J = 7.2 Hz, 2H), 1.81 – 1.59 (m, 2H).
 13
C NMR (126 MHz, DMSO-
d6) δ 174.42, 169.2, 166.4, 161.1, 156.9, 154.0, 150.8, 149.0, 128.9, 128.2, 122.3, 111.5, 
46.2, 33.0, 30.3, 25.8, 25.6. HRMS (ESI) calcd for C18H21N8O4 [M+H]
+





Compound 10b (0.054 g, 0.081 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11b (0.025 g, 72% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (400 MHz, DMSO-d6) δ 
8.61 (s, 1H), 7.57 (d, J = 7.4 Hz, 2H), 6.59 (d, J = 7.4 Hz, 2H), 4.43 (s, 2H), 3.20 – 3.04 
(m, 2H), 1.92 (t, J = 6.3 Hz, 2H), 1.56 – 1.30 (m, 4H).
 13
C NMR (126 MHz, DMSO-d6) δ 
169.3, 166.3, 154.0, 150.7, 148.9, 128.9, 128.2, 122.4, 111.5, 46.2, 32.3, 29.3, 23.0. 
HRMS (ESI) calcd for C19H23N8O4 [M+H]
+






Compound 10c (0.081 g, 0.12 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11c (0.048 g, 92% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (400 MHz, DMSO-d6) δ 
8.62 (s, 1H), 7.57 (d, J = 7.0 Hz, 2H), 6.59 (d, J = 7.2 Hz, 2H), 4.44 (s, 2H), 3.15 – 3.05 
(m, 2H), 1.90 (t, J = 7.2 Hz, 2H), 1.54 – 1.33 (m, 4H), 1.33 – 1.12 (m, 2H).
 13
C NMR 
(126 MHz, DMSO-d6) δ 169.4, 166.2, 161.2, 154.0, 150.7, 148.9, 128.9, 128.2, 122.5, 







Compound 10d (0.12 g, 0.17 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11d (0.066 g, 85% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, DMSO-d6) δ 
8.65 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.6 Hz, 2H), 4.48 (d, J = 5.8 Hz, 2H), 
3.17 (dd, J = 12.7, 6.4 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.53 – 1.40 (m, 4H), 1.26 (d, J = 
2.8 Hz, 4H).
 13
C NMR (126 MHz, DMSO-d6) δ 169.4, 166.3, 154.0, 150.7, 149.0, 128.9, 
128.2, 122.5, 111.5, 46.2, 32.5, 29.5, 28.7, 26.5, 25.4. HRMS (ESI) calcd for C21H27N8O4 
[M+H]
+





Compound 10e (0.13 g, 0.18 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11e (0.082 g, 97% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, DMSO-d6) δ 
8.65 (s, 1H), 7.60 (d, J = 8.0 Hz, 2H), 6.62 (d, J = 8.0 Hz, 2H), 4.48 (d, J = 4.4 Hz, 2H), 
3.21 – 3.12 (m, 2H), 1.92 (t, J = 14.3 Hz, 2H), 1.55 – 1.39 (m, 4H), 1.33 – 1.16 (m, 6H).
 
13
C NMR (126 MHz, DMSO-d6) δ 169.4, 166.3, 154.0, 150.7, 149.0, 128.9, 128.2, 122.5, 
112.8, 111.5, 55.2, 46.2, 32.5, 29.6, 28.8, 28.8, 26.7, 25.4. HRMS (ESI) calcd for 
C22H29N8O4 [M+H]
+




Compound 10f (0.053 g, 0.073 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11f (0.024 g, 70% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (400 MHz, DMSO-d6) δ 
8.71 (s, 1H), 7.57 (d, J = 6.4 Hz, 2H), 6.60 (d, J = 8.0 Hz, 2H), 4.53 (s, 2H), 3.14 (t, J = 
11.7 Hz, 2H), 1.89 (t, J = 8.4 Hz, 2H), 1.52 – 1.34 (m, 4H), 1.29 – 1.06 (m, 10H). HRMS 
(ESI) calcd for C23H31N8O4 [M+H]
+








Compound 10g (0.13 g, 0.17 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 11g (0.075 g, 89% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (400 MHz, DMSO-d6) δ 
8.66 (s, 1H), 7.56 (d, J = 8.5 Hz, 2H), 6.58 (d, J = 7.8 Hz, 2H), 4.48 (s, 2H), 3.21 – 3.05 
(m, 2H), 1.89 (t, J = 6.5 Hz, 2H), 1.54 – 1.37 (m, 4H), 1.21 (dd, J = 14.9, 5.8 Hz, 10H).
 
13
C NMR (126 MHz, DMSO-d6) δ 175.5, 167.2, 160.1, 152.8, 130.3, 128.8, 114.0, 66.5, 
39.8, 33.8, 29.2, 28.9, 28.8, 28.7, 28.6, 26.5, 25.2, 24.6. HRMS (ESI) calcd for 
C26H25N8O3 [M+H]
+
 497.2044 found 497.2060. 
 
 (S)-tert-Butyl 2-azido-5-oxo-5-((4-oxo-4-((trityloxy)amino)butyl)amino)pentanoate 
(12a): Representative protocol for amide synthesis with EDCI. 
The α-azido L-glutamic acid α-tert-butyl ester 1 (0.27 g, 1.17 mmol), EDCI (0.22 g, 1.17 
mmol) and HOBT (0.16 g, 1.17 mmol) were dissolved in DMF and stirred at room 
temperature for 30 min. The O-trityl protected hydroxamate 9a (0.3 g, 0.83 mmol) was 
added and the mixture allowed to stir overnight at room temperature. DCM was added to 
the reaction and then washed with H2O (3 x 50 mL) , NaHCO3 (1 x 50 mL) , brine (1x 50 
mL)  and dried with Na2SO4. The crude product was purified by preparative TLC using 
EtOAc:Hexanes (1:1) to yield 12a (0.23g, 45% yield).
 1
H NMR (400 MHz, CDCl3) δ 
7.54 – 7.20 (m, 15H), 3.87 – 3.70 (m, 1H), 3.12 – 2.99 (m, 1H), 2.96 – 2.85 (m, 1H), 2.28 




(101 MHz, CDCl3) δ 169.2, 141.9, 140.9, 129.0, 128.2, 127.8, 93.6, 83.0, 61.8, 39.3, 
32.1, 29.2, 28.0, 27.0, 22.5. 
 
 (S)-tert-Butyl 2-azido-5-oxo-5-((7-oxo-7-((trityloxy)amino)heptyl)amino)pentanoate 
(12b): 
The α-azido L-glutamic acid α-tert-butyl ester 1 (0.2 g, 0.87 mmol) was coupled to 9d 
(0.35 g, 0.87 mmol) in the presence of IBCF (0.12 g, 0.87 mmol) and NMM (0.27 g, 2.62 
mmol) as described for the synthesis of 2. Purification of the crude product was done by 
prep TLC in EtOAc:Hexanes (1:1) resulting in 12b (0.33g, 61 % yield).
 1
H NMR (400 
MHz, CDCl3) δ 7.53 – 7.12 (m, 15H), 3.78 (dd, J = 9.0, 4.8 Hz, 1H), 3.20 – 3.04 (m, 2H), 
2.28 – 2.19 (m, 2H), 2.19 – 2.08 (m, 1H), 1.93 (dt, J = 13.8, 10.5 Hz, 1H), 1.85 – 1.76 
(m, 1H), 1.62 – 1.51 (m, 1H), 1.46 (s, 9H), 1.42 – 1.29 (m, 3H), 1.28 – 0.92 (m, 5H).
 13
C 
NMR (101 MHz, CDCl3) δ 177.3, 171.4, 169.2, 141.9, 141.1, 129.0, 128.1, 127.8, 93.4, 
83.0, 61.8, 39.4, 32.1, 31.1, 29.2, 28.6, 28.0, 27.1, 26.5, 23.2. 
 
 (S)-tert-Butyl 2-azido-5-oxo-5-((8-oxo-8-((trityloxy)amino)octyl)amino)pentanoate 
(12c): 
The α-azido L-glutamic acid α-tert-butyl ester 1 (0.19 g, 0.83 mmol) was coupled to 9e 
(0.45 g, 1.08 mmol) in the presence of IBCF (0.11 g, 0.83 mmol) and NMM (0.25 g, 2.49 
mmol) as described for the synthesis of 2. Purification of the crude product was done by 
prep TLC in EtOAc:Hexanes (1:1) resulting in 12c (0.28g, 54% yield).
 1
H NMR (500 
MHz, CDCl3) δ 7.43 (d, J = 65.5 Hz, 15H), 3.85 (dd, J = 8.9, 4.9 Hz, 1H), 3.28 – 3.16 
(m, 2H), 2.30 (t, J = 7.2 Hz, 2H), 2.21 (dt, J = 13.5, 7.0 Hz, 1H), 1.99 (dq, J = 14.2, 7.0 
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Hz, 1H), 1.92 – 1.82 (m, 1H), 1.66 – 1.56 (m, 1H), 1.52 (s, 9H), 1.49 – 1.42 (m, 2H), 1.31 
– 0.99 (m, 8H).
 13
C NMR (126 MHz, CDCl3) δ 171.1, 169.1, 128.9, 128.0, 82.9, 61.6, 
39.4, 32.0, 29.2, 28.6, 27.8, 26.9, 26.3. 
 
 (S)-tert-Butyl 2-azido-5-oxo-5-((9-oxo-9-((trityloxy)amino)nonyl)amino)pentanoate 
(12d): 
The α-azido L-glutamic acid α-tert-butyl ester 1 (0.2 g, 0.87 mmol) was coupled to 9f 
(0.38 g, 0.87 mmol) in the presence of IBCF (0.12 g, 0.87 mmol) and NMM (0.27 g, 2.62 
mmol) as described for the synthesis of 2. Purification of the crude product was done by 
prep TLC in EtOAc:Hexanes (1:1) resulting in 12d (0.34g, 60% yield).
 1
H NMR (500 
MHz, CDCl3) δ 7.59 – 7.27 (m, 15H), 3.89 (ddd, J = 42.9, 8.9, 4.8 Hz, 1H), 3.31 – 3.12 
(m, 2H), 2.29 (t, J = 7.1 Hz, 2H), 2.25 – 2.16 (m, 1H), 1.99 (dq, J = 14.3, 7.0 Hz, 1H), 
1.93 – 1.79 (m, 1H), 1.60 (t, J = 20.4 Hz, 1H), 1.52 (s, 9H), 1.50 – 1.43 (m, 2H), 1.33 – 
0.99 (m, 10H).
 13
C NMR (126 MHz, CDCl3) δ 171.0, 169.1, 140.9, 128.9, 128.0, 82.9, 
61.6, 39.4, 32.0, 29.4, 28.7, 27.9, 26.9, 26.5. 
 
 (S)-tert-Butyl 2-amino-5-oxo-5-((4-oxo-4-((trityloxy)amino)butyl)amino)pentanoate 
(13a): 
To a solution of 12a (0.22 g, 0.39 mmol) in EtOH (6 mL) and H2O (2 mL), NH4Cl (0.094 
g, 1.76 mmol) and zinc powder (0.12 g) were added and the resulting mixture was stirred 
under reflux for 2 h. After completion of the reaction, the mixture was filtered through a 
cilite pad. Following the removal of the solvent, the crude product was purified by 
preparative TLC with DCM:MeOH:NH4OH (10:1:0.1) yielding 13a (0.097 g, 46% yield). 
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1
H NMR (400 MHz, CDCl3) δ 7.51 – 7.19 (m, 15H), 3.24 (s, 1H), 3.09 – 2.84 (m, 2H), 
2.21 (t, J = 7.4 Hz, 2H), 2.06 – 1.93 (m, 1H), 1.90 – 1.82 (m, 1H), 1.76 – 1.66 (m, 1H), 
1.64 – 1.54 (m, 2H), 1.43 (s, 9H), 1.40 – 1.36 (m, 1H).
 13
C NMR (101 MHz, CDCl3) δ 
176.9, 142.1, 140.9, 129.1, 128.1, 127.8, 127.6, 93.5, 81.2, 54.4, 39.2, 32.8, 30.4, 29.0, 
28.0, 22.8. 
 
 (S)-tert-Butyl 2-amino-5-oxo-5-((7-oxo-7-((trityloxy)amino)heptyl)amino)pentanoate 
(13b): 
 Compound 12b (0.28 g, 0.45 mmol) was reduced in the presence of NH4Cl (0.058 g, 
1.08 mmol) and zinc powder (0.042 g) as described for 13a. Prep TLC with 
DCM:MeOH:NH4OH (10:1:0.1) yielded 13b (0.25 g, 93% yield). 
1
H NMR (400 MHz, 
CDCl3) δ 7.52 – 7.10 (m, 15H), 3.59 – 3.40 (m, 1H), 3.21 – 3.01 (m, 2H), 2.43 – 2.24 (m, 
2H), 2.21 – 2.06 (m, 1H), 1.96 – 1.77 (m, 2H), 1.62 – 1.52 (m, 1H), 1.44 (s, 9H), 1.40 – 
1.34 (m, 3H), 1.23 – 1.05 (m, 5H).
 13
C NMR (101 MHz, cdcl3) δ 177.3, 172.2, 142.0, 
141.1, 129.0, 128.1, 127.9, 127.8, 127.7, 93.3, 82.2, 54.0, 39.4, 32.6, 31.1, 29.1, 28.6, 
28.0, 26.5, 24.9, 23.2. 
 
 (S)-tert-Butyl 2-amino-5-oxo-5-((8-oxo-8-((trityloxy)amino)octyl)amino)pentanoate 
(13c): 
 Compound 12c (0.25 g, 0.39 mmol) was reduced in the presence of NH4Cl (0.05 g, 0.94 
mmol) and zinc powder (0.036 g) as described for 13a. Prep TLC with 
DCM:MeOH:NH4OH (10:1:0.1) yielded 13c (0.20 g, 85% yield). 
1
H NMR (400 MHz, 
CDCl3) δ 7.58 – 7.11 (m, 15H), 3.37 – 3.24 (m, 1H), 3.16 (dd, J = 12.7, 6.4 Hz, 2H), 2.28 
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(t, J = 7.4 Hz, 2H), 2.11 – 2.01 (m, 1H), 1.87 – 1.69 (m, 2H), 1.61 – 1.51 (m, 1H), 1.48 – 
1.34 (m, 10H), 1.33 – 0.94 (m, 8H).
 13
C NMR (101 MHz, CDCl3) δ 177.3, 174.7, 172.3, 
141.9, 141.1, 129.0, 128.1, 127.9, 93.3, 81.4, 54.3, 39.4, 33.0, 31.1, 30.3, 29.7, 29.4, 28.8, 
28.0, 26.6, 23.2. 
 
 (S)-tert-Butyl 2-amino-5-oxo-5-((9-oxo-9-((trityloxy)amino)nonyl)amino)pentanoate 
(13d): 
Compound 12d (0.29 g, 0.45 mmol) was reduced in the presence of NH4Cl (0.057 g, 1.07 
mmol) and zinc powder (0.041 g) as described for 13a. Prep TLC with 
DCM:MeOH:NH4OH (10:1:0.1) yielded 13c (0.26 g, 92% yield). 
1
H NMR (400 MHz, 
CDCl3) δ 7.51 – 7.15 (m, 15H), 3.51 – 3.40 (m, 1H), 3.23 – 3.10 (m, 2H), 2.39 – 2.26 (m, 
2H), 2.20 – 2.06 (m, 1H), 1.98 – 1.77 (m, 2H), 1.64 – 1.36 (m, 12H), 1.33 – 0.85 (m, 
10H).
 13
C NMR (101 MHz, CDCl3) δ 177.4, 172.3, 141.9, 141.1, 129.0, 128.1, 127.9, 





Compound 13a (0.078 g, 0.14 mmol) was coupled to pteroyl azide (0.13 g, 0.29 mmol) in 
presence of TMG (0.05 g, 0.43 mmol) in DMSO as described for 5 to yield 14a (0.035 g, 
29% yield).
 1
H NMR (500 MHz, DMSO-d6) δ 8.66 (s, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.32 
(s, 16H), 6.64 (d, J = 8.4 Hz, 2H), 4.49 (d, J = 5.8 Hz, 2H), 4.24 – 4.15 (m, 1H), 2.85 – 
2.75 (m, 2H), 2.17 – 2.11 (m, 2H), 2.04 – 1.95 (m, 1H), 1.92 – 1.82 (m, 1H), 1.79 – 1.72 
 119 
(m, 2H), 1.40 (s, 9H), 1.34 – 1.27 (m, 2H). HRMS (ESI) calcd for C46H50N9O7 [M+H]
+
 





Compound 13b (0.22 g, 0.38 mmol) was coupled to pteroyl azide (0.16 g, 0.49 mmol) in 
presence of TMG (0.086 g, 0.75 mmol) in DMSO as described for 5 to yield 14b (0.08 g, 
24% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.62 (d, J = 8.7 Hz, 2H), 7.30 
(s, 19H), 6.61 (d, J = 8.9 Hz, 2H), 4.46 (d, J = 5.9 Hz, 2H), 4.24 – 4.13 (m, 1H), 2.97 – 
2.88 (m, 2H), 2.18 – 2.10 (m, 2H), 2.02 – 1.93 (m, 1H), 1.92 – 1.82 (m, 1H), 1.74 (t, J = 
7.7 Hz, 2H), 1.44 – 1.34 (m, 11H), 1.28 – 1.18 (m, 4H), 0.95 – 0.88 (m, 2H). HRMS 
(ESI) calcd for C49H56N9O7 [M+H]
+





Compound 13c (0.20 g, 0.34 mmol) was coupled to pteroyl azide (0.23 g, 0.50 mmol) in 
presence of TMG (0.097 g, 0.84 mmol) in DMSO as described for 5 to yield 14c (0.070 
g, 23% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.62 (d, J = 8.7 Hz, 2H), 
7.30 (s, 15H), 6.61 (d, J = 8.7 Hz, 2H), 4.46 (d, J = 5.8 Hz, 2H), 4.22 – 4.14 (m, 1H), 
3.01 – 2.91 (m, 2H), 2.15 (dd, J = 13.8, 6.8 Hz, 2H), 2.02 – 1.93 (m, 1H), 1.92 – 1.81 (m, 
 120 
1H), 1.74 (t, J = 7.0 Hz, 2H), 1.36 (s, 9H), 1.32 – 1.24 (m, 2H), 1.17 – 1.04 (m, 6H), 0.94 
– 0.81 (m, 2H). HRMS (ESI) calcd for C50H58N9O7 [M+H]
+





Compound 13d (0.25 g, 0.41 mmol) was coupled to pteroyl azide (0.21 g, 0.62 mmol) in 
presence of TMG (0.095 g, 0.82 mmol) in DMSO as described for 5 to yield 14d (0.065 
g, 17% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.62 (d, J = 8.4 Hz, 2H), 
7.30 (s, 12H), 6.61 (d, J = 8.5 Hz, 2H), 4.46 (d, J = 5.1 Hz, 2H), 4.26 – 4.11 (m, 1H), 
3.00 – 2.94 (m, 2H), 2.21 – 2.09 (m, 2H), 2.06 – 1.93 (m, 1H), 1.91 – 1.79 (m, 1H), 1.74 
(t, J = 8.6 Hz, 2H), 1.37 (s, 8H), 1.33 – 1.26 (m, 2H), 1.17 – 1.03 (m, 8H), 0.97 – 0.84 
(m, 2H). HRMS (ESI) calcd for C51H60N9O7 [M+H]
+
 910.4610 found 910.4603. 
 
 (S)-2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-
((4-(hydroxyamino)-4-oxobutyl)amino)-5-oxopentanoic acid (15a): 
Compound 14a (0.035 g, 0.042 mmol) was dissolved in neat TFA (2 mL)  and TIPS  (0.5 
mL) and the resulting mixture was stirred at room temperature for 2 h. The desired 
product 15a (0.022 g, 96% yield) was obtained as described for the synthesis of 6.
 1
H 
NMR (500 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.67 (d, J = 8.7 Hz, 2H), 6.65 (d, J = 8.7 Hz, 
2H), 4.51 (s, 2H), 4.29 (t, J = 10.8 Hz, 1H), 3.01 (dt, J = 13.2, 6.8 Hz, 2H), 2.22 – 2.13 
(m, 2H), 2.11 – 2.02 (m, 1H), 1.98 – 1.85 (m, 3H), 1.64 – 1.52 (m, 2H).
 13
C NMR (126 
MHz, DMSO-d6) δ 174.1, 171.7, 169.1, 166.6, 161.0, 153.8, 151.0, 149.4, 148.8, 129.3, 
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128.2, 121.6, 111.5, 52.4, 46.2, 38.4, 32.3, 30.2, 26.9, 25.6. HRMS (ESI) calcd for 
C23H28N9O7 [M+H]
+
 542.2106 found 542.2097. 
 
 (S)-2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-
((7-(hydroxyamino)-7-oxoheptyl)amino)-5-oxopentanoic acid (15b): 
Compound 14b (0.061 g, 0.069 mmol) was dissolved in neat TFA (2 mL)  and TIPS (0.5 
mL)  and the resulting mixture was stirred at room temperature for 2 h. The desired 
product 15b (0.043 g, quantitative yield) was obtained as described for the synthesis of 6.
 
1
H NMR (500 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.66 (d, J = 8.3 Hz, 2H), 6.65 (d, J = 8.2 
Hz, 2H), 4.51 (s, 2H), 4.35 – 4.20 (m, 1H), 3.00 (dd, J = 12.1, 6.1 Hz, 2H), 2.22 – 2.14 
(m, 2H), 2.11 – 2.01 (m, 1H), 1.97 – 1.85 (m, 3H), 1.52 – 1.41 (m, 2H), 1.39 – 1.30 (m, 
2H), 1.28 – 1.16 (m, 4H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 171.6, 166.6, 153.9, 
151.0, 148.8, 129.3, 128.3, 121.7, 111.5, 52.5, 46.2, 38.8, 32.5, 32.3, 29.3, 28.6, 26.9, 
26.4, 25.3. HRMS (ESI) calcd for C26H34N9O7 [M+H]
+
 584.2576 found 584.2568. 
 
 (S)-2-(4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5-
((8-(hydroxyamino)-8-oxooctyl)amino)-5-oxopentanoic acid (15c): 
Compound 14c (0.07 g, 0.078 mmol) was dissolved in neat TFA (2 mL)  and TIPS (0.5 
mL)  and the resulting mixture was stirred at room temperature for 2 h. The desired 
product 15c (0.058 g, quantitative yield) was obtained as described for the synthesis of 6.
 
1
H NMR (500 MHz, DMSO-d6) δ 8.69 (s, 1H), 7.66 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.8 
Hz, 2H), 4.52 (s, 2H), 4.35 – 4.20 (m, 1H), 3.09 – 2.89 (m, 2H), 2.22 – 2.14 (m, 2H), 2.09 




C NMR (126 MHz, DMSO-d6) δ 174.1, 171.6, 169.4, 166.5, 160.8, 153.6, 
151.0, 149.8, 148.7, 129.2, 128.2, 121.7, 111.5, 52.6, 46.1, 38.8, 32.5, 32.3, 29.3, 28.8, 
28.7, 26.9, 26.6, 25.4. HRMS (ESI) calcd for C27H36N9O7 [M+H]
+




((9-(hydroxyamino)-9-oxononyl)amino)-5-oxopentanoic acid (15d): 
Compound 14d (0.065 g, 0.071 mmol) was dissolved in neat TFA (2 mL) and TIPS (2 
mL) and the resulting mixture was stirred at room temperature for 2 h. The desired 
product 15d (0.037 g, 84% yield) was obtained as described for the synthesis of 6.
 1
H 
NMR (500 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.66 (d, J = 8.7 Hz, 2H), 6.65 (d, J = 8.7 Hz, 
2H), 4.51 (s, 2H), 4.34 – 4.20 (m, 1H), 3.00 (dd, J = 12.8, 6.7 Hz, 2H), 2.22 – 2.13 (m, 
2H), 2.09 – 2.03 (m, 1H), 1.98 – 1.85 (m, 3H), 1.54 – 1.41 (m, 2H), 1.41 – 1.30 (m, 2H), 
1.26 – 1.16 (m, 8H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 171.6, 169.4, 166.5, 161.1, 
155.6, 153.9, 151.0, 148.8, 129.2, 128.2, 121.6, 111.5, 52.6, 46.2, 38.8, 32.5, 32.3, 29.4, 





tert-Butyl (2-amino-4-(thiophen-2-yl)phenyl)carbamate (17): 
Zinc powder (4.75 g) was added to a solution of 16 (6.65 g, 20.74 mmol) in dioxane (180 
mL) and H2O (45 ml) and stirred overnight at 70°C. Upon completion, EtOAc was added 
and the mixture was washed with H2O (3 x 100 mL)  and brine (1 x 100 mL). The crude 
product was purified by column chromatography, eluting with EtOAc:Hexanes (2:1), to 
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obtain 17 (3.95 g, 54% yield).
 1
H NMR (400 MHz, CDCl3) δ 7.34 – 7.20 (m, 3H), 7.10 – 
6.98 (m, 3H), 1.52 (s, 9H).
 13
C NMR (101 MHz, CDCl3) δ 153.7, 144.1, 139.9, 132.2, 
127.9, 124.8, 124.4, 122.8, 117.5, 115.0, 80.7, 28.3. 
 
tert-Butyl (2-(4-azidobutanamido)-4-(thiophen-2-yl)phenyl)carbamate (19a):  
The azido carboxylic acid 18a (0.31 g, 2.41 mmol), EDCI (0.46 g, 2.41 mmol) and 
HOBT (0.33 g, 2.41 mmol) were dissolved in DMF and the mixture was stirred at room 
temperature for 30 min. Following the addition of 17 (0.5 g, 1.72 mmol), the reaction was 
allowed to stir at 70°C for 6 h. Once the reaction was completed, DCM was added and 
the mixture was washed with H2O (3 x 50 mL) , NaHCO3 (1 x 50 mL), brine (1 x 50 mL)  
and dried with Na2SO4. Solvent was evaporated off to give 19a (0.64 g, 92% yield) which 
was used without further purification.
 1
H NMR (400 MHz, CDCl3) δ 7.42 – 7.31 (m, 2H), 
7.28 – 7.19 (m, 2H), 7.04 (dd, J = 5.1, 3.6 Hz, 1H), 6.98 (s, 1H), 3.34 (t, J = 6.6 Hz, 2H), 
2.42 (t, J = 7.2 Hz, 2H), 1.95 (p, J = 6.9 Hz, 2H), 1.51 (s, 9H).
 13
C NMR (101 MHz, 
CDCl3) δ 171.3, 154.1, 143.1, 131.5, 130.1, 129.8, 128.1, 124.9, 124.6, 123.7, 123.3, 
122.6, 81.1, 50.7, 33.7, 28.3, 24.7. 
 
tert-Butyl (2-(7-azidoheptanamido)-4-(thiophen-2-yl)phenyl)carbamate (19b): 
The azido carboxylic acid 18b (0.41 g, 2.4 mmol) was coupled to 17 (0.5 g, 1.72 mmol) 
in the presence of EDCI (0.46 g, 2.41 mmol) and HOBT ( 0.33 g, 2.41 mmol) as 
described for 19a to give 19b (0.74 g, 98% yield) which was used without further 
purification.
 1
H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.4 Hz, 1H), 7.33 (dd, J = 8.4, 1.9 
Hz, 1H), 7.21 (ddd, J = 12.5, 8.3, 4.9 Hz, 3H), 7.07 – 6.95 (m, 1H), 3.22 (t, J = 6.9 Hz, 
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2H), 2.31 (t, J = 7.5 Hz, 2H), 1.74 – 1.61 (m, 2H), 1.60 – 1.51 (m, 2H), 1.49 (s, 9H), 1.34 
(t, J = 9.5 Hz, 4H).
 13
C NMR (101 MHz, CDCl3) δ 172.6, 154.1, 143.2, 131.3, 130.3, 
129.9, 128.0, 124.7, 124.6, 123.5, 123.2, 122.5, 80.8, 51.3, 36.9, 28.7, 28.3, 26.4, 25.4. 
 
tert-Butyl (2-(8-azidooctanamido)-4-(thiophen-2-yl)phenyl)carbamate (19c): 
The azido carboxylic acid 18c (0.45 g, 2.4 mmol) was coupled to 17 (0.5 g, 1.72 mmol) 
in the presence of EDCI (0.46 g, 2.41 mmol) and HOBT ( 0.33 g, 2.41 mmol) as 
described for 19a to give 19c (0.56 g, 72% yield) which was used without further 
purification.
 1
H NMR (500 MHz, CDCl3) δ 7.45 – 7.34 (m, 2H), 7.30 – 7.23 (m, 2H), 
7.06 (dd, J = 8.9, 5.0 Hz, 2H), 3.27 (t, J = 6.9 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 1.76 – 
1.66 (m, 2H), 1.65 – 1.56 (m, 2H), 1.53 (s, 9H), 1.42 – 1.31 (m, 6H).
 13
C NMR (126 
MHz, CDCl3) δ 172.4, 154.0, 143.1, 131.4, 129.9, 127.9, 124.6, 124.5, 123.4, 123.1, 
122.4, 80.8, 51.3, 36.9, 28.9, 28.7, 28.6, 28.1, 26.4, 25.3. 
 
tert-Butyl (2-(9-azidononanamido)-4-(thiophen-2-yl)phenyl)carbamate (19d): 
The azido carboxylic acid 18d (0.48 g, 2.41 mmol) was coupled to 17 (0.5 g, 1.72 mmol) 
in the presence of EDCI (0.46 g, 2.41 mmol) and HOBT (0.33 g, 2.41 mmol) as described 
for 19a. The crude product was purified by column chromatography using DCM:Acetone 
(30:1) as eluent to obtain 19d (0.56 g, 70% yield).
 1
H NMR (400 MHz, CDCl3) δ 7.29 
(dt, J = 8.4, 5.1 Hz, 2H), 7.16 (ddd, J = 5.5, 4.4, 1.1 Hz, 2H), 7.02 – 6.91 (m, 2H), 3.18 (t, 
J = 6.9 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 1.67 – 1.57 (m, 2H), 1.55 – 1.48 (m, 2H), 1.43 
(s, 8H), 1.33 – 1.18 (m, 8H).
 13
C NMR (101 MHz, CDCl3) δ 172.6, 154.1, 143.2, 131.5, 
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130.1, 128.0, 124.8, 124.7, 123.6, 123.2, 122.6, 80.9, 51.4, 37.1, 29.2, 29.1, 29.0, 28.8, 
28.3, 26.7, 25.6. 
 
tert-Butyl (2-(4-aminobutanamido)-4-(thiophen-2-yl)phenyl)carbamate (20a): 
To a solution of 19a (0.53 g, 1.37 mmol) in EtOH (9 mL), EtOAc (3 mL) and H2O (3 
mL), NH4Cl (0.18 g, 3.42 mmol) and zinc powder (0.23 g) were added and the resulting 
mixture was stirred under reflux for 2 h. After completion of the reaction, the mixture 
was filtered through a cilite pad. The crude product was purified by preparative TLC with 
DCM:MeOH:NH4OH (8.5:1.5:0.3) yielding 20a (0.40 g, 78% yield). 
1
H NMR (400 
MHz, CDCl3) δ 7.66 – 7.45 (m, 2H), 7.31 (d, J = 8.1 Hz, 1H), 7.15 (s, 2H), 6.97 (s, 1H), 
2.80 – 2.53 (m, 2H), 2.42 – 2.29 (m, 2H), 1.86 – 1.69 (m, 2H), 1.52 – 1.38 (m, 9H).
 13
C 
NMR (101 MHz, CDCl3) δ 172.8, 153.9, 143.3, 131.2, 130.6, 129.1, 128.0, 124.6, 124.0, 
123.7, 123.0, 122.6, 80.6, 40.8, 34.4, 28.3, 27.3. 
 
tert-Butyl (2-(7-aminoheptanamido)-4-(thiophen-2-yl)phenyl)carbamate (20b): 
Compound 19b (0.55 g, 1.24 mmol) was reduced with NH4Cl (0.16 g, 2.98 mmol) and 
zinc (0.21 g) as described for 20a resulting in 20b (0.38 g, 74% yield).
 1
H NMR (400 
MHz, CDCl3) δ 7.58 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.17 (t, J 
= 3.8 Hz, 2H), 7.02 – 6.89 (m, 1H), 2.70 – 2.48 (m, 2H), 2.27 (t, J = 7.2 Hz, 2H), 1.67 – 
1.53 (m, 2H), 1.45 (s, 9H), 1.36 (d, J = 5.6 Hz, 2H), 1.29 – 1.15 (m, 4H).
 13
C NMR (101 
MHz, CDCl3) δ 172.9, 154.1, 143.3, 131.1, 130.5, 130.0, 128.0, 124.7, 124.5, 123.4, 
123.1, 122.5, 80.6, 41.7, 36.8, 32.7, 28.8, 28.3, 26.4, 25.5. 
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tert-Butyl (2-(8-aminooctanamido)-4-(thiophen-2-yl)phenyl)carbamate (20c): 
Compound 19c (0.40 g, 0.87 mmol) was reduced with NH4Cl (0.12 g, 2.19 mmol) and 
zinc (0.14 g) as described for 20a resulting in 20c (0.32 g, 86% yield).
 1
H NMR (400 
MHz, CDCl3) δ 7.55 (s, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 3.4 Hz, 1H), 7.19 – 
7.04 (m, 2H), 6.94 (s, 1H), 2.64 – 2.47 (m, 2H), 2.32 – 2.15 (m, 2H), 1.67 – 1.49 (m, 2H), 
1.42 (s, 9H), 1.27 – 0.93 (m, 8H).
 13
C NMR (101 MHz, CDCl3) δ 173.0, 154.1, 143.2, 
131.1, 130.5, 130.0, 128.0, 124.6, 123.4, 123.0, 122.4, 80.5, 41.7, 36.9, 32.7, 28.9, 28.3, 
26.5, 25.5. 
 
tert-Butyl (2-(9-aminononanamido)-4-(thiophen-2-yl)phenyl)carbamate (20d): 
Compound 19d (0.45 g, 0.95 mmol) was reduced with NH4Cl (0.13 g, 2.39 mmol) and 
zinc (0.16 g) as described for 20a resulting in 20d (0.34 g, 79% yield).
 1
H NMR (400 
MHz, CDCl3) δ 7.60 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.19 (d, J 
= 5.7 Hz, 2H), 7.04 – 6.91 (m, 1H), 2.63 (t, J = 8.7 Hz, 2H), 2.30 (t, J = 7.2 Hz, 2H), 1.73 
– 1.56 (m, 2H), 1.46 (s, 9H), 1.41 (s, 2H), 1.24 (s, 8H).
 13
C NMR (101 MHz, CDCl3) δ 
172.9, 154.2, 143.3, 131.2, 130.4, 130.1, 128.0, 124.7, 124.6, 123.4, 123.1, 122.5, 80.6, 




The α-azido L-glutamic acid α-tert-butyl ester 1 (0.13 g, 0.56 mmol), EDCI (0.11 g, 0.56 
mmol) and HOBT (0.076 g, 0.56 mmol) were dissolved in DMF and stirred at room 
temperature for 30 min. Compound 20a (0.15 g, 0.34 mmol) was added and the mixture 
 127 
allowed to stir overnight at room temperature. DCM was added to the reaction and then 
washed with H2O (3 x 50 mL) , NaHCO3 (1 x 50 mL), brine (1 x 50 mL)  and dried with 
Na2SO4. Solvent was evaporated off and the crude product was purified by preparative 
TLC using DCM:MeOH:NH4OH (8.5:1.5:0.3) to yield 21a (0.23g, 98% yield).
 1
H NMR 
(400 MHz, CDCl3) δ 7.59 – 7.49 (m, 2H), 7.36 (dd, J = 8.4, 1.7 Hz, 1H), 7.20 (t, J = 3.7 
Hz, 2H), 7.00 (dd, J = 4.8, 3.8 Hz, 1H), 3.78 (dd, J = 8.7, 4.8 Hz, 1H), 3.29 – 3.20 (m, 
2H), 2.36 (t, J = 11.1 Hz, 2H), 2.25 (t, J = 7.1 Hz, 2H), 2.18 – 2.04 (m, 1H), 2.00 – 1.89 
(m, 1H), 1.86 – 1.75 (m, 2H), 1.47 (s, 9H), 1.45 (s, 9H).
 13
C NMR (101 MHz, CDCl3) δ 
172.4, 169.2, 153.9, 143.2, 131.0, 130.5, 129.5, 128.0, 124.7, 124.4, 123.6, 123.1, 122.3, 




Compound 1 (0.12 g, 0.50 mmol) was coupled to 20b (0.15 g, 0.36 mmol) with EDCI 
(0.096 g, 0.50 mmol) and HOBT (0.068 g, 0.50 mmol) as described for 21a to give 21b 
(0.22 g, 98% yield).
 1
H NMR (400 MHz, CDCl3) δ 7.57 – 7.44 (m, 2H), 7.33 (d, J = 8.4 
Hz, 1H), 7.18 (d, J = 4.5 Hz, 2H), 7.03 – 6.90 (m, 1H), 3.76 (dd, J = 8.9, 4.8 Hz, 1H), 
3.10 (dd, J = 12.9, 6.6 Hz, 2H), 2.30 (t, J = 7.2 Hz, 2H), 2.22 (t, J = 7.2 Hz, 2H), 2.17 – 
2.05 (m, 1H), 1.96 – 1.83 (m, 1H), 1.64 – 1.54 (m, 2H), 1.45 (s, 9H), 1.44 (s, 9H), 1.41 – 
1.32 (m, 2H), 1.30 – 1.18 (m, 4H).
 13
C NMR (101 MHz, CDCl3) δ 172.9, 171.6, 169.2, 
154.0, 143.2, 131.1, 130.5, 129.8, 128.0, 124.7, 124.5, 123.4, 123.1, 122.5, 83.0, 80.7, 




Compound 1 (0.11 g, 0.49 mmol) was coupled to 20c (0.15 g, 0.35 mmol) with EDCI 
(0.093 g, 0.49 mmol) and HOBT (0.066 g, 0.49 mmol) as described for 21a to give 21c 
(0.23 g, quantitative yield).
 1
H NMR (400 MHz, CDCl3) δ 7.53 – 7.41 (m, 2H), 7.39 – 
7.30 (m, 1H), 7.18 (t, J = 3.8 Hz, 2H), 6.99 (dd, J = 4.9, 3.8 Hz, 1H), 3.76 (dd, J = 9.0, 
4.8 Hz, 1H), 3.13 (dd, J = 13.4, 6.7 Hz, 2H), 2.32 (t, J = 7.3 Hz, 2H), 2.21 (t, J = 7.2 Hz, 
2H), 2.15 – 2.03 (m, 1H), 1.89 (ddd, J = 15.6, 13.9, 6.9 Hz, 1H), 1.71 – 1.57 (m, 2H), 
1.46 (s, 9H), 1.44 (s, 9H), 1.42 – 1.37 (m, 2H), 1.31 – 1.22 (m, 6H).
 13
C NMR (101 MHz, 
CDCl3) δ 172.8, 171.5, 169.2, 154.0, 143.3, 131.1, 130.4, 129.9, 128.0, 124.7, 124.5, 





Compound 1 (0.087 g, 0.38 mmol) was coupled to 20b (0.15 g, 0.27 mmol) with EDCI 
(0.072 g, 0.38 mmol) and HOBT (0.051 g, 0.38 mmol) as described for 21a to give 21d 
(0.20 g, quantitative yield).
 1
H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 15.0, 9.4 Hz, 
2H), 7.34 (dd, J = 8.4, 2.0 Hz, 1H), 7.20 (dd, J = 4.1, 2.9 Hz, 2H), 7.00 (dd, J = 4.9, 3.7 
Hz, 1H), 3.77 (dd, J = 9.0, 4.8 Hz, 1H), 3.16 (dd, J = 13.6, 6.5 Hz, 2H), 2.34 (t, J = 7.4 
Hz, 2H), 2.22 (t, J = 7.1 Hz, 2H), 2.17 – 2.07 (m, 1H), 1.97 – 1.85 (m, 1H), 1.71 – 1.61 
(m, 2H), 1.47 (s, 9H), 1.45 (s, 9H), 1.43 – 1.39 (m, 2H), 1.30 – 1.18 (m, 8H).
 13
C NMR 
(101 MHz, CDCl3) δ 172.8, 171.4, 169.2, 154.0, 143.3, 131.2, 130.4, 130.0, 128.0, 124.7, 
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124.5, 123.5, 123.1, 122.5, 83.1, 80.7, 61.8, 39.5, 37.0, 32.1, 29.4, 28.9, 28.8, 28.3, 28.0, 




To a solution of 21a (0.21 g, 0.37 mmol) in EtOH (9 mL) and H2O (3 mL) was added 
NH4Cl (0.049 g, 0.91 mmol) and zinc powder (0.06 g) and the resulting mixture was 
stirred under reflux for 3 h. After completion of the reaction, the mixture was filtered 
through a cilite pad. The crude product was purified by preparative TLC with 
DCM:MeOH (10:1) yielding 22a (0.13 g, 63% yield). 
1
H NMR (400 MHz, CDCl3) δ 7.72 
(s, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.23 (dd, J = 8.9, 8.1 Hz, 2H), 
7.06 – 6.98 (m, 1H), 3.36 – 3.20 (m, 3H), 2.39 (t, J = 6.2 Hz, 2H), 2.32 – 2.24 (m, 2H), 
2.14 – 2.06 (m, 1H), 1.93 – 1.83 (m, 2H), 1.79 – 1.70 (m, 1H), 1.49 (s, 9H), 1.43 (s, 9H).
 
13
C NMR (101 MHz, CDCl3) δ 172.3, 154.0, 143.4, 131.1, 130.4, 129.8, 128.0, 124.7, 




Compound 21b (0.22 g, 0.34 mmol) was reduced in the presence of NH4Cl (0.046 g, 0.86 
mmol) and zinc powder (0.056 g) as described for 22a yielding 22b (0.14 g, 68% yield).
 
1
H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 31.0, 8.4 Hz, 3H), 7.29 – 7.18 (m, 2H), 7.10 
– 6.94 (m, 1H), 3.29 – 3.07 (m, 2H), 2.37 (t, J = 5.5 Hz, 2H), 2.32 – 2.19 (m, 2H), 2.15 – 




(101 MHz, CDCl3) δ 172.5, 143.3, 131.5, 130.2, 128.0, 124.8, 123.6, 123.2, 122.6, 81.4, 




Compound 21c (0.23 g, 0.36 mmol) was reduced in the presence of NH4Cl (0.086 g, 1.61 
mmol) and zinc powder (0.11 g) as described for 22a yielding 22c (0.20 g, 90% yield).
 1
H 
NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.3 Hz, 
1H), 7.20 (d, J = 4.3 Hz, 2H), 7.06 – 6.93 (m, 1H), 3.20 – 3.07 (m, 2H), 2.99 – 2.75 (m, 
2H), 2.35 (t, J = 7.1 Hz, 2H), 2.25 (t, J = 14.4 Hz, 2H), 2.04 (dd, J = 20.4, 9.4 Hz, 1H), 
1.84 – 1.72 (m, 1H), 1.70 – 1.61 (m, 2H), 1.47 (s, 9H), 1.40 (s, 9H), 1.34 – 1.18 (m, 6H).
 
13
C NMR (101 MHz, CDCl3) δ 172.9, 154.1, 143.3, 131.2, 130.4, 130.1, 128.0, 125.0, 
123.5, 123.1, 122.6, 82.0, 80.7, 77.4, 77.1, 76.8, 50.4, 39.4, 36.9, 32.7, 29.2, 28.7, 28.4, 




Compound 21d (0.20 g, 0.30 mmol) was reduced in the presence of NH4Cl (0.073 g, 1.36 
mmol) and zinc powder (0.089 g) as described for 22a yielding 22d (0.17 g, 88% yield).
 
1
H NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.44 (t, J = 11.0 Hz, 1H), 7.32 (dd, J = 8.4, 
1.6 Hz, 1H), 7.22 – 7.13 (m, 2H), 7.04 – 6.92 (m, 1H), 3.18 – 3.03 (m, 2H), 2.34 (t, J = 
7.3 Hz, 2H), 2.31 – 2.20 (m, 2H), 2.10 – 1.94 (m, 1H), 1.87 – 1.70 (m, 1H), 1.71 – 1.60 
(m, 2H), 1.46 (s, 9H), 1.41 (m, 10H), 1.36 – 1.15 (m, 9H).
 13
C NMR (101 MHz, CDCl3) δ 
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173.0, 154.1, 143.3, 131.1, 130.5, 130.0, 128.0, 124.7, 124.5, 123.4, 123.1, 122.5, 81.9, 





Compound 22a (0.12 g, 0.21 mmol) was coupled to pteroyl azide (0.19 g, 0.41 mmol) in 
the presence of TMG (0.071 g, 0.62 mmol) in DMSO as described for the synthesis of 5 
to yield 23a (0.045 g, 26% yield).
 1
H NMR (500 MHz, DMSO-d6) δ 8.66 (s, 1H), 7.75 (d, 
J = 1.9 Hz, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 5.1, 1.0 
Hz, 1H), 7.48 – 7.38 (m, 2H), 7.12 (dd, J = 5.0, 3.6 Hz, 1H), 6.66 (dd, J = 14.6, 8.9 Hz, 
2H), 4.49 (d, J = 6.0 Hz, 2H), 4.24 (dd, J = 12.3, 9.4 Hz, 1H), 3.15 – 3.08 (m, 2H), 2.38 
(t, J = 7.3 Hz, 2H), 2.21 (dt, J = 14.2, 7.1 Hz, 2H), 2.09 – 1.99 (m, 1H), 1.97 – 1.87 (m, 
1H), 1.74 (dd, J = 16.3, 9.0 Hz, 2H), 1.46 (s, 9H), 1.40 (s, 9H). HRMS (ESI) calcd for 
C42H51N10O8S [M+H]
+





Compound 22b (0.12 g, 0.20 mmol) was coupled to pteroyl azide (0.18 g, 0.41 mmol) in 
the presence of TMG ( 0.07 g, 0.61 mmol) in DMSO as described for the synthesis of 5 
to yield 23b (0.038 g, 21% yield).
 1
H NMR (500 MHz, DMSO-d6) δ 8.66 (s, 1H), 7.73 (d, 
J = 1.9 Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.4 Hz, 1H), 7.52 (dd, J = 5.1, 1.1 
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Hz, 1H), 7.47 – 7.40 (m, 2H), 7.13 (dd, J = 4.5, 3.0 Hz, 1H), 6.65 (d, J = 8.8 Hz, 2H), 
4.49 (d, J = 5.9 Hz, 2H), 4.24 – 4.16 (m, 1H), 3.03 (dd, J = 12.9, 6.7 Hz, 2H), 2.40 – 2.35 
(m, 2H), 2.24 – 2.12 (m, 2H), 2.06 – 1.97 (m, 1H), 1.94 – 1.85 (m, 1H), 1.65 – 1.54 (m, 
2H), 1.47 (s, 10H), 1.42 – 1.36 (m, 12H), 1.35 – 1.27 (m, 4H). HRMS (ESI) calcd for 
C45H57N10O8S [M+H]
+





Compound 22c (0.17 g, 0.28 mmol) was coupled to pteroyl azide (0.25 g, 0.56 mmol) in 
the presence of TMG (0.097 g, 0.84 mmol) in DMSO as described for the synthesis of 5 
to yield 23c (0.070 g, 28% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 7.71 (s, 
1H), 7.62 (d, J = 8.6 Hz, 2H), 7.58 (d, J = 8.7 Hz, 1H), 7.49 (d, J = 4.5 Hz, 1H), 7.44 – 
7.37 (m, 2H), 7.12 – 7.08 (m, 1H), 6.61 (d, J = 8.5 Hz, 2H), 4.44 (d, J = 6.0 Hz, 2H), 4.23 
– 4.12 (m, 1H), 3.03 – 2.94 (m, 2H), 2.34 (t, J = 7.5 Hz, 2H), 2.20 – 2.11 (m, 2H), 2.02 – 
1.94 (m, 1H), 1.91 – 1.82 (m, 1H), 1.62 – 1.54 (m, 2H), 1.42 (s, 9H), 1.37 (s, 9H), 1.32 – 
1.20 (m, 8H). HRMS (ESI) calcd for C46H59N10O8S [M+H]
+





Compound 22d (0.17 g, 0.27 mmol) was coupled to pteroyl azide (0.24 g, 0.53 mmol) in 
the presence of TMG (0.091 g, 0.80 mmol) in DMSO as described for the synthesis of 5 
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to yield 23d (0.11 g, 46% yield).
 1
H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1H), 7.69 (d, 
J = 2.1 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 5.1 Hz, 
1H), 7.45 – 7.36 (m, 2H), 7.10 (dd, J = 5.0, 3.7 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 4.46 (d, 
J = 6.0 Hz, 2H), 4.23 – 4.12 (m, 1H), 3.02 – 2.94 (m, 2H), 2.34 (t, J = 7.5 Hz, 2H), 2.15 
(dd, J = 12.6, 6.6 Hz, 2H), 2.01 – 1.93 (m, 1H), 1.91 – 1.83 (m, 1H), 1.64 – 1.54 (m, 2H), 
1.44 (s, 9H), 1.41 – 1.38 (m, 2H), 1.37 (s, 9H), 1.32 – 1.21 (m, 8H). HRMS (ESI) calcd 
for C47H61N10O8S [M+H]
+





Compound 23a (0.032 g, 0.037 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 24a (0.03 g, 
quantitative yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, 
DMSO-d6) δ 8.66 (s, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.50 (s, 1H), 7.36 (d, J = 4.8 Hz, 1H), 
7.27 – 7.18 (m, 2H), 7.07 – 7.03 (m, 1H), 6.77 (d, J = 8.3 Hz, 1H), 6.65 (d, J = 8.5 Hz, 
2H), 4.50 (s, 2H), 4.32 (t, J = 10.6 Hz, 1H), 3.11 (dt, J = 12.8, 6.7 Hz, 2H), 2.33 (t, J = 
7.4 Hz, 2H), 2.22 (t, J = 7.3 Hz, 2H), 2.14 – 2.06 (m, 1H), 1.99 – 1.88 (m, 1H), 1.78 – 
1.65 (m, 2H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 171.8, 171.4, 166.7, 153.9, 151.0, 
148.8, 144.5, 129.3, 128.5, 124.1, 123.6, 123.5, 122.9, 121.6, 121.3, 116.6, 111.5, 65.2, 
52.4, 46.2, 38.3, 33.4, 32.3, 31.0, 26.9, 25.6, 15.5. HRMS (ESI) calcd for C33H35N10O6 S 
[M+H]
+





Compound 23b (0.039 g, 0.043 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 24b (0.027 g, 84% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, DMSO-d6) δ 
8.67 (s, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 1.8 Hz, 1H), 7.36 (d, J = 4.9 Hz, 1H), 
7.26 – 7.20 (m, 2H), 7.07 – 7.03 (m, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.65 (d, J = 8.6 Hz, 
2H), 4.50 (s, 2H), 4.28 (t, J = 10.9 Hz, 1H), 3.08 – 2.99 (m, 2H), 2.34 (t, J = 7.4 Hz, 2H), 
2.19 (t, J = 8.4 Hz, 2H), 2.08 – 2.02 (m, 1H), 1.97 – 1.88 (m, 1H), 1.65 – 1.53 (m, 2H), 
1.43 – 1.34 (m, 2H), 1.35 – 1.25 (m, 4H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 
171.6, 166.6, 151.0, 148.8, 144.5, 129.3, 128.5, 128.2, 123.6, 122.7, 121.6, 121.4, 111.5, 
65.2, 52.6, 46.2, 38.8, 36.1, 32.3, 29.3, 28.7, 26.9, 26.5, 25.4, 15.5. HRMS (ESI) calcd 
for C36H41N10O6 S [M+H]
+





Compound 23c (0.032 g, 0.035 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 24c (0.025 g, 93% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, DMSO-d6) δ 
8.67 (s, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 4.6 Hz, 1H), 
7.27 – 7.21 (m, 2H), 7.07 – 7.03 (m, 2H), 6.79 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 8.8 Hz, 
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2H), 4.51 (s, 2H), 4.32 – 4.23 (m, 1H), 3.08 – 2.99 (m, 2H), 2.34 (dd, J = 9.4, 5.4 Hz, 
2H), 2.22 – 2.15 (m, 2H), 2.08 – 2.01 (m, 1H), 1.98 – 1.87 (m, 1H), 1.65 – 1.57 (m, 2H), 
1.44 – 1.25 (m, 8H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 171.8, 171.6, 171.1, 171.0, 
166.5, 161.0, 153.8, 151.0, 149.3, 148.8, 144.5, 129.2, 128.5, 128.2, 124.5, 123.7, 123.6, 
123.4, 122.6, 121.7, 121.5, 121.4, 117.0, 111.5, 52.6, 46.2, 36.1, 32.3, 30.9, 29.4, 29.3, 








Compound 23d (0.034 g, 0.037 mmol) was dissolved in neat TFA (2 mL) and TIPS (0.5 
mL) and stirred at room temperature for 2 h. The desired product 24d (0.022 g, 79% 
yield) was obtained as described for the synthesis of 6.
 1
H NMR (500 MHz, DMSO-d6) δ 
8.67 (s, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.51 (s, 1H), 7.37 (d, J = 5.0 Hz, 1H), 7.28 – 7.21 
(m, 2H), 7.08 – 7.02 (m, 1H), 6.80 (d, J = 8.3 Hz, 1H), 6.65 (d, J = 8.4 Hz, 2H), 4.51 (s, 
2H), 4.35 – 4.25 (m, 1H), 3.05 – 2.97 (m, 2H), 2.34 (t, J = 7.3 Hz, 2H), 2.19 (t, J = 11.0 
Hz, 2H), 2.11 – 2.00 (m, 1H), 1.97 – 1.86 (m, 1H), 1.67 – 1.54 (m, 2H), 1.40 – 1.22 (m, 
10H).
 13
C NMR (126 MHz, DMSO-d6) δ 174.1, 171.8, 171.6, 166.5, 161.0, 153.8, 151.0, 
148.8, 144.4, 129.2, 128.5, 128.2, 123.7, 123.4, 122.6, 121.7, 121.5, 111.5, 52.6, 46.2, 
36.1, 32.3, 29.4, 29.1, 29.0, 26.9, 26.7, 25.5. HRMS (ESI) calcd for C38H45N10O6 S 
[M+H]
+
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CHAPTER 4  




 Histone deacetylase inhibitors (HDACi) by triggering a variety of cellular 
pathways have displayed significant potential as cancer chemotherapy agents. Responses 
to HDACi exposure in transformed cells include differentiation, cell cycle arrest, 
increased immunogenicity, apoptosis, and autophagy.
1,2
 These responses culminate in the 
decreased of tumor size and/or cell death. However, due to the ability of cancer cells to 
adapt to their microenvironments, various mechanisms of resistance to HDACi have been 
described.
3
 These drug-resistance mechanisms may explain the lack of efficacy of 
HDACi seen in certain clinical trials. Furthermore, the understanding of such 
mechanisms can result in the development of combination therapies with other cytotoxic 
agents capable of potentiating the clinical effects of HDACi.  
 
4.2. Mechanisms of Resistance to HDACi 
4.2.1. Efflux pumps 
 P-Glycoproteins including multidrug resistance proteins are upregulated in 
malignant cells upon exposure to cytotoxic agents.
4
 These efflux pumps whose substrates 
encompass a wide range of molecules exclude chemotherapeutics from malignant cells 
thus minimizing exposure of the drugs to their intracellular targets.
5
 Although various 
HDACi such as sodium butyrate, FK228 (Romidepsin), valproic acid and TSA were 
found to increase the expression of the P-glycoprotein, only FK228 (Romidepsin) is a 
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substrate of these efflux pumps.
6,7,8
 These pumps do not constitute an important 
mechanism of resistance to HDACi treatment as hydroxamate and carboxylic acid based 





4.2.2. Changes in HDAC expression level 
 Although this mechanism has not been proven clinically, it has been observed in 
various cell lines upon exposure to HDACi. Following exposure to a inhibitor, cancer 
cells can upregulate their HDACs expression enabling them to compensate for the 
HDACi's presence. In melanoma cells, resistance to sodium butyrate was achieved by the 
overexpression of HDAC1.
10
 Furthermore, in HL-60 leukemia cells lacking HDAC6, 




4.2.3. Expression of apoptosis related proteins 
 The induction of apoptosis is a balancing act between the expression of pro-
apoptotic genes (Bax, Bak, Bim, Bmf and caspases) and anti-apoptotic genes (BCL2, 
BCL-XL and XIAP).
12
 HDACi treatment, by promoting the expression of pro-apoptotic 
genes, induce cancer cell death.
13
 However, this response is blunted when anti-apoptotic 




4.2.4. Increased antioxidant production 
 Increase in reactive oxygen species (ROS) is important in HDACi-induced 
cytotoxicity.
15
 The upregulation of ROS production has been linked to a disruption of the 
mitochondrial membrane, a decreased production of the antioxidant thioredoxin and the 
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upregulation of thioredoxin-binding protein 2 (TBP-2) which is a negative regulator of 
thioredoxin.
1,16
 As such, an increase in antioxidant production such as glutathione can 
mitigate the damages due to the ROS production upon exposure of cancer to HDACi.
17
     
 
4.3. Novel mechanism of resistance to HDACi 
 Balasubramanian et al discovered that in T-cells, the HDAC8 selective inhibitor 
PCI-34051, induces apoptosis through a Ca
2+
 signaling pathway involving the 
phospholipase C-γ1 (PLC-γ1).
18
 Upon exposure to PCI-34051, Ca
2+
 is released from the 
endoplasmic reticulum (ER), resulting in the release of mitochondrial cytochrome c. The 
cytochrome c in turn binds to the inositol 1,4,5 triphosphate receptors (IP3R) enabling the 
activation of PLC-γ1 leading to further release of Ca
2+
 and mitochondrial cytochrome c 
through a positive feedback mechanism. 
19,20
 In Jurkat Jγ, a mutant Jurkat cell line with 
no detectable PLC-γ1 activity, the HDAC8 selective PCI-34051 did not induce cell death, 
suggesting the crucial role of PLC-γ1 in HDAC8 inhibitor induced apoptosis. We decided 
to examine the requirement of PLC-γ1 in the apoptosis induced by selective HDACi 
(HDAC1 and 6), pan-inhibitors including IR-2-17 and the clinically approved SAHA and 








Table 4.1: Structures and HDAC inhibition profile of selected HDAC inhibitors. 
 
Compound IC50 (μM) 
HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 HDAC10 
 
PCI-34051* 
4 > 50 > 50 2.9 0.01 13 
 
Tubastatin A† 
16.4 > 30 > 30 0.015 0.854 > 30 
 
SHI1:2‡ 
0.007 0.049 10 > 10 > 10 - 
 
SAHA* 
0.028 0.06 0.044 0.022 0.41 0.04 
 
FK228 (Romidepsin)** 
0.036 0.047 NT 14 NT NT 
 
IR-2-17*** 



















4.3.1. Anticancer activity of selected compounds against wild type Jurkat and the 
Jurkat subline Jγ 
 The wild type Jurkat and its mutant subline Jγ were exposed to tubastatin A and 
selected compounds aforementioned in Table 4.1. Against the wild type Jurkat, all the 
tested compounds were very potent with FK228 (Romidepsin) having a single digit 
nanomolar IC50 (Table 4.2). In Jurkat Jγ, the potency of all the compounds was 
diminished, however, the degree of resistance of Jurkat Jγ cells varied from one 
compound to the other. The isoform selective HDACi, Tubastatin A (HDAC6) and 
SHI1:2 (HDAC1), and SAHA did not show any anticancer activity at the highest tested 
concentration of 20 μM, whereas F 228 and IR-2-17 had IC50s of 830 nM and 17.34 μM 
respectively suggesting the crucial role of PLC-γ1 in the apoptosis potentiation of these 
compounds (Table 4.2). The single digit nanomolar IC50 of FK228 against the wild Jurkat 
is in agreement with previous studies which established FK228 as a potent drug against 
leukemia cells.
24
  This observed potency is attributable to the reduced form of FK228 
(red-FK228) which ensues following the cellular uptake of FK228 (Figure 4.1). Not only 
is red-FK228 a much more potent HDACi than FK228, but its formation also results in 
the depletion of cellular antioxidants such glutathione leading to an increased production 
of ROS.
25
 The FK228-induced apoptosis is much more sensitive to the lack of PLC-γ1 as 
its IC50 was increased by 277 fold in Jγ compared to 25 fold for IR-2-17 (Table 4.2). 
Although SHI1:2, tubastatin A and SAHA did not displayed any anticancer activity at 20 
μM, it is possible that these compounds may show anticancer activity at higher 





Table 4.2: Anticancer activity of selected compounds (IC50 in μM) 
 Wild Jurkat Jurkat Jγ Resistance increase in Jγ 
compared to wild type 
Jurkat 
SHI1:2 2.73 ± 0.35 NI - 
Tubastatin 
A 
3.38 ± 0.26 NI - 
SAHA 1.49 ± 0.10 NI - 
FK228 0.003 ± 0.001 0.830 ± 0.100 277 
IR-2-17 0.700 ± 0.140 17.34 ± 2.30 25 
NI: No inhibition at 20 μM 
 







4.3.2. Phospholipase C-γ2 may be responsible for apoptosis potentiation in Jurkat Jγ 
subline 
 PLC-γ1 is a key player in potentiating both the intrinsic and extrinsic apoptotic 
pathways, however, its total loss in Jγ does not render this cell line completely 
impervious to HDACi induced apoptosis though a degree of resistance is present. This 
observation points to the presence of other phospholipases capable of participating in all 
the pathways requiring PLC-γ1. Indeed in T-cells, the phospholipase C-γ2 (PLC-γ2) is 




4.3.3. Mutations in PLC-γ1 activation pathways as potentially novel mechanisms of 
HDACi resistance 
  ased on the resistance of Jurkat Jγ cells (no PLC-γ1 activity) to HDACi-induced 
apoptosis, it can be implied that mutations in malignant cells resulting in such phenotype 
(loss of PLCγ1) can constitute a novel mechanism of resistance to HDACi. However, 
such mutations in any organism are lethal at the embryonic stage emphasizing the crucial 
role of PLC-γ1 in processes such as embryogenesis, cellular homeostasis and potentially 
cancer.
27
 Furthermore, the Jγ subline is an artificial product of mutagenesis-mutant 
selection on the wild type Jurkat as opposed to a cell line isolated from a leukemia patient 
and whose survival is due to the residual expression of the PLC-γ2.
27 
Loss-of-function 
mutations of PLC-γ1 have not been linked to tumorigenesis whereas multiple gain-of-
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 Although, loss-of-function mutations in PLC-γ1 have not been described in 
cancer, mutations in the IP3R (downstream of the PLC-γ1 pathway) on the ER may result 
in resistance to apoptosis including HDACi-induced. As previously mentioned, initial 
Ca
2+
 release upon apoptosis induction triggers cytochrome c release from the 
mitochondria which potentiates further Ca
2+
 release from the ER upon binding to the 
IP3R. Abrogation of the binding interactions between cytochrome c and IP3R can prevent 
the late phase Ca
2+
 release upon apoptosis. This scenario has been described by Boehning 
and coworkers who showed that the mutation of key glutamic acids residues within the 
cytochrome c binding domain of IP3R prevents the binding of cytochrome c resulting in 
resistance to apoptosis while retaining the ability of other cellular pathways to mobilize 
Ca
2+
 through PLC-γ1  and IP3R.
30
    
 
4.4. Conclusion 
 Through exposure of wild type Jurkat and Jurkat Jγ cells to selected compounds 
we explored the indispensability of PLC-γ1 in the potentiation of HDACi-induced 
apoptosis. Previous work by Balasubramanian suggested that the apoptotic pathway 
induced in Jurkat cells by an HDAC8 specific inhibitor requires the potentiation of PLC-
γ1.  ased on this current work, I found that selective HDAC1 and HDAC6 inhibitors also 
have a similar PLC-γ1 requirement in order to induce apoptosis in Jurkat cells. 
Furthermore, the lack of activity displayed by the pan-inhibitor and clinically approved 
SAHA, and the decreased potency of IR-2-17 (Macrolide-based pan-inhibitor) and 
 150 
F 228 (clinically approved) in Jurkat Jγ cells suggest that all HDACi-induced apoptosis 
in Jurkat cells is potentiated by PLC-γ1. Although mutations resulting in the loss of PLC-
γ1 function have not been described in cancer, mutations abrogating the interactions of 
IP3R with cytochrome c can constitute a novel mechanism of resistance to HDACi-
induced apoptosis. The ensuing mutations will only prevent the late phase Ca
2+
 release 
upon apoptosis induction while maintaining the cell ability to mobilize cellular Ca
2+
 for 
other metabolic demands.  
 
4.5. General procedures and experimental 
 Jurkat J.γ1 were obtained from ATCC (Manassas, VA, USA), Jurkat wild type 
cell line was kindly donated by Dr. John McDonald and grown on recommended medium 
supplemented with 10% fetal bovine serum (Global Cell Solutions, Charlottesville, VA, 
USA) and 1% pen/Strep (Cellgro, Manassas, VA) at 37°C in an incubator with 5% CO2. 
Tubastatin A was purchased from Sigma-Aldrich (St. Louis, MO, USA). FK228 was 
purchased from Medchemexpress (Princeton, NJ, USA). SHI1:2 was synthesized as 
previously reported.
22
 The CellTiter 96 AQueous One Solution Cell Proliferation assay 
(MTS) kit was purchased from Promega (Madison, WI, USA). 
Cell viability assay 
 Jurkat and Jurkat J.γ1 cells were maintained in  RPMI 1640 supplemented with 10 
% FBS and 1% pen/strep.  These cells were incubated in media containing the various 
compounds for 72 hours. Cell viability was measured using the MTS assay according to 
manufacturer protocol. The DMSO concentration in the cell media during the cell 
viability experiment was maintained at 0.1%.     
 151 
4.6. References 
1. Johnstone, R. W., Histone-deacetylase inhibitors: novel drugs for the treatment of 
 cancer. Nature Review Drug Discovery 2002, 1 (4), 287-299. 
 
2. Gammoh, N.; Lam, D.; Puente, C.; Ganley, I.; Marks, P. A.; Jiang, X., Role of 
 autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic 
 cell death. Proceedings of the National Academy of Sciences of the United States 
 of America 2012, 109 (17), 6561-6565. 
 
3. Fantin, V. R.; Richon, V. M., Mechanisms of Resistance to Histone Deacetylase 
 Inhibitors and Their Therapeutic Implications. Clinical Cancer Research 2007, 13 
 (24), 7237-7242. 
 
4. Hagmann, W.; Faissner, R.; Schnolzer, M.; Lohr, M.; Jesnowski, R., Membrane 
 drug transporters and chemoresistance in human pancreatic carcinoma. Cancers 
 2010, 3 (1), 106-25. 
 
5. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J., A Family of Drug Transporters: the 
 Multidrug Resistance-Associated Proteins. Journal of the National Cancer 
 Institute 2000, 92 (16), 1295-1302. 
 
6. Jin, S.; Scotto, K. W., Transcriptional Regulation of the MDR1 Gene by Histone 
 Acetyltransferase and Deacetylase Is Mediated by NF-Y. Molecular and Cellular 
 Biology 1998, 18 (7), 4377-4384. 
 
7. Morrow, C. S.; Nakagawa, M.; Goldsmith, M. E.; Madden, M. J.; Cowan, K. H., 
 Reversible transcriptional activation of mdr1 by sodium butyrate treatment of 
 human colon cancer cells. Journal of Biological Chemistry 1994, 269 (14), 
 10739-46. 
 
8. Lee, J. S.; Paull, K.; Alvarez, M.; Hose, C.; Monks, A.; Grever, M.; Fojo, A. T.; 
 Bates, S. E., Rhodamine efflux patterns predict P-glycoprotein substrates in the 
 National Cancer Institute drug screen. Molecular Pharmacology 1994, 46 (4), 
 627-638. 
 
9. Peart, M. J.; Tainton,  . M.; Ruefli, A. A.; Dear, A. E.; Sedelies,  . A.; O’Reilly, 
 L. A.; Waterhouse, N. J.; Trapani, J. A.; Johnstone, R. W., Novel Mechanisms of 
 Apoptosis Induced by Histone Deacetylase Inhibitors. Cancer Research 2003, 63 
 (15), 4460-4471. 
 
10. Bandyopadhyay, D.; Mishra, A.; Medrano, E. E., Overexpression of Histone 
 Deacetylase 1 Confers Resistance to Sodium Butyrate–Mediated Apoptosis in 
 Melanoma Cells through a p53-Mediated Pathway. Cancer Research 2004, 64 
 (21), 7706-7710. 
 152 
11. Fiskus, W.; Rao, R.; Fernandez, P.; Herger, B.; Yang, Y.; Chen, J.; Kolhe, R.; 
 Mandawat, A.; Wang, Y.; Joshi, R.; Eaton, K.; Lee, P.; Atadja, P.; Peiper, S.; 
 Bhalla, K., Molecular and biologic characterization and drug sensitivity of pan-
 histone deacetylase inhibitor–resistant acute myeloid leukemia cells. Blood 2008, 
 112 (7), 2896-2905. 
 
12. Bolden, J. E.; Peart, M. J.; Johnstone, R. W., Anticancer activities of histone 
 deacetylase inhibitors. Nature Review Drug Discovery 2006, 5 (9), 769-784. 
 
13. Bolden, J. E.; Shi, W.; Jankowski, K.; Kan, C. Y.; Cluse, L.; Martin, B. P.; 
 MacKenzie, K. L.; Smyth, G. K.; Johnstone, R. W., HDAC inhibitors induce 
 tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death & 
 Disease 2013,  4, e519. 
 
14. Robey, R. W.; Chakraborty, A. R.; Basseville, A.; Luchenko, V.; Bahr, J.; Zhan, 
 Z. R.; Bates, S. E., Histone Deacetylase Inhibitors: Emerging Mechanisms of 
 Resistance. Molecular Pharmaceutics 2011, 8 (6), 2021-2031. 
 
15. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; 
 Kofler, R.; Smyth, M. J.; Johnstone, R. W., The histone deacetylase inhibitor and 
 chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-
 death pathway characterized by cleavage of Bid and production of reactive 
 oxygen species. Proceedings of the National Academy of Sciences 2001, 98 (19), 
 10833-10838. 
 
16. Butler, L. M.; Zhou, X.; Xu, W.-S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; 
 Richon, V. M., The histone deacetylase inhibitor SAHA arrests cancer cell 
 growth, up-regulates thioredoxin-binding protein-2, and down-regulates 
 thioredoxin. Proceedings of the National Academy of Sciences 2002, 99 (18), 
 11700-11705. 
 
17. Xu, W.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P. A., Intrinsic apoptotic 
 and thioredoxin pathways in human prostate cancer cell response to histone 
 deacetylase inhibitor. Proceedings of the National Academy of Sciences 2006, 103 
 (42), 15540-15545. 
 
18. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J., 
 A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces 
 apoptosis in T-cell lymphomas. Leukemia 2008, 22 (5), 1026-1034. 
 
19. Wozniak, A. L.; Wang, X.; Stieren, E. S.; Scarbrough, S. G.; Elferink, C. J.; 
 Boehning, D., Requirement of biphasic calcium release from the endoplasmic 




20. Boehning, D.; Patterson, R. L.; Sedaghat, L.; Glebova, N. O.; Kurosaki, T.; 
 Snyder, S. H., Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, 
 amplifying calcium-dependent apoptosis. Nature Cell Biology 2003, 5 (12), 1051-
 1061. 
 
21. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P., 
 Rational Design and Simple Chemistry Yield a Superior, Neuroprotective 
 HDAC6 Inhibitor, Tubastatin A. Journal of the American Chemical Society 2010, 
 132 (31), 10842-10846. 
 
22. Methot, J. L.; Chakravarty, P. K.; Chenard, M.; Close, J.; Cruz, J. C.; Dahlberg, 
 W. K.; Fleming, J.; Hamblett, C. L.; Hamill, J. E.; Harrington, P.; Harsch, A.; 
 Heidebrecht, R.; Hughes, B.; Jung, J.; Kenific, C. M.; Kral, A. M.; Meinke, P. T.; 
 Middleton, R. E.; Ozerova, N.; Sloman, D. L.; Stanton, M. G.; Szewczak, A. A.; 
 Tyagarajan, S.; Witter, D. J.; Paul Secrist, J.; Miller, T. A., Exploration of the 
 internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 
 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters 2008, 18 (3), 
 973-978. 
 
23. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, 
 H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S., FK228 
 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. 
 Cancer Research 2002, 62 (17), 4916-4921. 
 
24. Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, 
 S., Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma 
 U-937 cells in vitro and in vivo. Biochemical Pharmacology 2002, 64 (7), 1079-
 1090. 
 
25. Mizutani, H.; Hiraku, Y.; Tada-Oikawa, S.; Murata, M.; Ikemura, K.; Iwamoto, 
 T.; Kagawa, Y.; Okuda, M.; Kawanishi, S., Romidepsin (FK228), a potent histone 
 deacetylase inhibitor, induces apoptosis through the generation of hydrogen 
 peroxide. Cancer Science 2010, 101 (10), 2214-2219. 
 
26. Coggeshall, K. M.; McHugh, J. C.; Altman, A., Predominant expression and 
 activation-induced tyrosine phosphorylation of phospholipase C-gamma 2 in B 
 lymphocytes. Proceedings of the National Academy of Sciences 1992, 89 (12), 
 5660-5664. 
 
27. Irvin, B. J.; Williams, B. L.; Nilson, A. E.; Maynor, H. O.; Abraham, R. T., 
 Pleiotropic Contributions of Phospholipase C-γ1 (PLC-γ1) to T-Cell Antigen 
 Receptor-Mediated Signaling: Reconstitution Studies of a PLC-γ1-Deficient 




28. Chung, S.-H.; Kim, S.-K.; Kim, J. K.; Yang, Y.-R.; Suh, P.-G.; Chang, J.-S., A 
 double point mutation in PCL-[gamma]1 (Y509A/F510A) enhances Y783 
 phosphorylation and inositol phospholipid-hydrolyzing activity upon EGF 
 stimulation. Experimental and Molecular Medicine 2010, 42, 216-222. 
 
29. Everett, K. L.; Bunney, T. D.; Yoon, Y.; Rodrigues-Lima, F.; Harris, R.; Driscoll, 
 P. C.; Abe, K.; Fuchs, H.; Hrabé de Angelis, M.; Yu, P.; Cho, W.; Katan, M., 
 Characterization of Phospholipase Cγ Enzymes with Gain-of-Function Mutations. 
 Journal of Biological Chemistry 2009, 284 (34), 23083-23093. 
 
30. Boehning, D.; van Rossum, D. B.; Patterson, R. L.; Snyder, S. H., A peptide 
 inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks 
 intrinsic and extrinsic cell death pathways. Proceedings of the National Academy 

















COMPARISON OF HDAC INHIBITION PROFILE USING THE 
STANDARD FLUOROMETRIC ASSAY FLUOR DE LYS AND SELF-
ASSEMBLED MONOLAYERS FOR MATRIX-ASSISTED LASER 
DESORPTION MASS SPECTROMETRY (SAMDI-MS) 
 
 
5.1. Introduction  
 Protein acetylation and deacetylation are key regulatory mechanisms involved in 
the modulation of nearly 2,000 targets.
1
 This has bolstered the importance in cellular 
homeostasis of histone acetyl transferase (HAT) and histone deacetylase (HDAC) which 
mediate protein acetylation and deacetylation respectively. HDACs are not only involved 
in the regulation of healthy cells' activity but have been linked to the pathogenesis of 
various illnesses including inflammatory, parasitic, neurodegenerative diseases and 
cancer.
2,3,4
 Although meaningful progresses have been made in understanding the 
involvement of all the different 18 human HDAC isoforms (Zinc and NAD
+
 dependent) 
in cellular functions and diseases, significant obstacles are still to be overcome.  Such 
roadblocks include the development of a suitable HDAC activity assay with very low 
false positive possessing enough selectivity allowing the activity of a specific isoform to 
be distinguished from that of the other 17 isoforms in a cellular extract or milieu.
5,6
  This 
endeavor will enable us to parse out the role of each isoform and gain a better 
understanding of their mechanism of action. Furthermore, having an assay that can be 
automated thus compatible with high-throughput-screening (HTS) will make it an 
invaluable tool in the drug discovery field as HDAC inhibitors (HDACi) are emerging as 
potential therapeutics for various diseases.  
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 A brief discussion will be included on sirtuins (NAD
+
 dependent HDAC) assays 
and I will focus on zinc dependent HDACs assays.  
 
5.2. History of HDAC assays 
5.2.1. Sirtuins assays 
 Class III histone deacetylase or sirtuins catalyze the deacetylation of histones and 
non-histone proteins using nicotinamide adenine dinucleotide (NAD
+
) as cofactor (Figure 
5.1).
7,8
 Assays to measure the activity of these enzymes are based on a direct or indirect 
detection of the metabolites generated from the reaction. During the HPLC-based assay, 
the deacetylated product is separated from the acetylated substrate and quantified using 
HPLC. The use of radioactive substrate is not required making this assay safer for lab 
personnel. A limitation of the HPLC-based assay is the requirement for larger volume 
injection for samples with low peptide concentration.
9
 During the deacetylase assay, the 
acetate group is transferred from the lysine residue unto the NAD
+
 (Figure 5.1). Such 
acetyl moiety is hydrolyzed and isolated during the charcoal-binding assay unlike the 
substrates and other metabolites which are sequestered by the activated charcoal (Figure 
5.2A). A [
3
H]acetylated substrate is needed as the [
3
H]acetate is quantified via 
scintillation count.
9
 The other by-products of the deacetylation, nicotinamide and O-
Acetyl-ADP-Ribose can also be monitored and quantified using the TLC-based assay. 
The quantification of nicotinamide or O-Acetyl-ADP-Ribose using a densitometer 








 respectively as cofactor for the sirtuins 
reaction (Figure 5.2B).
9,10
 All the assays aforementioned are direct reporter of sirtuins 
activity, whereas indirect measurement assays have been recently developed including 
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the fluorogenic assay which relies on the release of a fluorophore coupled to a substrate. 
This assay can be used for all classes of HDACs and as such will be discussed in more 
detail in upcoming sections. Another assay that indirectly determine the sirtuins activity 
relies on an enzyme-coupled system in which the nicotinamide generated from the 
deacetylation reaction is metabolized by nicotinamidase into ammonia and nicotinic acid. 
Glutamate dehydrogenase transfers the ammonia thus generated to α-ketoglutarate in the 
presence of NAD(P)H yielding glutamate and NAD(P)
+
which is monitored at 340nm 
(Figure 5.2C).
11























Figure 5.2: Schematic of selected sirtuins assays. * symbolizes radioactive labeling A) 
Charcoal-binding assay: radioactively labeled [
3
H]-acetate-lysine is used and [
3
H]-acetate 









 is used; C) 







Figure 5.2: Schematic of selected sirtuins assays. * symbolizes radioactive labeling A) 
Charcoal-binding sirtuins assay: radioactively labeled [
3
H]-acetate-lysine is used and 
[
3









 is used; C) 
Enzyme-coupled detection of nicotinamide based on NH3 release by nicotinamidase.
9,11 
 
5.2.2. Zinc dependent HDAC assays 
 The original assay widely used to measure HDAC activity relied on radioactively 
labeled acetylated histones as substrate. Following the incubation of the [
3
H]-acetyl-
histone with HDAC and hydrolysis of the radioactively labeled acetate, the reaction 
mixture is extracted with organic solvent to collect the triturated acetate group. 
Quantification of the released [
3
H]-acetate using scintillation count is correlated to the 
HDAC activity.
14
 Besides the radioactivity which can be problematic for laboratory 
personnel and the generation of highly toxic waste, obtaining the radioactively labeled 
histones is labor intensive as it involves repeated exposure of chickens to 
phenylhydrazine, followed by sacrificing them to collect their reticulocytes and labeling 




 Moreover, the organic extraction 
required for the [
3
H]-acetate quantification prevents the automation of this assay for HTS. 
The organic extraction was abrogated with the scintillation proximity assay, but the 
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protocol for histones labeling and isolation still stand as does the use of radioactive 
materials.
16
 Although immunoblotting of acetylated histone has been one of the first non-
radioactive technique used to determine HDAC activity, all the labor involved does not 
make it an attractive technique, especially for drug discovery.
17
 These assays though 
labor intensive and not amenable to HTS, measure directly the HDAC activity using their 
natural acetylated histone substrates.  
 The first non-radioactive HDAC assay was developed by Hoffmann et al using a 
HPLC with a fluorescence detector to indirectly report HDAC activity (Figure 5.3). A 7-
amino-4-methylcoumarin (AMC) tagged ε-acetylated lysine is used as a substrate which 
has a different retention time than the deacetylated AMC-Lys-NH2 substrate on an HPLC 
trace (Figure 5.3A).
18
 Despite being easily synthesized, the AMC-Lys-ε-Acetyl substrate 
does not resemble the natural histone and possess a higher affinity to HDAC as 
demonstrated by KM values of 0.68 μM and 20 μM respectively.
18
 Furthermore, the 
required HPLC renders its compatibility with HTS difficult. 
 
5.3. Fluorogenic HDAC assay      
 This assay revolutionized the study of HDAC and their inhibition by allowing 
automation and adaptability with HTS. It built on advances made by Hoffmann and 
coworker by retaining the use of a fluorophore (AMC), but established the monitoring of 
the fluorophore as an indirect measurement of HDAC activity. A short peptide sequence, 
containing an ε-acetylated lysine residue and a C-terminus conjugated to a fluorophore 
such as AMC, is used as substrate. Upon incubation of this substrate (ε-Acetyl-
Lys(AMC)-peptide) with the HDAC enzyme, the lysine residue is deacetylated and 
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subsequent addition of trypsin to the deacetylated substrate (NH2-Lys(AMC)-peptide) 






Figure 5.3:  Schematic of the non-radioactive HDAC assay. A) HPLC monitoring of 
AMC as reporter of HDAC activity: 1 (tret= 6.99 min), 2 (tret= 5.54 min), flow rate = 1.2 
mL/min, Multospher 100 RP-18, 250 X 4 mm, Phenomenex, acetonitrile/water (40:60), 
0.01% trifluoroacetic acid.
18
 B) HDAC fluorogenic assay: fluorescence of AMC 
(fluorophore) as indirect reporter of HDAC activity Step 1: incubation of the substrate (ε-
Acetyl-Lys(AMC)-peptide) containing a quenched fluorophore (AMC) with HDAC; Step 
2: Incubation with trypsin releases the fluorophore from the peptide sequence. Free AMC 














5.4. Pitfalls of the fluorogenic assay 
 The strategy of using a fluorescent reporter for various assay has been a popular 
one as it can be adapted easily to various systems, detected easily and used for HTS.
20
 
However, such labeling method can result in the perturbation of the enzymatic activity 
yielding false positive.
6
 The activation of sirtuins (SIRT) by resveratrol epitomized such 
effect. Using the Fluor de Lys-SIRT1 substrate linked to a fluorophore, resveratrol was 
found to activate SIRT1 resulting in various health benefits.
21
 Subsequent studies 
revealed that in the absent of the fluorophore, such activation was abrogated suggesting 
that the previously observed activation is an artifact due to the presence fluorophore.
22
 
Furthermore, incorporation of the fluorophore decreased the affinity of the substrate for 
the SIRT1 and concomitant use of resveratrol yielded a tighter binding between the 
fluorophore-containing substrate and the enzyme.
23
 The use of label-free substrate can 
resolve such issue and also eliminate the additional steps needed to label the substrate.
20
 
 The fluorogenic assay requires the addition of trypsin to release the fluorophore. 
This added step increases the likelihood of error. Trypsin inhibitors can result in false 
positive during the said assay. Thus, a potent trypsin inhibitor with little to no HDAC 
inhibitory activity can prevent the release of the fluorophore. In this case, such compound 
will be reported as potent HDACi. A mandatory trypsin inhibition assay on potential 
HDACi has been suggested prior to running the HDAC fluorogenic assay to discriminate 
true HDAC inhibition from trypsin inhibitor-induced false positive.
19
 Reproducibility and 
accuracy can also be of a great concern as extra steps are added. Also, eliminating the 
extra steps needed for the indirect monitoring of HDAC activity minimize the rate of 
false positive and improve data accuracy. The second step in the conventional 
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fluorogenic can be abrogated by the use of the Caliper EZ reader II system which detects 
directly the fluorescence of the fluorophore tagged substrate and deacetylated product 
following electrophoretic separation.
24
 Although additional step was no longer required 
for this assay, it still uses a fluorophore tagged substrate which can have a modified 
affinity for the enzyme and results in artificial sirtuins activation in the presence of 
resveratrol as previously described.
21
 This situation also stands to benefit from the use of 
label-free substrates as various alternative strategies are in place to monitored the changes 




5.5. HDAC assay using the self-assembled mono-layers for matrix assisted laser 
desorption ionization time-of-flight mass spectrometry (SAMDI-MS)      
 Fluorogenic HDAC assay which is to date the most used assay has two main 
challenges: finding an oligopeptide sequence resembling the natural substrate of each 
HDAC isoforms and directly measure the enzymatic activity. As a label-free method, 
SAMDI-MS can be used to measure the activity of various enzymes including HDAC, 
caspases and other enzymes. 
26,27
 In the context of HDAC activity assay, the label-free 
peptide substrate with an acetylated lysine residue is immobilized onto a plate. Upon 
exposure to the HDAC, the loss of the acetyl group is detected by mass spectrometry as a 
change in the mass to charge ration (m/z) of 42 (Figure 5.4), thus providing a direct 
measure of HDAC activity.
20
 An alternative protocol involves conducting a solution-









Figure 5.4: HDAC activity assay using SAMDI-MS. The acetylated substrate (Ac-
GRK
Ac
FGC-NH2) is immobilized on a gold plate. Exposure of this substrate to HDAC 





 The fluorogenic assay, due to its use of a relative few substrates not optimized for 
all HDAC isoforms, suffers from a lack of selectivity. In a milieu such as a cell lysate 
which contains multiple isozymes, one may not objectively measure the contribution of 
each isoform to the overall HDACs activity. The SAMDI-MS assay comes with specific 
substrates (amino acids sequences) for various HDACs, thus potentially addressing the 







Δm/z = 42 
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Table 5.1: Specific substrate of selected deacetylase enzymes.
29
 










       
 
 
5.6. Comparison of the fluorogenic and SAMDI-MS for monitoring HDAC activity: 
HDAC inhibition profile of pteroic hydroxamate based compounds 
 In our lab, we first experienced the dissimilarity between the fluorogenic and the 
SAMDI-MS assays by measuring the HDAC8 inhibition profile of selected ketolide-
based HDACi.
30
 Furthermore, using the fluorogenic assay, we were unable to elucidate 
the HDAC inhibition profile of 3-hydroxypyridin-2-thione based compounds due to the 
inconsistency of measured IC50s (data not shown). Such inconsistencies were resolved 
using the SAMDI-MS assay.
31,28
 Based on these previous observations, we decided to 
conduct a detailed study by comparing the HDAC1, 6 and 8 inhibition profile of novel 
HDACi using the SAMDI-MS and commercial fluorogenic assays. Specifically, we 
synthesized pteroic acid based HDACi and measured their HDAC inhibitory profile using 
both Fluor de lys and the SAMDI-MS assays (Table 5.2). Overall, the IC50 values 
obtained from both assays are not identical, however, similar trends are observable for 






Table 5.2: HDAC inhibition profile of pteroic acid based HDAC inhibitor: Fluorogenic 










SAMDI‡ Fluor de 
lys† 
SAMDI‡ Fluor de 
lys† 
SAMDI‡ 
(1) 8000 ± 2000 22.1 ± 1.7% 4000 1460 ± 310 NI 25 ± 18% 
(2) 190 ± 30 6150 ± 1320 52 ± 6 212 ± 15 7000 ± 2000 39 ± 6% 
(3) 70 ± 8 79.6± 12.6 50 ± 5 43.6 ± 8.4 5400 ± 800 41 ± 17% 
(4) 53 ± 7 23.4 ± 4.2 22 ± 3 12.2 ± 0.2 NI 1060 ± 320 
(5) 11 ± 1 16.1 ± 2.8 76 ± 9 55.4 ± 2.2 NI 9380 ± 1720 
(6) 104 ± 9 524± 36 4.9 ± 0.4 10.2 ± 1.0 NI 7590 ± 2120 
(7) 270 ± 20 53± 7% 70 ± 10 476 ± 48 NI 40 ± 10% 
SAHA 42 ± 3 38 ± 2 34 ± 2 144 ± 23 2800 ± 200 232 ± 19 
 % inhibition at 10 μM; NI: No Inhibition at 10 μM; †HDAC assay performed through a 
contractual agreement with  PS biosciences; ‡HADC assay performed by James 









 All the compounds seem to be more active when their HDAC1 inhibition 
inhibitory profile is measured using the fluorogenic assay except for the 6-methylene 
compound (n=4). Furthermore, there is a great variation between the IC50 values provided 
for the 4 and 9-methylene compounds by the SAMDI-MS and the fluorogenic assays, 
with the latter showing almost a 33-fold increase in the potency of these compounds 
against HDAC1 relative to the SAMDI-MS. Despite the discrepancy between the 
absolute IC50 values afforded by both methodologies, the observed trend for the HDAC1 
inhibition is similar. An increase in the linker length improves the anti-HDAC1 activity 
starting from 3-methylene linker with the optimum length being the 7-methylene spacer 
group. 
 Against HDAC6, both assays suggest that the 3-methylene linker compound is the 
least potent in the series, however, the fluorogenic assay reported an IC50 4-fold lower 
than that given by the SAMDI-MS. With increasing linker chain length, there is no 
observable trend in the IC50s provided by both assays. The only silver lining is that both 
assays designated the 8-methylene compound as the most potent HDAC6 inhibitor 
followed by the 6-methylene and 5-methylene linker. Furthermore, the IC50s of the three 
most active HDAC6 inhibitors obtained from both assays are nearly similar.    
 The dissimilarity between the two assays is made more glaring by the 
measurement of the HDAC8 inhibition activities of the pteroic acid based HDACi. The 
fluorogenic assay revealed that only 2 compounds have measureable, though weak IC50s. 
The inability to estimate the HDAC8 inhibitory activity of most of these compounds may 
be due to fluorophore label-induced change in the affinity of the substrate for the HDAC8 
enzyme, analogous to the previous observation on HDAC8 and SIRT1.
26,32
 If the 
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fluorophore label increases the affinity of substrate for HDAC8, the pteroic based 
inhibitors (weak HDAC8 inhibitors) may not be able to effectively compete against the 
said substrate.
23
 Since the substrates for SAMDI-MS assay are not labeled, such artificial 
alteration in the substrates’ HDAC binding affinities is quite unlikely. This may partly 
explain the determination of the HDAC8 inhibitory activities of these pteroic acid based 
HDACi (Table 5.2). Based on the foregoing, fluorogenic assays, such as the one used 
here, may not be effective in gauging the HDAC8 inhibitory profile of these and possibly 
many HDACi. Moreover, Riester and coworkers demonstrated that HDAC8 is the most 
selective of all HDACs for its substrate,
33
 hence, the substrate optimization performed 
prior to the SAMDI-MS may have been beneficial relative to the fluorogenic assay where 
such optimization was not done.  
 Using different substrates, tubastatin A was found by Butler et al to have an IC50 
> 30 μM against HDAC 2, whereas Wagner and coworkers reported an IC50 of 0.360 μM 
against the same isoform. Such discrepancy can also be addressed by the standardization 
of isoform optimized substrates for all HDAC assays described in the literature. This will 
not only result in an increased reproducibility and accuracy of HDAC assays but also 
allow an objective comparison between HDACi developed by different laboratories. 
34,35
  
 The SAMDI-MS assay has addressed some of the problems seen with commonly 
used HDAC assays including fluorophore tag-induced perturbation of substrate binding 
affinities, false positive as seen with resveratrol and the indirect measurement of HDAC 
activity which can result in data inconsistency. However, a concern that it has not 
completely been addressed is the development of isoform specific substrates, though 
significant efforts have been made in that direction. Isoform specific substrates may not 
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be needed for closely related HDAC isoforms such as HDACs 1, 2 and 3. In fact 
attainment of substrate specificity among such closely related isoforms may not be 
feasible as they all have the same natural substrates, histones. On the other hand, 
substrate specificity may be achievable between the class I isoform (HDAC1, 2, 3) and 
the class IIb HDAC6 as these two classes have very distinct substrates: histones and 
cytoplasmic proteins respectively.
36
 Obtaining a sub-class selective substrate can 
constitute the initial step towards the discovery of a class I selective HDACi devoid of 
any activity against class IIa HDAC isoforms. Such small molecule may prove to be 
advantageous for HDACi therapy as class I isoforms are overexpressed in many 
malignancies as opposed to class IIa which are cardioprotective.
37,38
    
 
5.7. Conclusion   
 The fluorogenic HDAC assay has been one of the most used to evaluate HDAC 
activity due to their ease and compatibility with automation screening platforms such as 
HTS. However, fluorophore labeled substrates have been shown to interfere with the 
HDAC enzymatic activities. Also, the limited substrate peptide sequences may not allow 
the distinction between the activities of various HDAC isozymes in a cellular lysate. 
Furthermore, the indirect measurement of HDAC activity heightens concern about data 
accuracy and the likelihood of false positive.  On the other hand, the SAMDI-MS, a 
label-free technique, does not require any modifications to the substrate and enables a 
direct monitoring of HDAC activity. Furthermore, the substrate sequences have been 
optimized relative to the fluorogenic assay. These attributes confer a higher level of 
specificity and consistency to the SAMDI-MS data. In the examples cited, the major 
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discrepancy between SAMDI-MS and fluorogenic assays was seen with HDAC8, 
possibly due to the influence of the fluorophore label on substrate affinity. It is therefore 
possible that for compounds with lower anti-HDAC activity, the increased affinity of the 
substrate ensuing from the presence of the fluorophore can hinder the measurement of the 
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CONCLUSION AND FUTURE PERSPECTIVES 
 
 HDACs have emerged as valid targets for cancer therapy. This resulted in the 
development of HDACi and the FDA approvals of SAHA and FK228 (Romidepsin) for 
CTCL. However, these drugs, as pan-inhibitors of HDACs, target isoforms not involved 
in tumorigenesis as well. They are also associated with various side effects including 
cardiotoxicity and have not been efficacious against solid tumors. Two strategies have 
been suggested to boost the therapeutic effects of HDACi: the design of isoform selective 
inhibitors, and the targeted delivery of HDACs pan-inhibitors to malignant cells.   
 To this end, I explored the potential of isoform-selective HDACi as anticancer 
agents by synthesizing and testing 3-hydroxypyridin-2-thione (3HPT) based HDACi 
which were selective for HDAC6 and/or HDAC8. Selected 3HPT based compounds 
displayed anticancer activity against various cancer cell lines including DU145, LNCaP, 
Jurkat and the Jurkat subline J-γ which is resistant to SAHA-induced apoptosis. Although 
the 3HPT based inhibitors are active against certain cancer cells lines and lack 
cytotoxicity against healthy cells, they may not fared well in clinical trials just as other 
isoform-selective HDACi such as MS275. This suggests that isoform-selective HDACi 
may not be clinically indicated as monotherapy for cancer patients. However, these 
selective HDACi can still be considered as standalone therapy for other illnesses 
involving HDACs.     
 In light of the lack of clinical efficacy observed with isoform selective HDACi, I  
selectively delivered HDAC pan-inhibitors to FR(+) cancer cells using folic or pteroic 
acids as homing devices. Among the folic- and pteroic-based HDACi, only the pteroic-
based had anticancer activities due to their inhibition of HDAC1. I devised a novel 
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approach which combined both isoform selectivity and targeting, resulting in the targeted 
delivery of isoform selective HDACi. This led to the design, synthesis and testing of 
folate-based biaryl benzamide HDACi selective for HDAC1. These biaryl benzamide 
compounds did not however displayed any anticancer activity against KB or HeLa cells. 
FR as a delivery system has a low efficiency (15-25%), suggesting that for a drug to 
display cellular activity through this pathway, it must be highly potent against its primary 
target.
1
 The observed lack of cytotoxicity of the benzamide-based HDACi may reside in 
their diminished efficacy against HDAC1. It can be implied from the folate/pteroic 
targeting of HDACi that only compounds with IC50 below 20 nM against a HDAC 
isoform may be the only HDACi to show cellular activity through this delivery system. 
Other targeting ligands which may possess higher delivery efficiencies may constitute 
viable alternative to FR targeting of HDACi. Such endeavor has been attempted by the 
Oyelere et al. using macrolide antibiotic to selectively delivered HDACi to lung tissues.
2
    
 I also attempted to understand the mechanism of resistance of HDACi-induced 
apoptosis in Jurkat J-γ. This work showed that phospholipase C is crucial for HDACi-
induced apoptosis. Identifying the key players in the apoptotic pathway cannot only 
provide an understanding of the mechanisms of apoptosis but also identify the possible 
sites where mutations can result in resistance to apoptosis in general but to HDACi in 
particular. This endeavor can lead to an appropriate choice of chemotherapy agents to be 





Therapeutic future of HDACi 
 The clinical trials conducted thus far on isoform-selective HDACi suggest their 
safety in patients.
3,4
 However, these molecules are also not efficacious as 
monotherapeutic agents against many malignancies.
5
 For isoform-selective HDACi to be 
further considered as anticancer drugs, they must be used in combination with other 
chemotherapy drugs. The additive effect ensuing from such combination can lead to a 
reduction in the posology of the chemotherapeutic agents including that of HDACi. 
Careful considerations should be made prior to the selection of the combination therapy. 
Exposure of cancer cells to certain HDACi result in the up-regulation of the P-
Glycoproteins (P-gp) which can efflux drugs from cancer cells.
6
 To avoid a premature 
resistance to the chemotherapy regiment, one should select a HDACi that does not up-
regulate the P-gp. Alternatively, the adjunct chemotherapy agent should not be a substrate 
of these P-gp pumps if the selected HDACi up-regulate these efflux pumps. Furthermore, 
the dosing schedule of each component of the combination therapy has to be studied, to 
optimize the impact of the said combination. For example, the combination of HDACi 
and topoisomerase inhibitors has been shown to be efficacious only when the HDACi is 
administered prior to the topoisomerase inhibitors.
7
 
   The only currently approved HDACi for cancer therapy are pan-inhibitors.
5
 Thus 
pan-inhibitors may be the only way forward for HDACi as monotherapy against cancer. 
Although the pan-inhibition of HDACs may prove to be more effective against cancer 
cells, it also can result in increased adverse reactions. A potential solution to this dilemma 
is the targeted delivery of these pan-inhibitors to malignant cells. Such targeted delivery 
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can also result in an increased accumulation of the HDACi in the tumor, potentially 
boosting their potency against solid tumors. 
 HDACi have also displayed therapeutic application in other illnesses including 
neurodegenerative, parasitic, and inflammatory diseases. In such instances, isoform-
selective HDACi can be efficacious as monotherapy. For example, leishmania has been 
shown to be sensitive to selective HDAC6 inhibition (unpublished data). 
 HDACi have the potential to be elixirs for many diseases including cancer. To 
reach such status, these molecules should be used as part of personalized medicine. This 
implies that the selection of a specific HDACi for the treatment of a patient's disease 
should be based on biomarkers from the patient, and the condition to be treated: targeted 
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C NMR characterization of folate and 
















Scheme S1: Synthesis of pteroyl azide 4. a) TFAA, THF rt; b) THF, ice; c) Hydrazine, 
DMSO, rt; d) tBuONO, KSCN, TFA, rt. 
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